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ABSTRACT 
 
DYNAMICS OF ENDOGENOUS CARDIAC REPAIR AND METHODS FOR ENHANCED 
POST-INJURY CELL THERAPY 
Jeremy Alan Elser 
Kenneth Margulies, MD 
 
Heart attacks are a leading cause of mortality in the United States, responsible for over 
500,000 deaths annually.  Despite advancing treatments for acute heart attack, 5-year 
mortality exceeds 50% as the organ fails to heal the resulting scar. 
 
Recent studies revealed modest cardiac regeneration occurring throughout life and 
accelerating (albeit insufficiently) post-injury.  However, the magnitude is contested with 
some studies indicating low cardiomyocyte formation and others indicating rapid 
formation of increasingly inferior cardiomyocytes.  Resolving this question determines 
the needed strategy for repair augmentation.  Chapter 3 scrutinizes current apparently-
paradoxical studies and offers a unified estimate of cardiomyocyte turnover via a hybrid-
model software platform. 
 
As limited engraftment (<2%) was cited as a primary impediment in bone marrow cell 
(BMC) infusion clinical trials, Chapter 4 recapitulates these trials in an intact-organ 
murine model--the isolated perfused heart. Flow cytometry enables objective, sensitive 
identification of strongly-retained BMC phenotypes.  Results show that endothelial P-
selectin surfaces at 30 minutes post ischemia-reperfusion injury, leading to preferential 
engraftment of c-kit+ BMCs (which exhibit superior P-selectin adherence in vitro).   
 
vi 
 
Chapter 5 adapts the flow cytometry technique to measurement of absolute cell retention 
(non-ratiometric) to evaluate chemotactic properties of Stromal Derived Factor (SDF)-
eluting implants of polymerized hyaluronic acid.  Stem cells home to chemokine 
concentration gradients and thus SDF-eluting hydrogels can draw infused stem cells to 
the implant site.  The hydrogel increases cardiac BMC homing by 5-fold, confirming that 
local chemokine milieu alteration can augment BMC therapy. 
 
Leveraging Chapter 4 results, Chapter 6 artificially stimulates P-selectin 
endothelialization in quiescent endothelium to improve BMC engraftment rates even 
after endogenous activation subsides.  Low-dose peroxide, a reactive oxygen species 
known to induce brief inflammation, when delivered prior to BMC infusion, enhances 
retention by 3-fold.  Interestingly, peroxide-induced c-kit+ BMC retention rates are 
equivalent to true ischemic injury rates, while c-kit-negative BMCs also experience 
enhanced engraftment. 
 
This work spans the scientific process, conducting basic research of natural physiology 
and leveraging results to propose and test two promising therapeutic strategies—
alteration of local chemokine concentrations and endothelial adhesion molecule display. 
 Additionally, new techniques, including computational methods and flow cytometry-
based engraftment assays enable future work in cardiac regeneration. 
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CHAPTER 1 
1.  Overview of Cardiac Stem Cell Therapy 
 
1.1 Cardiac Injury 
Heart failure (HF) is a leading cause of disability and death which accounts for 
approximately one million hospitalizations, over 50,000 deaths, and almost $35 billion in 
health care costs in the United States each year [1].  Despite therapeutic advances in 
the treatment of myocardial infarction, hypertension, valvular heart disease and 
cardiomyopathies, the prevalence of HF continues to grow.  Mortality rates remain high 
with 50% of HF patients dying within five years of initial diagnosis [2].   
 
Progressive loss of cardiomyocytes (CM), due to myocardial infarction (MI) and/or 
programmed cell death (apoptosis), is a feature of most causes of HF.  Therefore, 
therapies to increase the number of functional CMs are expected to improve the course 
of this syndrome.   
 
The human heart was long believed to have virtually no capacity for new CM formation 
after childhood.  This conclusion was drawn largely from the heart’s inability to repair 
tissue damaged after myocardial infarction [3].  However, increasing evidence supports 
the existence of endogenous cardiac renewal and repair mechanisms that contribute to 
normal homeostasis and responses to pathological insults, which could be augmented to 
prevent heart failure.   
 
1.2 Cardiomyogenesis in Physiological Homeostasis 
Overturning the dogma of the adult human heart as a terminally differentiated organ, 
Bergmann et al used a fate-mapping approach to demonstrate and quantify the rate 
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cardiomyocyte renewal [4].  Recognizing that an era of nuclear bomb tests between 
1955 and 1963 (when the nuclear Test Ban Treaty was signed) produced a spike in 
atmospheric carbon14 (C14), these investigators used cardiac specific markers to 
identify and isolate CMs from hearts obtained at the time of autopsy.  Because the C14 
content of CM DNA should reflect the atmospheric the ambient C14 level at the time of 
cell formation, differences between the actual C14 content of DNA and the predicted 
level based on atmospheric C14 levels provided a means of identifying net cell 
replacement.  In fact, higher than expected C14 CM DNA levels observed among those 
born before 1955 and the lower than expected C14 CM DNA levels observed those born 
after 1963 supported the replacement of some CMs during adult life.  Even after 
accounting for previously described CM nuclear division (poly-ploidization), these 
investigators estimated that about 1% of CMs are replaced annually at the age of 25 and 
that this rate gradually decreases to about 0.45% annually by age 75.   
 
In 2010, Kajstura et al performed extensive histological analyses of 74 non-diseased 
hearts of various ages to evaluate the presence of a proposed class of cardiomyocyte 
stem cells (CSCs) and the fraction of these cells undergoing mitosis at time of patient 
death.  Supported by in vitro cycling and apoptosis kinetics parameters, mathematical 
modeling was used to compute the annual turnover rate as a function of patient age.  
Kajstura reported a turnover rate approximately 7% in young adult males that increases 
to 32% with advanced age, with even higher rates of cardiac myocyte turnover 
calculated among females [5].   
 
While these two studies both confirm that new CM formation exists in the healthy, adult 
human heart, the discrepancy in magnitude is perplexingly large.  As abundant 
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endogenous cardiac regeneration influences potential therapies, clarification of the true 
reconstructive ability of the heart is critical. 
 
1.3  Cardiomyogenesis in Pathophysiologic Response 
Several lines of evidence suggest that cardiomyogenesis can occur in adult hearts 
following injury or trauma.  In humans, some of the strongest data comes from sex-
mismatched transplanted hearts (male recipient, female donor) in which Y-chromosome 
positive cardiac myocytes (as well as endothelial cells and smooth muscle cells) have 
been found within the cardiac allografts obtained from a female donor.  Though the rates 
of this phenomenon vary considerably in different reports [6,7], higher rates of allograft 
chimerism were observed when the donor hearts suffered acute ischemic events [7], 
suggesting that host-derived progenitor cell recruitment may be injury-responsive.  In 
addition, Urbanek et al reported increases in endogenous cardiac stem/progenitor cells 
(S/PCs) in hearts from patients who died from acute MI and, to a lesser extent, in 
patients with end-stage chronic post-MI cardiomyopathy [8].   
 
In animal models, recent reviews highlight studies demonstrating activation of 
endogenous cardiac repair processes in response to experimental cardiac injury [9, 10].   
Some studies have employed bone-marrow ablation and reconstitution with GFP-
labeled cells, and then reported GFP-labeled cardiac myocytes, vascular cells and 
fibroblasts within and around the infarcted myocardium [11].  Other studies have 
employed direct myocardial injection of enriched and labeled S/PCs derived from 
autologous sources [12] or from allogeneic donors, including humans [13].  Most studies 
indicate that local myocardial injury augments cell engraftment into the recipient 
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myocardium, but other studies suggest a high rate of attrition for these newly engrafted 
cells [14].   
 
The degree to which endogenous S/PCs contribute to the native response to 
myocardial injury and failure in the adult mammalian heart remains a key unresolved 
question.  Studies in mice by Fazel et al indicate that MI triggers homing of bone 
marrow-derived progenitors expressing the c-kit surface marker to the murine heart and 
that these cells contribute to angiogenesis and reduced post-infarct dilation [15].  
Because very few new cardiac myocytes or blood vessels appeared to be derived from 
the GFP-labeled bone marrow cells, this report concluded that secretion of angiogenic 
cytokines by bone marrow-derived c-kit+ cells accounts for their beneficial impact 
independent of any direct myocardial incorporation as new cardiac myocytes or 
vascular structures [15].  Additionally, subsequent studies by Hsieh et al used a fate-
mapping approach in mice to demonstrate that early increases in myocardial c-kit+ cells 
precede new cardiac myocyte formation following experimental MI or pressure overload 
[16].  Together, these studies in animal models indicate that myocardial injury and 
failure induce a demonstrable, but relatively minor, endogenous repair response.  
  
1.4 Augmentation of the Repair Response 
A series of randomized, controlled clinical trials (RCTs) have attempted to augment the 
repair response through the manipulation of endogenous or delivered S/PCs.  
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1.4.1 Mobilization of Bone Marrow Progenitors 
The first BMPC (Bone Marrow Progenitor Cell) trials delivered Granulocyte Colony 
Stimulating Factor (G-CSF) to the bloodstream post-infarction in an effort to stimulate 
progenitor cell release from the bone marrow, but did not involve administration of S/PCs 
directly.  This strategy has been shown to temporarily increase circulating progenitor 
concentration, as defined by concentration of CD34+ cells [17].  However, placebo 
controlled, double blind clinical trials such as STEMMI [18] found no improvement for G-
CSF treatment over controls.  In fact, a meta-analysis of four blinded and six nonblinded 
trials found no statistically significant improvement in ejection fraction (EF) or decrease 
in infarct size when using G-CSF [19].  For this meta-analysis, G-CSF doses ranged 
from 2.5-10 ug/kg per day for delivery periods of 4-10 days.  Delay between coronary 
angioplasty and treatment ranged from 90 +/- 35 minutes in the FIRSTLINE-AMI trial to 5 
days for the MAGIC-Cell and REVIVAL-2 trials.  Based on these findings, direct cell 
administration to the heart has emerged as the dominant therapeutic approach in recent 
clinical trials, though G-CSF may be used in conjunction with other interventions. 
 
1.4.2 Direct Delivery of Unfractionated Bone Marrow Cells. 
Following a series of small interventional trials, several larger RCTs have been 
performed using the direct injection of bone marrow cells into the coronary arteries or 
myocardium.  Several studies have shown modest but consistent improvements in 
cardiac performance and overall mortality, although the mechanism for their benefit 
remains uncertain.  REPAIR-AMI, the largest RCT to date, included 204 patients and 
found that delivering bone-marrow S/PCs 4 days post-MI increased left ventricular 
ejection fraction (by 3.2±1.3 %) at 4 months.  Although the difference compared with 
placebo was lost by 12 months, a subanalysis focusing on patients with a baseline EF 
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below the median of 48.9% had statistically significant increases in EF compared to 
placebo throughout the experiment [20].  These results mirrored the BOOST trial in 
which bone marrow cells administered 5 days post-PCI was associated with a 6.7% 
absolute increase in EF in the bone marrow treated group compared with a 0.7% in the 
control group (p=0.0026) [21].  Here again, intergroup differences were no longer 
significant during later follow up (18 months), suggesting that the benefit of infused 
BMCs may be in speeding recovery but not in long-term benefit.  A meta-analysis of 13 
randomized controlled trials (811 patients) determined that intracoronary injection of 
BMCs improves EF by 2.99 points (p=0.0007) over 3-6 months, though not all trials have 
been positive [22, 23].  Supplementing these findings are several other recent trials 
including the unblinded BALANCE study which reported that delivery of BMCs 7 days 
following AMI decreased 5-year mortality (2.35 vs. 0.35% annual mortality rates, p=0.03) 
and increased EF (4.6% differential EF improvement over baseline for BMC delivery vs. 
a decrease of 5.8% differential EF for controls [24].   In patients with an EF less than 
45%, the MYSTAR (n=60) study found no difference in the improvement in EF and 
reduction in infarct size when a dual cell introduction method (intramyocardial and 
intracoronary injection) was utilized at 3-6 weeks vs. 3-4 months post MI, though MI size 
was smaller in treated hearts than in controls [25].    
 
1.4.3 Direct Delivery of Purified Stem Cells 
Lackluster results from the bone marrow cell trials prompted investigation of alternative 
and sub-population cell sources with higher regenerative potential.  Chen et al evaluated 
mesenchymal stem cells (MSCs) in a placebo-controlled trial of 69 patients and reported 
the largest increases in EF for trial groups over controls when delivering 8-10 billion 
MSCs via intracoronary injection at about 18 days after Percutaneous Intervention (PCI).  
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At three and six months, the study reported an average EF of 67±11% and 67±3% in 
MSC-treated patients, compared with 53±18 and 54±5 in placebo-treated controls.  
Several other cardiac performance measurements supported these results [26].    
 
Two additional reports describing the effects of enriched bone marrow cell subsets 
reported rather modest benefits.  In a blinded study of 22 patients reported by Katritsis, 
1-2 million BMCs enriched for MSCs (about 33%) and endothelial progenitor cells 
(EPCs, about 66%) improved wall-score indices and tissue viability were observed 
without significant improvement in EF [27].  A clinical trial utilizing intracoronary delivery 
of AC133+ enriched bone marrow cells 2 weeks after MI reported significant 
improvements in EF and perfusion defects when compared with control patients 
receiving no cell therapy [28].   
 
Two ongoing clinical trials are also evaluating the therapeutic potential of MSCs.  The 
Prospective Randomized assessment Of MEsenchymal stem cell THErapy in patients 
Undergoing Surgery (PROMETHEUS, clinicaltrials.gov ID: NCT00587990) is a placebo-
controlled study that of intracardiac injection of expanded autologous MSCs in patients 
who require coronary artery bypass surgery and who have an EF between 20 and 50%.  
The Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT, 
clinicaltrials.gov ID: NCT00768066) is a similar study in which autologous MSCs or 
autologous whole bone marrow are delivered percutaneously by means of the 
BioCardia® delivery system.   
 
Additionally, therapeutic cells derived from autologous heart biopsy tissue are being 
evaluated.  Cardiac Stem Cells in Patients with Ischemic CardiOmyopathy (SCIPIO), an 
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open-label trial in which harvested resident c-kit+ cardiac cells are expanded and re-
delivered intracoronarily, has yielded encouraging interim results including increased 
Left Ventricular Ejection Fraction (LVEF) and decreased infarct size at 1 year  [29].  
Similarly, phase 1 results from the CArdiosphere-Derived aUtologous stem Cells to 
reverse ventricular dysfunction (CADUCEUS) trial, in which CD105+/CD45- cardiac 
biopsy cells were re-implanted in injured hearts, show reductions in scar mass and 
improvements in cardiac contractility at 6 months [30]. 
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CHAPTER 2 
2.  Specific Aims 
Each year over 500,000 Americans suffer myocardial infarctions.  While many of these 
patients survive the acute phase of the injury, the resulting tissue death and scar 
formation initiate a remodeling process that ultimately destroys the organ.  Thus, the 5-
year mortality rate for victims of myocardial infarction exceeds 50%.  Over the past 
decade, there has been an increasing appreciation that augmenting native repair 
mechanisms via administration of exogenous stem or progenitor cells (S/PCs) might 
provide fruitful approaches for reducing morbidity and mortality following myocardial 
infarction.  While cell therapy, using infused bone marrow-derived progenitors to 
stimulate endogenous cardiac repair, has yielded modest improvements in cardiac 
performance, the magnitude of this repair has been insufficient to improve clinical 
outcomes.  Despite many interventional studies of cell therapy, the underlying 
physiology of endogenous repair is poorly understood.  The magnitude of adult 
cardiomyocyte formation rates is highly controversial and therefore the baseline context 
of myocardial injury and repair efforts are unknown.  Furthermore, though low 
engraftment rates are cited as a primary limitation of current cell therapies, mechanisms 
of infused cell engraftment are also unknown.  Accordingly, this dissertation describes a 
series of inquiries that examine three timely questions:  what is the baseline 
cardiomyocyte turnover rate in the nondiseased heart, what mechanisms are involved in 
S/PC cell homing/engraftment to the heart, and can these insights into engraftment 
mechanisms be exploited to increase the retention rates of infused cells and improve 
future cardiac cell therapeutic techniques. 
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Global Hypothesis:  We hypothesize that endogenous cardiac repair can be understood 
and augmented via manipulation of the extant repair phenomena and mechanisms.  
Specifically, this work will test the four hypotheses that are described below.  The overall 
goal of this study is to identify and manipulate mechanisms of cell-based cardiac repair 
to increase cardiac retention of infused cells thereby enhancing the effectiveness of 
cardiac repair strategies. 
 
Specific Aim 1:  To quantify baseline cardiac repair levels in normal adult human 
hearts by critically evaluating and synthesizing prominent studies of maintenance 
cardiomyocyte formation rates.  A computerized, agent-based model will be 
programmed to incorporate data and modeling techniques used in the primary literature 
describing adult cardiomyocyte turnover rates, which currently offer conflicting 
estimations.  Using this hybrid model, the mathematical models and underlying 
assumptions present in existing literature will be probed for validity, self-consistency, 
thoroughness, robustness, and sensitivity to parameter variance.  A composite estimate 
of cardiomyocyte turnover in normal adult human hearts will be formulated, thus 
illuminating the baseline level of cardiomyogenesis and providing biological context for 
cell therapy in injured hearts. 
Specific Hypothesis 1: Scrutiny of the methodology and mathematical 
constructions in existing relevant literature will help clarify alternative theories of adult 
cardiomyocyte formation rates in normal human hearts. 
 
Specific Aim 2:  To identify bone marrow cell subtypes with strong engraftment 
capability and subsequently identify primary mechanisms responsible for the 
observed engraftment superiority.  Freshly-harvested bone marrow cells will be 
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labeled and infused into a murine intact organ model of ischemia-reperfusion injury (the 
Isolated Perfused Mouse Heart).  The phenotypic distribution of labeled cells retained in 
the heart after infusion will be analyzed via flow cytometry and compared to the 
distribution of the infused cell source to identify subtypes with superior relative 
engraftment rates.  Biomarker co-expression analysis, functional antagonists, and flow 
chamber molecular interaction studies will be used to identify the adherence 
mechanisms used by these preferentially-engrafting cells. 
Specific Hypothesis 2: Upon infusion to the injured heart, phenotypic subsets 
within heterogeneous bone marrow will engraft preferentially relative to other subsets 
using mechanisms that, once identified, can inform future improvements to cell therapy. 
 
Specific Aim 3:  To increase bone marrow cell homing from the systemic 
circulation to the injured heart using a chemokine-eluting hydrogel implanted 
upon the epicardial surface.  Chemotactic factors will be encapsulated in a 
methacrylated macromer solution.  In an in vivo murine model, a cryoinjury will be 
surgically performed to simulate myocardial infarction.  In some trials, the chemokine-
laced polymer will be photo-polymerized into a hydrogel patch deployed on the 
epicardial surface of the injury site.  At three hours post-injury, labeled syngenic bone 
marrow cells will be injected into the cryoinjured mouse via the femoral vein.  Blood will 
be harvested and the presence of labeled cells will be quantified at 1 and 7 days post-
injury.  At 7 days post-injury, hearts will be excised and digested for quantification of 
labeled cell content via flow cytometry.  Histology on non-digested hearts will determine 
the spatial distribution of labeled cells within the heart relative to the injury site. 
Specific Hypothesis 3:  Site-specific, extended-release delivery of chemotactic 
factors will encourage homing of infused bone marrow cells to the injured heart.   
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Specific Aim 4:  To increase bone marrow cell engraftment from the coronary 
circulation to the injured heart using an adjuvant endothelial stimulant prior to cell 
infusion.  A chemical adjuvant will be selected based on the results of Specific Aim 2.  
Isolated-Perfused Mouse Hearts will be prepared and treated with the chemical adjuvant 
(contained in the perfusate solution) prior to infusion of labeled bone marrow cells.  The 
absolute number of retained cells will be quantified using flow cytometry and compared 
to untreated hearts to determine impact of the adjuvant on total retention.  Additionally, 
flow cytometry will be used to identify the impact of the adjuvant on phenotypic subset 
relative retention rates.    
Specific Hypothesis 4:  Intracoronary infusion of adjuvant chemicals prior to bone 
marrow cell delivery will increase the absolute overall engraftment rate of bone marrow 
cells and/or specific subsets of bone marrow cells.  
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CHAPTER 3 
3.  Modeling Myocyte Turnover in the Adult Human Heart 
 
3.1 Introduction 
The human heart was long believed to have virtually no capacity for new cardiomyocyte 
(CM) formation occurring after childhood.  This conclusion was drawn largely from the 
heart’s inability to repair tissue damaged after myocardial infarction [1].  However, 
studies of sex-mismatched heart transplant recipients and reports of myogenic 
progenitors within human hearts raised doubts about the absence of new CM formation 
within adult human hearts [2-5].  A landmark study by Bergmann et al [6] utilized a pulse-
chase approach to identify and quantify the rate of new CM formation in normal human 
hearts based on the average percentage of Carbon14 (C14) in the DNA of CMs in 12 
autopsied human hearts (demographics reproduced in Table 3.1).  Bergmann and 
colleagues compared the C14 content in cardiac myocyte DNA at the time of death to 
the known atmospheric concentrations of C14 at the time of the subject’s birth 
(reproduced in Figure 3.1) [7,8], with differences reflecting cell cycle activity as would 
occur during CM formation.  Subjects born before the spike in atmospheric C14 were 
found to have more C14 in their CM nuclei than was present at time of birth while 
subjects born after the C14 spike had less C14 in their CM nuclei, suggesting new CMs 
had been created and incorporated new C14 into their DNA.  Based on mathematical 
modeling that considered atmospheric C14, CM DNA C14 content, and DNA 
polyploidization estimates, Bergmann et al reported a CM turnover rate of approximately 
1% per annum during youth, decreasing to 0.5% during advancing age.   
 
In 2010, Kajstura et al [9] performed extensive histological analyses of 74 non-diseased 
hearts of various ages to evaluate the presence of a proposed class of cardiomyocyte 
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stem cells (CSCs) and the fraction of these cells undergoing mitosis at time of subject 
death.  Supported by in vitro cycling and apoptosis kinetics parameters, mathematical 
modeling was used to compute the annual turnover rate as a function of subject age.  
Kajstura reported a turnover rate approximately 7% in young adult males that increases 
to 32% with advanced age of 100 years, with even higher rates of CM turnover 
calculated for females.   
 
While these two studies both confirm that new CM formation exists in the healthy, adult 
human heart, the discrepancy in magnitude and age progression is perplexingly large.  
Accordingly, we developed a hybrid mathematical model designed to evaluate the two 
models simultaneously.  The hybrid model automaton algorithm is described in Figure 
3.2 and is programmed to accept turnover rate (CM formation, apoptosis rate, and 
polyploidization) parameters that vary with subject age and sex, such as those found in 
the Kajstura paper (Figure 3.2 Mode A); however, these variables may be substituted for 
time-varying CM formation and destruction rates as employed by Bergmann (Figure 3.2 
Mode B).   By applying this model to the two data sets, we have identified explanations 
for their discrepancies and defined whether differences can be reconciled, while 
providing a tool for modeling data derived from subsequent inquiries.  
 
We first examine the Kajstura model in isolation.  This section is divided into 3 main 
subsections: (3.3.1) confirming the hybrid model’s fidelity in reproducing identical 
conclusions (outputs) to the Kajstura manuscript when the Kajstura measurements 
(inputs) are used, (3.3.2) evaluating the sensitivity of the Kajstura model to variations in 
input parameters and assumptions, and (3.3.3) addressing important factors that were 
not considered in the Kajstura document.  We then provide a similar three-subsection 
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analysis of the Bergmann manuscript in isolation with (3.3.4) confirmation of hybrid 
model fidelity to the Bergmann methodology, (3.3.5) sensitivity analysis of the Bergmann 
model to its parameters and assumptions, and (3.3.6) model modification based on 
heretofore unconsidered factors.  Finally in subsection 3.3.7, we seek turnover scenarios 
that are consistent with both datasets when reasonable estimates of input variable 
uncertainty are included and unproven assumptions are challenged and modified.  
Table 3.1 Bergmann Subject Dataset 
Code Gender Birth Year Lifespan (Yrs) 
ND60 M 1933 73 
ND67 M 1939 68 
ND73 M 1944 63 
ND61 M 1948 58 
ND51 M 1955 51 
ND56 M 1964 43 
ND68 M 1967 40 
ND50 F 1967 39 
ND69 M 1973 34 
ND71 M 1983 24 
ND54 F 1983 23 
ND74 F 1987 20 
Table 3.1.  Modeled Subject Genders, Birth Years, and Lifespans.  Modeled subject input 
parameters were extracted from the Bergmann study. 
 
 
Figure 3.1.  Input Atmospheric C14 Levels from 1930-2007.  In accordance with the Bergmann 
approach, C14 measurements were extracted from the Levin datasets (Europe from 1959-2003, 
and 2003-2007) and scaled to the Bergmann unit system.  Years prior to 1955 were estimated as 
null as no human nuclear activity occurred during this time.  For modeling purposes, a 1 year 
smoothing function was applied, consistent with the Bergmann approach. 
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Figure 3.2. Hybrid Model Automaton Algorithm.  Subject hearts are modeled by initiating a 
“Starting CM Count” for the subject at the “Start Age” of the simulation (typically birth) and a 
“Subject Lifespan” that determines the number of year-repetitions.  An age distribution of CM at 
the time of subject autopsy is produced either via Mode A or Mode B.  Mode A uses variables and 
formulas from the Kajstura methodology to perform iterations of CM creation and destruction 
throughout each year-iteration according to the duration and frequency of these cycles.  In this 
formulation, NCSC = Number of Cardiac Stem Cells, %Cyc = Fraction of CSCs cycling, and E = 
Number of CSC divisions occurring before loss of pluripotency.  Alternatively, Mode B uses input 
annual creation and destruction values directly and these values may be dependent on either the 
subject age (at time of CM formation or at current iteration of production/destruction) or on the 
age of the CM undergoing destruction.  There are two main outputs: (1) a distribution of surviving 
CM by CM age and (2) an end average C14 measurement, modeling the Bergmann methodology 
applied to model hearts, which is produced by incorporation of the CM age distribution with 
atmospheric C14 timecourse data and human polyploidization magnitudes/rates.  
 
 
 
3.2 Methods 
3.2.1 Modeling Approach 
A JAVA-based mathematical model heart was developed in which a modeled subject’s 
end-of-life CM age distributions, defined by the modeled subject’s lifespan and CM 
turnover dynamics, could be computed.  These age distributions were produced by 
initializing the model with a starting number of CMs and then iteratively forming new 
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CMs and destroying existing CMs in accordance with formation/destruction parameters 
either specified with direct numeric rates or computed from component parameters, as 
those shown in Figure 3.2.   In some model simulations, apoptotic elimination was 
formulated to selectively target CMs based on subject age or CM age (iteration of CM 
formation within the progression of iterations) whereas other model regimes assumed 
random CM elimination. 
 
When a timeline of atmospheric C14 was included as a reference input and the model 
heart was assigned a finite birth (start) year on that timeline, each CM formed in the 
simulation was assigned a DNA C14 value roughly equal to the appropriate atmospheric 
C14 level at the time of CM formation but adjusted for polyploidization.  Polyploidization 
adjustment was computed by, for each CM age group in the simulation, beginning with 
the atmospheric C14 level at time of CM age group formation and iteratively (for each 
year between from formation until subject death) replacing that C14 number with a 
weighted average of the number (weighted by 100%) and the atmospheric C14 level 
contemporary to the next iteration’s polyploidization event (weighted by the percentage 
of CM undergoing polyploidization at that stage in the subject’s life, as specified by the 
Adler/Bergmann sigmoidal polyploidization curve).   
 
Under these conditions, each CM surviving to the end of the simulation contributed DNA 
C14 to an average CM DNA C14 value for the modeled subject.  Subtracting the initial 
atmospheric C14 level (at the start of simulation) from this final C14 weighted average 
yielded a ΔC14 value associated with the modeled subject.   
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In some analyses, the inverse operation was performed—converting an experimentally 
measured ΔC14 value (or a simulated ΔC14 value) attributed to a subject, into a best fit 
turnover solution—the turnover dynamics that best produce the observed or target ΔC14 
value.  For this task, a numerical solver evaluated a wide range of turnover solutions 
(constant or time-varying depending on specified restrictions) by generating a time-of-
death CM age distribution resulting from each potential turnover solution in the testable 
range.  Then, for each CM age group in each hypothetical distribution, the C14 
contributed by a CM in the age group was computed (with polyploidization correction as 
aforementioned).  Multiplying the fractional representation of each CM age group by the 
polyploidization-adjusted C14 contribution of that age group yields a net ΔC14 value for 
the potential turnover solution.  The turnover dynamics yielding the closest fit to the 
measured or target ΔC14 is selected as the best fit solution.  
 
3.2.2 Sources of Input Parameters 
Age-dependent, gender-dependent parameter values for the number of CSCs, fraction 
of such CSCs cycling at any given moment, number of CSC divisions prior to 
senescence, and fraction of CM undergoing apoptosis at any given moment were 
extracted from the Kajstura manuscript.  Thus for any modeled subject of any age or 
gender, a single value for each of these parameters (derived from regression models of 
74 subjects computed in the Kajstura document) could be referenced and incorporated 
into a dynamic model heart.  The formula for single-iteration CM count change (Figure 
3.2, Mode A) was also obtained from the Kajstura manuscript.       
 
Similarly, raw data regarding subject-specific year of birth, year of death, and CM DNA 
C14 levels for each of 12 subjects studied in the Bergmann manuscript were extracted.  
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These CM DNA C14 levels were reported by Bergmann as differential C14 
measurements (measured C14 relative to 1955, prior to the rise in atmospheric C14.  
These differential measurements were converted to ΔC14 values by subtraction from the 
initial C14 levels (also differentials from 1955 values) for use in the hybrid model.  The 
polyploidization age progression formula was obtained from the Bergmann manuscript.     
 
3.2.3 Examination of Kajstura Manuscript in Isolation Using Hybrid Model 
The Kajstura manuscript proposes two complementary modeling methods—a 
hierarchically-structured cell kinetics model (controlled by CSC cycling rates and CM 
apoptosis rates) and an age-structured cell kinetics model (controlled by CM half-life and 
apoptosis rates).  In the hierchically-structured model, an initial cell population of 500 
Million CM/10 g tissue was used to start the simulation.  Then, for each year in the 
simulation, CM were iteratively created or destroyed based on the assumed modeling 
parameters (enumerated in Figure 3.2, Mode A).  For the age-structured model, CM age 
distributions at time of subject death were produced for simulated subjects (defined by 
age at time of death and gender) according to the formula utilized by Kajstura et al, a 
modified version of the McKendrick von Foerster population dynamics formula:  
       
        
  
   
 
      
   where n(a) is the number of CM of a given age present at 
time of autopsy (for 10 g tissue), N is the initial number of CM present in 10 g tissue, a is 
the age of the CM, h is the halflife of a CM, and µ(a,t) is a mortality function dependent 
on a and the subject age t.  In the hybrid model, µ(a,t) is realized by iteratively computing 
for all t (0 to lifespan) the number of CM destroyed (given as “per million” values by 
Kajstura measurements) and deducting the destroyed CM from the then-current total. 
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3.2.4 Examination of the Bergmann Manuscript in Isolation Using Hybrid Model 
The ability of the hybrid model to faithfully emulate the Bergmann methodology for 
computation of turnover levels from ΔC14 data was measured by substituting the hybrid 
model inputs with the single turnover value (or age-progression series of values) 
concluded by Bergmann in the Bergmann document for each of the 12 Bergmann 
subjects (modeled hearts with birth date and lifespan equivalent to that of a Bergmann 
subject).  After integrating atmospheric C14, polyploidization data, and turnover 
derivation methodology from the Bergmann document, closeness of hybrid model output 
turnover to input turnover was observed, allowing quantification of distortion caused by 
the hybrid modeling procedure. 
 
To determine inherent sensitivity of the Bergmann algorithm, a wide range of input 
turnovers was supplied to the hybrid model (as substitution for CM formation/destruction 
parameters) and output turnover for each input was reported.  The impact of 
polyploidization correction on turnover estimations for the 12 Bergmann subjects was 
performed by conducting simulations with scaled fractions of subject-specific 
polyploidization correction factors measured in the Bergmann document and reporting 
the outputted turnover estimation.  The impact of a delay in incorporation of atmospheric 
C14 into human tissue was performed by running the hybrid model with the bomb curve 
moved forward in time by the proposed delay.  Effect of initial C14 values on the hybrid 
model was performed by running the hybrid model with initial C14 levels (generally 
obtained from 1-year smoothing of atmospheric C14 readings obtained by Levin [7, 8]) 
with the minimal or maximal readings obtained during that 1-year period. 
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3.2.5 Turnover Models Simultaneously Compatible with Bergmann and Kajstura Data 
A global fit solver was produced to identify turnover parameter combinations most 
consistent with the ΔC14 measurements made by Bergmann.  To test the global fit 
solver’s equivalence to the Bergmann global fit solver, model regimes utilized by 
Bergmann were subjected to the hybrid model global fit solver and optimum parameter 
selection and mean squared error were compared to those reported by Bergmann.   
 
In one of the Bergmann models (denoted Scenario E2 by Bergmann), the best-fit 
parameters γ0 and γ1 were disregarded by Bergmann in favor of artificially restricted 
values to minimize the value of γ1, thus achieving maximal differentiation from the 
Bergmann constant turnover scenario (denoted Scenario A by Bergmann).  In our 
analysis, comparisons of the new models to the Bergmann E2 model utilize the 
parameters chosen by Bergman.  However, we find the best fit parameters for this model 
to be γ0 =0.45, γ1 =0.4, with a SSE of 29,793 (AIC=3.57) when ranges are γ0:{0, 0.5} at 
increments of 0.01 and γ1:{0,2} at increments of 0.05.   
 
An alternative model (denoted Time-Varying Birth Rate, Time Varying-Death Rate or 
“TVB-TVDR”), inspired by the Kajstura conclusion of subject age (time)-increasing 
turnover with subject age (time)-increasing vulnerability of newly formed CMs to 
apoptosis, was evaluated for quality of fit with the Bergmann ΔC14 measurements in the 
12 subject dataset from the Bergmann document.  The TVB-TVDR model was 
constructed of four independent parameters with CM formation dependent on Bs and Bi 
(forming a linear curve dependent on subject age) and Ds and Di determining an annual 
death rate experienced by CM formed in a given subject year: 
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Ranges of values for the TVB-TVDR (with fully independent variables) were as follows:  
Bs:{-1.0%/year
2, +1.0%/year2}, Bi:{0%/year, 10%/year}, Ds:{-1.0%/year
2, +1.0%/year2}, 
Di:{0%/year, 10% /year} with slopes (Bs, Ds) tested at increments of 0.05%/year
2 and 
intercepts (Bi, Di) tested at increments of 0.1%/year).  Notably, the parameter sweep 
included negative, constant, and positive temporal dependence.  Though the concept of 
subject age-dependent inferiority of newly-created CMs is conceptually derived from the 
Kajstura findings, single age-dependent CM formation/death rates were used in this 
model and thus no formulas, parameters, values, or assumptions from the Kajstura 
manuscript were used in this exercise.   
 
Parameterized model fits to the Bergmann end C14 measurements were compared by 
computing the Sum of Squared Error (SSE)--for each of the 12 Bergmann subjects, 
squaring the subtraction difference between the measured end C14 value and the 
model’s predicted value, then summing over all 12 subjects.  To compare models with 
differing numbers of parameters, the Akaike Information Criteria (AIC) score was 
computed according to the formula in the Bergmann manuscript—specifically, 
AIC=log2(SSE/10
4)+N, where N is the number of parameters.  Similarly to SSE, a lower 
AIC score indicates superior model fit. 
 
3.2.6 Hybrid Model Integration of Kajstura and Bergmann Models 
The 12 Bergmann subjects were modeled (i.e. models were created using birth date and 
lifespans equivalent to the Bergmann subject set) with input turnover dynamics as 
prescribed by Kajstura, Bergmann, or with turnover dynamics using best global 
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parameter fits to the Bergmann data (as identified by the global solver) to produce CM 
age histograms at time of modeled subject death.  Expected ΔC14 levels corresponding 
to each of these CM age histograms were then produced for comparison to the ΔC14 
observations made by Bergmann for these subjects.   
 
3.3 Results 
3.3.1 Hybrid Model Demonstrates Fidelity to Kajstura Model 
The Kajstura manuscript proposes two complementary modeling methods—a 
hierarchically-structured cell kinetics model (controlled by CSC cycling rates and CM 
apoptosis rates) and an age-structured cell kinetics model controlled by CM half-life and 
apoptosis rates).  We first verified that our hybrid model successfully reproduces the 
Kajstura hierarchically-structured model’s age-dependent rates of CM apoptosis, 
formation, and turnover results when the primary input parameters (enumerated 
schematically in Figure 3.2, Mode A), extracted from the Kajstura measurements, are 
incorporated (Figure 3.3).  We then validated the hybrid model’s ability to recapitulate 
the age-structured cell kinetics model, which is responsible for generating CM age 
distributions for modeled subjects in the Kajstura manuscript.  For any simulated subject 
(defined by turnover rates and a selected subject lifespan), the model generates an age 
distribution of CMs present in the heart at the end of the simulation (time of subject 
death).  These age distributions are also in excellent agreement with the Kajstura results 
for both genders (Figure 3.4).  Thus, the hybrid model outputs the Kajstura cell dynamics 
results when the Kajstura inputs are used, confirming that the model is a faithful means 
of probing the Kajstura analysis.   
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Figure 3.3.  The Hybrid Model Successfully Reproduces Kajstura Cell Dynamics Results 
from Kajstura Input Parameters.  A)  If cardiomyogenesis is removed from the model, the 
Kajstura CM count trajectories for male and female subjects decay identically with the trajectories 
reported in the Kajstura manuscript.  B)  Hybrid model myocyte formation for both male and 
females is identical to the temporal trend reported in the Kajstura manuscript.  C)  Hybrid model 
CM turnover for both male and females is identical to the temporal trend reported in the Kajstura 
manuscript.  Collectively, these results indicate that the hybrid model captures the Kajstura model 
dynamics and is functioning as intended. 
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Figure 3.4.  The Hybrid Model Successfully Reproduces Kajstura CM Age Distribution.  
Male and female distributions for young, middle-aged, and old subjects were extracted from the 
Kajstura manuscript via a pixel-counting method.  The hybrid model produced age distributions 
for these age groups for both genders.  The hybrid models are highly overlapping with the 
reported Kajstura results and are nearly identical in average CM age for the various age groups 
for both genders.  The trend towards sharper, younger distributions with advancing age is 
captured by the hybrid model for both genders.  These results indicate that the hybrid model is a 
reliable mechanism for modeling subjects using the Kajstura parameters. 
 
 
3.3.2 Parameter and Assumption Sensitivity in the Kajstura Model 
Manipulating this hybrid model in hierarchical-structure mode demonstrates the 
sensitivity of modeling conclusions to variation in input parameters.  Turnover estimates 
in the Kajstura model are exquisitely sensitive to estimates of the expansion exponent 
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(the number of cell divisions a CSC is expected to undergo before losing regenerative 
capability), with a 20% variance in this parameter causing a 200% variance in estimated 
turnover (Figure 3.5).  The Kajstura manuscript determined this expansion exponent by 
comparison of the relative abundances of CSCs to transit amplifying cells (classified by 
phenotypic markers) found in autopsy tissue.  Such phenotypic categorization into 
discrete progenitor cell populations likely oversimplifies a more complex lineage 
progression.  Further justification for investigation of this exponent comes from analyzing 
total CM counts over the course of a lifespan (accounting for proliferation and 
apoptosis).  For example, under the reported Kajstura parameters, modeled female CM 
count increases with age, peaks in middle age, and then decreases but does not fall to 
levels of youth.  Such a net increase in cardiomyocyte count is not consistent with the 
net decreases reported elsewhere [10].  Notably, applying a 20% decrease in the 
expansion exponent produces model hearts with a monotonically decreasing trajectory 
(Figure 3.6).   
Figure 3.5.  Sensitivity of the Kajstura Analysis Estimate of CM Turnover to the Expansion 
Exponent Variable.  The Expansion Exponent is the number of divisions that a Cardiac Stem 
Cell is expected to undergo before becoming senescent (non-replicative).  The hybrid model was 
tested with the value of the exponent (which changes with subject age and is gender-specific) 
decreased by 20% (E=80%) or increased by 20% (E=120%).  Acute sensitivity to the exponent is 
shown as a 20% variation in E results in a 2-fold change in turnover for A) Male and B) Female.   
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Figure 3.6.  Kajstura CM Count Trajectories and Sensitivity to Input Variables.  The number 
of CM in the heart is assumed to be 500 Million/10 gram tissue at age 20 (reported in the Kajstura 
manuscript).  The hybrid model is applied for male and female hearts while one variable is either 
at 80%, 100%, or 120% of the value reported in the Kajstura manuscript.  A)  The duration of 
apoptosis is varied (100% = 4 hours, based on literature maximum values for other cell types).  B)  
The duration of mitosis is varied (100% = 26 hours, in vitro cycling of CSCs observed by 
Kajstura).  C)  The expansion exponent—number of CSC divisions prior to loss of replicative 
ability—is varied.  CM count change with age (a function of CM formation and apoptotic 
destruction) is most sensitive to the Expansion Exponent.  Under parameters reported by 
Kajstura (E = 100%), modeled female hearts contain more CM per 10 grams in middle-age than 
at youth.  Reduction of the Expansion Exponent by 20% produces a monotonically decreasing 
CM count trajectory for females. 
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While the Kajstura turnover estimates are computed via the hierarchical-structured 
model using the expansion exponent and as a primary variable, the Kajstura CM age 
distributions are generated via the age-structured model using a CM half-life parameter 
that indirectly incorporates, though is separate from, the apoptosis duration parameter.  
This half-life is computed using a phenotyping technique similar to that used for the 
expansion exponent.  The effect of variation in this parameter on the CM age 
distributions is shown for young, middle-aged, and older modeled hearts in Figure 3.7.  A 
20% variation in this parameter will cause as much as a 45% variation in average 
cardiomyocyte age at time of subject death.   
 
Together, these analyses demonstrate that the CM turnover estimates in the Kajstura 
models are particularly sensitive to the magnitude of the expansion exponent (in the 
hierarchical model of CM turnover) and the CM half-life parameter (in the age-structed 
model of end-of-life CM age distributions). 
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Figure 3.7.  Sensitivity of CM Age Histograms for Young, Middle-Aged, and Old Subjects to 
Input Variables.  The hybrid model was run with either  A)  apoptosis cycle duration at 80%, 
100% (4 hours), or 120% of the value used in the Kajstura manuscript or  B)  CM half life at 80%, 
100%, or 120% (function of subject age) of the value used in the Kajstura manuscript.  80% 
values are indicated in red.  100% values are indicated in black.  120% values are indicated in 
green.  For both male and female modeled hearts, and for all age groups, decreasing apoptosis 
duration resulted in slightly younger CM age distributions, while increasing apoptosis resulted in 
slightly older CM age distributions.  Age distributions were more sensitive to half life (which 
indirectly incorporates apoptosis) and, for all age groups and both genders, decreasing half life 
resulted in younger distributions while increasing half life resulted in older distributions.  The 
effect of half life was most noticeable on younger model hearts.        
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3.3.3 New Considerations Applied to the Kajstura Model 
Turnover estimates in the Kajstura model are also affected by assumptions about 
changes in total CM number that are derived from average CM volume and apoptosis 
rates as a function of age.  When only changes in average CM volume are considered, 
estimates of turnover closely parallel rates of formation.  In fact, in the Kajstura plot of 
“annual turnover of myocytes” vs. subject age, dividing the regression line of the 
turnover plot by the regression line of the preceding CM formation plot indicates that a 
value of approximately 500 million CM per 10 g of tissue was employed by Kajstura et al.  
However, the Kajstura primary input parameters do not concur with an assumption of 
constant CM presence and instead lead to fluctuations with age (Figure 3.6, blue traces).  
When the number of CM present is allowed to fluctuate as dictated by the Kajstura 
model and measured parameters, and when turnover is defined as the number of new 
CM formed in a given year divided by the number of CM present at that year in the 
subject’s lifespan, turnover plots are as shown in Figure 3.8.  Interestingly, the age-
dependent decline in total CMs in male hearts amplifies the annual turnover in males 
while a net gain of CM suppresses the turnover rate in females.   
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Figure 3.8.  Apoptosis-Dependent Definition of CM Turnover in the Kajstura Model.  The 
hybrid model was parameterized in accordance with the Kajstura published values for Cardiac 
Stem Cell number, cycling frequency, mitosis duration, and expansion exponenent.  Turnover 
was computed as newly formed CM divided by either a constant CM density (5,000,000 CM per 
10 g tissue, as in the Kajstura publication) or a variable CM density determined by iterative 
production and destruction of CM using the aforementioned Kajstura CM formation parameters in 
conjunction with the Kajstura CM apoptosis parameters.  The simulation is performed for A) 
Males and B) Females 
 
35 
 
In turn, a time-varying CM count allows examination of the impact of CM apoptosis on 
turnover rate. Although the Kajstura manuscript empirically measures apoptotic rate 
using TUNEL staining, alternative estimations of apoptosis using similar techniques have 
reported discordant results.  One such study of human healthy human hearts by Mallet, 
et al found similar magnitudes of apoptosis but no age-dependency (although apoptosis 
was higher in males than females, in agreement with the Kajstura paper) [11].  A version 
of the model using Kajstura parameters with the apoptosis rate substituted by Mallet is 
shown in Figure 3.9; such parameterization generates relatively low annual CM turnover 
for males and females (below 5%) declining with age to 2%--a finding larger but 
substantially more concordant with the Bergmann conclusions though primarily driven by 
large net gains in CM count.   
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Figure 3.9.  Kajstura Turnover with Alternative Apoptosis Parameters.  The hybrid model 
was parameterized in accordance with the Kajstura published values for Cardiac Stem Cell 
number, cycling frequency, mitosis duration, and expansion exponenent, as well as either the 
Kajstura apoptosis parameters (red) or from an alternative estimation by Mallet (blue).  To include 
apoptosis (and thus, non-constant CM heart content) in the computation of CM turnover, turnover 
for a given year was computed as “newly formed CM in that year divided the CM density at that 
year as determined by preceding iterative production and destruction of CM,” rather than as 
“newly formed CM in year divided by a constant 5,000,000 CM/10 g tissue” as was done in the 
Kajstura manuscript.  The simulation is performed for A) Males and B) Females 
 
 
37 
 
The impact of varying the magnitude of apoptosis also merits consideration.   Peri-
mortem increases in tissue TUNEL staining becomes significant around 24 hours post-
mortem and can double the apparent apoptotic fractions (highly tissue dependent) [12].  
Alternatively, TUNEL staining has been shown to underestimate apoptosis (particularly 
when high levels of necrosis occur) with sensitivities ranging from 60-90% [13].  
Therefore, Figure 3.10 illustrates the impact of potential apoptosis variation in the 
Kajstura model.  The absolute rate of apoptosis has a roughly linear impact on turnover 
estimation.  Notably, at extremely small multiples of apoptosis fractions found by 
Kajstura (but with the same age-increasing trajectory), reported turnover in the Kajstura 
model becomes low and age-decreasing, albeit primarily dominated by a net gain in CM 
content that serves as the denominator in this formulation of the turnover definition. 
 
Figure 3.10.  Kajstura Model Turnover Conclusions under Various Apoptotic CM Fractions.   
The hybrid model was parameterized in accordance with the Kajstura published values for 
Cardiac Stem Cell number, cycling frequency, mitosis duration, and expansion exponent, as well 
as either the Kajstura apoptotic CM fraction as a function of time (A=1X) or some multiple of that 
parameter (A=0X, 0.25X, 0.5X, 1.5X, 2X).  To include apoptosis (and thus, non-constant CM 
heart content) in the computation of CM turnover, turnover for a given year was computed as 
“newly formed CM in that year divided the CM density at that year as determined by preceding 
iterative production and destruction of CM.”  The simulation is performed for A) Males and B) 
Females 
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3.3.4 Hybrid Model Demonstrates Fidelity to Bergmann Dataset 
The hybrid model, generally parameterized with CM formation/destruction parameters, 
produces CM age distributions for simulated subjects as described above.  If a subject 
birth date is also supplied, the hybrid model can cross-reference the birth years of all 
CMs remaining at the end of the simulation with atmospheric C14 levels at various 
points in history (reproduced in Figure 3.1), to calculate an associated ΔC14 for the 
simulation.  An age-dependent polyploidization compensation factor must also be 
supplied; this polyploidization compensation is a function of both the Bergmann/Adler 
data [14] for human poly-ploidization rate age-dependency and also the simulated CM 
formation/destruction rates (unique to each simulation).  A numerical solver then 
translates simulated ΔC14 values into annual turnover levels for any simulated subject 
under various model assumptions (such as constant or fluctuating turnover, independent 
or dependent formation/destruction rates, etc).     
 
The hybrid model fidelity to the Bergmann analytical system can be shown in a 3-part 
process outlined schematically in Figure 3.11.  Briefly, the subject-specific constant 
annual CM turnover rate and polyploidization rate measurements obtained by Bergmann 
were substituted as input for the cellular formation/destruction parameters.  Subject-
specific CM age distributions were built from this parameterization scheme, and 
subsequently, simulated end C14 levels were produced from these age distributions by 
cross-referencing historical atmospheric C14 levels.  Under these conditions, the hybrid 
model produced faithful estimates of end C14 (within 10% of the Bergmann measured 
raw values from autopsy, Figure 3.12A).  Furthermore, the hybrid model polyploidization 
compensator module, parameterized using the sigmoidal formula applied by Bergmann 
(derived from the Bergmann/Adler composite polyploidization measurements), performs 
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identical compensation to that applied by Bergmann (Figure 3.12B).  Finally, the 
numerical solver constructed for the hybrid model that converts subject-specific ΔC14 
values (obtained by subtracting initial C14 values, equivalent to atmospheric C14 at time 
of birth, from the end C14 modeled values) into estimates of annual CM turnover also 
functioned identically to the Bergmann system with no distortions, as shown by the 
solver’s ability to convert the simulated ΔC14 values into the original input turnovers 
(Figure 3.12C).  Thus the hybrid model application to C14 data provides an excellent 
representation of the Bergmann analytical system without distortion. 
 
Figure 3.11.  Hybrid Model Validation Strategy.  To demonstrate hybrid model fidelity to the 
Bergmann system, the hybrid model CM formation/destruction inputs were substituted with the 
constant turnover levels concluded by Bergmann.  When the hybrid model’s polyploidization 
function is disabled, the hybrid model computed ΔC14 levels expected to be produced by such 
stipulated turnover (these values may be compared to the non-polyploidization-corrected values, 
i.e. raw measured values obtained by Bergmann [Bergmann Fig 3A/3B] for closeness).  Similarly, 
when the hybrid model’s polyploidization function was enabled, the hybrid model computed ΔC14 
levels expected to be produced by such stipulated turnover (these may be compared for 
closeness to Bergmann’s post-ploidy corrected ΔC14 values [Bergmann Fig 3D]).  If both tests 
report similar C14 values to those reported by Bergmann, than the model introduces no unwanted 
distortions in the development of CM age histograms or in computing C14 values from them.  
Also, if both tests conform to Bergmann, than the hybrid model compensates for polyploidization 
identically to Bergmann.  Furthermore, non-polyploidization-corrected C14 values can be fed into 
the hybrid model’s numerical solver (which has a polyploidization correction module equivalent to 
that used to test the aforementioned points), and the resulting turnover conclusions can be 
compared with the Bergmann concluded turnover results to validate that no distortions are 
caused by the numerical solver. 
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Figure 3.12.  Hybrid Model Validation Results.  The validation strategy described in Figure 
3.11 is applied.  When the Bergmann final concluded turnover levels were used as the hybrid 
model input, the hybrid model created simulated hearts for each subject (displayed individually 
from oldest on the left to youngest on the right) and estimated final average C14 content based 
on the age histograms produced for each subject under these turnover conditions.  A) The raw 
C14 measurement produced matched those in the Bergmann manuscript.  B) The hybrid model 
then computed C14 attributable to poly-ploidization, which again matched the Bergmann 
conclusions.  C)  After compensating for poly-ploidization, the Hybrid Model’s numerical solver 
converted C14 values into annual turnovers which matched the initial parameterization values. 
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3.3.5 Parameter and Assumption Sensitivity in the Bergmann Model 
Because the polyploidization correction factor is used to directly minimize the concluded 
annual turnover level, precision in this estimate might be important.  In fact, other studies 
provide diverse, generally reduced values for poly-ploidization in healthy adults [15-18].  
In one representative study by Takamatsu et al, human age-dependent polyploidization 
was found to follow a sigmoidal time course with poly-ploidization essentially completed 
during adolescence and ultimately resulting in an average cardiomyocyte DNA content 
of approximately 3.0n (with diploid counted as 2n) [19].  In comparison to Takamatsu, 
the Bergmann/Adler dataset shows a similar temporal sequence but an ultimate average 
cardiomyocyte DNA content of approximately 3.8n.  Substituting the a poly-ploidization 
correction based on the Takamatsu data (about 20% less than the Bergmann correction 
factor), rather than using the more severe Bergmann correction, would results in a 
modest 25% increase in the Bergmann turnover estimates for younger subjects from 
1.3%±0.2% annually under the Bergmann estimate to 1.6%±0.1% under the Takamatsu 
estimate, p<0.15), while estimates of turnover for the 4 oldest subjects, born such that 
polyploidization occurred prior to the atmospheric C14 spike, are largely unaltered 
(Figure 3.13A).   As true poly-ploidization magnitude is disputed, a more complete 
analysis of the impact of polyploidization magnitude is provided in Figure 3.13B, which 
plots the subject-specific concluded turnover resulting from a range of polyploidization 
scaling (from 0%, ie no polyploidization, to 200% of the Bergmann/Adler values).  In 
general, increases in assumed polyploidization levels result in lower estimates of 
turnover and the effect is linear for most subjects, but does depend on the unique timing 
of the subject’s life within the atmospheric C14 level trace. 
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Figure 3.13.  Cardiomyocyte Turnover Estimates using Bergmann Approach and Dataset 
with Bergmann Various Poly-ploidization Correction Factors.  A) Takamatsu et al concluded 
a poly-ploidization level approximately equal to 78% of the level concluded by Bergmann with 
nearly identical age progression.  Substituting a poly-ploidization correction factor based on the 
Takamatsu conclusion to the Bergmann ΔC14 dataset yields modestly higher estimates of 
turnover that concluded by Bergmann for subjects born after the rise in atmospheric C14 
(1.3%±0.2% by Takamatsu versus 1.6%±0.1% by Bergmann, p<0.15).  The substitution of 
Takamatsu correction factor has no impact on the 4 modeled subjects born prior to 1950 because 
poly-ploidization largely completes prior to C14 atmospheric rise for these subjects 
(0.18%±0.08% by Takamatsu versus 0.15%±0.09%).  B) A wide range of poly-ploidization 
magnitudes (with unchanged age relationship) are applied to the hybrid modeled subjects.  A 
scaling of 100% is equivalent to the Bergmann values used by Bergmann, whereas 200% is 
equivalent to twice the level of ploidization and 0% indicates an assumption that poly-ploidization 
does not exist.  In general, there is a negative linear relationship between concluded turnover and 
poly-ploidization correction.  The turnover estimates for the 3 oldest subjects, having completed 
adolescence prior to the rise in atmospheric C14, are not dependent on poly-ploidization 
correction (not shown). 
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3.3.6 New Considerations Applied to the Bergmann Model 
The Bergmann manuscript makes the simplifying assumption that C14 incorporated into 
DNA corresponds instantaneously to the atmospheric concentration at the time of cell 
formation.  However, this assumption is questionable in light of a study by Broecker et al 
that analyzed C14 incorporation into the food supply and human tissue.  Broecker 
concluded a delay, dependent on diet, of up to 2 years [20].  Such a delay substantially 
affects turnover levels in subjects meeting both of two criteria: (1) true turnover is low 
(~1% annually) such that hearts at time of subject death are substantially composed of 
original CMs and (2) subjects are born in a time of rapidly changing atmospheric C14 
such that a small delay results in substantially different initial C14 values.  Thus, while 
the older (pre-bomb subjects) are largely unaffected by delays of atmospheric C14 
incorporation into CM DNA, younger subjects are highly susceptible; a 2-year delay can 
result in a nearly 5-fold change in turnover for some subjects.   Among the 5 youngest 
subjects in the Bergmann dataset, a 2-year delay causes average turnover conclusion to 
increase from 1.4%±0.1% to 5.7%±0.8%, p<0.001 (Figure 3.14A).   
 
Similarly, the atmospheric C14 measurements from the Levin dataset [7, 8] show wide 
monthly variations that indicate the variability of the metric.  As a further illustration of the 
sensitivity of C14 tracer studies to initial conditions, the hybrid model was seeded with 
initial C14 values for each subject taking on either the highest or lowest atmospheric 
C14 measurement obtained within 12 months of subject birth and results are shown as 
error bars upon the concluded turnover obtained when the 1 year smoothing function is 
applied (Figure 3.14B); extreme fluctuation is observed ranging in nearly all subjects 
from 0% annual turnover to several multiples of the smoothed-C14 conclusions. 
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Figure 3.14.  Hybrid Model Simulations for the Bergmann Subject Dataset under Various 
Initial C14 Incorporation Assumptions.  A) The hybrid model was parameterized with turnover 
levels as concluded by Bergmann to generate an assumed CM age histogram at time of autopsy.  
The hybrid model then determined an associated ΔC14 for each surviving CM in each modeled 
subject under the assumption that atmospheric C14 is either instantly incorporated into newly 
formed CM DNA or that there is a 2-year delay (such that CM DNA C14 concentrations are equal 
to the atmospheric concentration 2 years prior to CM formation).  The numerical solver was used 
to derive corresponding turnover levels (assuming constant turnover) from computed ΔC14 
values.  B) The hybrid model was parameterized with turnover levels as concluded by Bergmann 
to generate an assumed CM age histogram at time of autopsy.  The hybrid model then 
determined an associated ΔC14 for each surviving CM in each modeled subject under the 
assumption that atmospheric C14 is instantly incorporated into newly formed CM DNA.  However, 
initial C14 levels (specifying the C14 content of initial CMs, which comprise the bulk of CMs 
present at time of autopsy in low turnover models), were assigned C14 levels equal to either (1) 
the 1-year smoothed atmospheric C14 level at time of subject birth, or (2) the lowest C14 level 
measured by Levin within 1 year of subject birth, or (3) the highest C14 level measured by Levin 
within 1 year of subject birth.  Subject ΔC14 levels were then computed and the numerical solver 
was used to derive corresponding turnover levels (assuming constant turnover).  The turnover 
levels derived from smoothed C14 measurements are shown as blue bars, with the turnover 
levels produced by using minimal and maximal atmospheric C14 levels as initial C14 levels are 
shown as error bars. 
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The 3 oldest subjects (ND60, ND67, and ND73) in the Bergman dataset are interesting 
for several reasons.  The analysis of these subjects, born in 1933, 1939, and 1944 
respectively, are independent of complications from polyploidization and initial C14 
levels as the increase in atmospheric C14 takes place after their adolescence.  
Bergmann deduced, based on the fact that the measured end C14 values for these 
subjects is lower than contemporary atmospheric conditions, that a large fraction of CMs 
produced either at birth or shortly after (prior to the atmospheric C14 spike), must persist 
until death.  Accordingly, these subjects were computed to have undergone very low 
annual turnover rates of 0.10%, 0.09%, and 0%, respectively, by Bergmann (under the 
Bergmann “Scenario A” constant turnover scenario).  For example, the meaning of this 
metric suggests that for the oldest subject, during each year from birth to death, 0.10% 
of CMs were replaced at random by newly-formed CMs; at the end of the subject’s 73 
year lifespan, 90% of original CMs would remain and the 10% of CMs that were created 
post-birth contain the necessary C14 to raise the measured average level to 21.30.   
 
However, the younger subjects (aged 19-43 at time of death) all report average annual 
turnover values ranging from 1-2%.  In contrast to the Scenario A assumptions, a true 
model of turnover ought to require that older subjects go through a phase in youth that is 
similar to that of the youthful subjects, i.e. that subjects ND60, ND67, and ND73 each 
experienced phases of their lives (at least from age 0-40) where turnover was on the 
order of 1-2% annually.  Such turnover levels, even allowing turnover to cease entirely at 
age 40, would have reduced the final contribution of initial CMs in these 3 subjects to 
65% of the total CM count, substantially less than the claimed approximately 90% under 
Scenario A.  Indeed, such turnover would lead to ΔC14 values of 62, 77, and 84 per mil 
(final average C14 less initial at birth), far greater than the measured 21.3, 18.84, and 
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3.65.  Allowing turnover to continue beyond year 40 actually serves to partially reconcile 
the simulated ΔC14 values with the paradox by allowing for elimination of the high-C14 
CMs generated during the atmospheric C14 spike, with increasing turnover providing 
better agreement (although, as contemporary C14 levels never fall below the observed 
ΔC14 results, no amount of turnover can fully resolve this paradox).   
 
Bergmann also highlights a modified version of Scenario A in which total cell count is 
again constant (full CM replacement) but turnover can change with subject age.  The 
global solution (derived from C14 measurements in all 12 subjects) was: 
                                            
However, for all 3 of the eldest study subjects, ΔC14 measurements should have 
exceeded 100 per mil (101, 110, and 116 for ND60, ND67, and ND73, respectively) 
according to this model, several multiples above the observed.   This model also 
demonstrates the inherent incompatibility of C14 measurements in the oldest subjects 
with C14 measurements in the younger subjects. 
 
Another notable phenomenon occurs for subjects born before the atmospheric C14 
spike; at a certain patient-specific value of measured ΔC14, the numerical solution 
bifurcates creating a satisfactory low and high solution.  Beyond the bifurcation point, the 
low solution reports a turnover estimate of 0.75%, whereas the high solution remains 
approximately truthful to the ideal at all turnover levels.  This effect is illustrated in Figure 
3.15 where annual CM turnovers ranging from 0-40% are used as the sole input to the 
hybrid model.  The hybrid model then computes estimated ΔC14 for each subject under 
each turnover input scenario and then solves for a best-fit constant turnover solution 
using either using either the low or high solution.  While the measured ΔC14 for subjects 
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born before the C14 spike is below the threshold needed to make a high solution viable, 
the high solution becomes viable at surprisingly low ΔC14 measurements (approximately 
60 per mil), lower than the ΔC14 measurement that could have been expected in these 
subjects from the global Scenario A best-fit data (by which Bergmann concluded 1% 
annual turnover).  These facts exist independent of complications from polyploidization 
as the simulation was conducted using input parameter turnover assumed to be true (i.e. 
with polyploidization appropriately compensated for, regardless of its true value).   
 
Figure 3.15.  Simulations Derived from Applying Pre-specified Annual CM Turnover Rates 
to Bergmann Model Analysis Method.  A model was produced for each of the 12 Bergmann 
subjects (defined by their lifespans and birth years).  Instead of cycling dynamics parameters 
from the Kajstura manuscript, true constant annual turnover was specified as input (Figure 3.2 
Mode B). The category “Older Subjects” includes ND60, ND67, ND73, ND61, and ND51 from the 
Bergmann study, while the category “Young Subjects” includes ND56, ND68, ND50, ND69, 
ND71, ND54, and ND74.   When true turnover input is high (beginning at 4%/year and fully 
apparent by 10%/year), the resulting ΔC14 has two numerical solutions—a low solution (plotted in 
A) and a high solution (plotted in B).  The high solution tracks the true (ideal) input whereas the 
low solution asymptotes at 0.75%/year.  Although the ΔC14 levels obtained by Bergmann for 
older subjects (~20 per mil) are too low for the high solution to be enabled (~60 per mil, not 
shown), this graph illustrates that, for measured ΔC14 exceeding a certain discrete threshold, a 
bifurcation point exists such that adoption of the low solution leads to insensitivity. 
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Alternatively, the scenario ultimately favored by Bergmann, denoted “Scenario E2,” 
allowed CM destruction rates to be inversely proportional to CM age while time-varying 
CM formation rates balanced destruction to keep a constant total CM count.  
Formulaically, the model is represented below (where t represents the subject age and a 
represents the age of a given CM: 
Time Dependent CM Formation Rate: 
                      
 
 
         
 
 
             
 
 
      
Age Dependent CM Destruction Rate: 
      
    
      
  
In this model, younger CM (when the CM’s a is low regardless of the subject year t in 
which it was formed) are destroyed more frequently than CM that have persisted to an 
older age a. 
 
This model, when fitted with γ0 = 0.123 and γ1 = 1.42 as dictated by Bergmann, yields 
turnover values with magnitude and age-dependency similar to Scenario A.  The 
expected end C14 values for ND60, ND67, and ND73 under this scenario are 58, 68, 
and 82, respectively, which mitigates the inconsistency but still drastically exceeds the 
measured values. 
 
Combining (1) the fact that the low measured C14 values observed in the 3 oldest 
subjects (used by Bergmann to eliminate the high solution) are incompatible with 
measured C14 values from the younger subjects with (2) the fact that a high turnover 
solution becomes viable with unexpectedly low C14 measurements—not substantially 
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higher than was actually observed, a high-turnover scenario for elderly subjects 
becomes reasonable.  
 
3.3.7 Models Simultaneously Compatible with Bergmann and Kajstura Datasets 
The prior results demonstrate that both models have reasonable uncertainty in 
concluded turnover estimates.  In the Kajstura manuscript, these uncertainties stem 
primarily from strong sensitivity to primary input variables (particularly ones that can only 
be measured indirectly).  In the Bergmann manuscript, uncertainty arises both from a 
conspicuous inconsistency in data from old versus young subjects and also from 
assumptions regarding the incorporation of atmospheric C14 into CM DNA.  In section 
3.3.7, we attempt to vary key input parameters and modify tenuous model assumptions 
to find scenarios that are simultaneously compatible with both datasets. 
 
The Bergmann manuscript applied 8 separate scenarios (defined by the way in which 
parameters are assumed to fluctuate relative to each other, to subject age, and to CM 
age in various combinations) to the dataset of 12 subjects.  Bergmann performed a 
global regression analysis to determine which turnover parameters best fit the measured 
ΔC14 data for each scenario.  Reported turnover levels were obtained from the 
optimized parameters for the scenario that best fit the observed ΔC14 of the 12 subjects.     
 
To test new models beyond the original 8 evaluated by Bergmann, we constructed a 
global numerical solver that allows all linear turnover solutions to be evaluated.    The 4-
parameter generic model, denoted as the Time-Varying Birth Rate/Time Varying-Death 
Rate (TVB-TVDR) model, assumed a linear dependence of CM formation rate and CM 
annual destruction rate on subject age (where death rate controls not the fractional 
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destruction of CM at Subject Age, but the rate at which CM produced at that Subject Age 
will be destructed annually such that CM formed at different times may be destroyed at 
different rates), thus generating the parameters Bs, Bi, Ds, and Di as shown: 
                                              
                                        
In this construction, the annual CM formation rate at birth is given by Bi, and is increased 
or decreased to a new value in each subsequent year as dictated by the value of Bs.  
Thus, in a linear model, Bi is the “Intercept” and Bs is the “Slope with respect to subject 
age.”  Each CM, once formed, is assigned an annual death rate dependent on the year 
of the subject’s life in which it was formed such that a cohort of CM formed during a 
certain year of a subject’s life will be fractionally depleted (as determined by that cohort’s 
computed Annual Death Rate, which has a slope Ds and intercept Di) in each 
subsequent year of subject life.  Notably, this model differs conceptually from the 
Bergmann’s E2 model, which allowed each CM (regardless of when it was formed in the 
subject’s life) to experience a death rate dependent on the age of the CM.  To clarify, the 
Bergmann E2 model assumes that every CM experiences an identical “death likelihood 
trajectory” regardless of how old the subject was at the time of formation whereas the 
TVB-TVDR model assumes that CM formed at different times in the subject’s life are 
fundamentally different (experience different annual death rates). 
 
To verify the fidelity of the numerical solver and thus justify its ability to compare the best 
fit of models from the Bergmann manuscript to new, less-restrictive TVB-TVDR models, 
we recapitulate various Bergmann models and demonstrate that our solver produces 
identical best-fit results.  For example, in the constant turnover scenario (Scenario A, 
Bergmann Supplement), where Myocyte Formation Rate(%) = Annual Death Rate(%) by 
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assumption, the solver computed a best-fit annual turnover rate of 0.99% (Bs = Ds = 0, Bi 
= Di = 0.99%) with a sum of squares error (SSE) of 45,168—highly comparable to the 
Bergmann solver’s result of 1.0% with an SSE of 27,770.  As another example, the 
solver also computed a best-fit CM formation rate of 1.3% with best-fit destruction rate of 
0.0%, SSE = 43,376, for Bergmann’s Scenario B—the regime where CM birth and 
destruction rates are constant but not necessarily equal— in which Bergmann concluded 
identical rates of 1.3% and 0.0% with SSE = 27000).   
 
Of the 8 scenarios tested by Bergmann, no model allowed CM formation rate to change 
with subject age while simultaneously allowing new CMs to experience destruction rates 
dependent on subject age at time of formation.  Because the Kajstura data suggests that 
CM formation increases with age, but that CMs formed in advanced age are shorter-
lived, we evaluated such a model using the global solver by allowing all 4 parameters of 
the TVB-TVDR to vary independently (notably, TVB-TVDR parameter sweeps allowed 
for positive, constant, and negative age-dependency and used no data, methods, or 
influences from Kajstura aside from this conceptual rationale).  To compare the fit quality 
of models with different numbers of parameters, we compute the Akaike Information 
Criteria (AIC) value for the Sum of Squared Error (SSE) associated with each model 
using the formula employed by Bergmann; this formula essentially penalizes models with 
many parameters to give an adjusted fit values (with low AIC scores suggesting better 
fit). 
 
The global best fit for the TVB-TVDR model was Bs = 0.10%, Bi = 2.5%, Ds = 0.5%, Di = 
1.0% and SSE = 5589 (AIC=3.16)—a scenario of age-increasing turnover but where CM 
created at late subject age are destroyed more quickly than predecessor CM.  This and 
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other scenarios (not shown) report superior AIC scores than the constant turnover 
scenario (Scenario A) of (Bs = Ds = 0, Bi = Di = 0.99%), which yielded AIC=3.18 in the 
Hybrid Model.  Similarly, the TVB-TVDR model achieves better fit than Bergmann’s 
preferred model of Cumulative Survival with Cell Replacement Inversely Proportional to 
Cell Age (denoted as “E2” in the Bergmann supplementary information), which yielded a 
SSE of 29,578 (AIC=3.56).  The end C14 values produced by the best-fit TVB-TVDR 
model are greatly superior for each subject (including the critically important most elderly 
3 subjects) than either the Bergmann or Kajstura models (Figure 3.16).   
 
 
 
 
 
 
 
53 
 
 
Figure 3.16.  Performance of Various Model Scenarios.  A) Representative CM age histogram 
for oldest Bergmann subject (ND70) under Kajstura, Bergmann Scenario E2, Bergmann Scenario 
A, and TVB-TVDR best-fit models. Age distribution is bimodal in the Best Global Fit TVB-TVDR 
model with a cohort of original CMs persisting until death, bolstered by low death rate and high 
initial representation, and young CMs produced due to high rates and having undergone few 
annual death cycles. B) Representative CM age histogram for youngest subject (ND74).  C) 
Expected end C14 (time of autopsy) measurements for the various scenarios (Bergmann 
measured values supplied for reference).  The TVB-TVDR model, by selective depletion of 
intermediate CMs, fits both older and younger subjects well despite having a comparatively high 
(with regards to the Bergmann conclusions) turnover of 4.5% increasing to 15% by age 70.  The 
Bergmann models (E2 and A) capture the general temporal pattern but shows substantial 
deviations numerically; particularly for the oldest 3 subjects which are the lynchpin of the low 
turnover solution hypothesis.  The Kajstura turnover actually fits older subjects better than the 
constant turnover scenario due to the elimination of CM produced during the highest atmospheric 
C14 concentrations, but fails to match younger subjects as the high turnover drives all Kajstura 
predicted C14 levels to peri-mortem levels.  Error bars represent the simulated end C14 
concentrations for each subject when either the lowest or highest initial atmospheric C14 (within 1 
year of time of subject birth) levels are used (except for the Kajstura model, which has no 
sensitivity to initial C14 concentration due to obliteration of nearly all initial CMs; for this model 
set, the primary variable “CM Half Life” is varied to 80% or 120% of values concluded by 
Kajstura).  *Of interest, the best fit TVB-TVDR model (age-increasing CM formation) would 
increase total CM in adolescence to a peak of 130% of initial count (birth) by age 20, which would 
then decrease to 87% of count at birth by year 70 (not shown).   
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Figure 3.17 describes the relationship between CM turnover and subject age.  The TVB-
TVDR best fit model is parameterized as described and polyploidization correction is 
performed as according to the Bergmann estimates.  Notably, no Kajstura turnover 
dynamics are incorporated in the creation of the TVB-TVDR dataset.  The best fit model 
(with age-increasing turnover) is displayed as a solid blue line.  The zone of best-fit TVB-
TVDR parameter solution sets compatible with Bergmann datasets is determined by 
repeating the computation while substituting the initial C14 values for each subject with 
either the higher or lower of initial C14 values found within 1 year of the subject’s birth, 
thus roughly illustrating precision.  Turnover is defined as the number of new CM formed 
in a given year divided by the number present in the heart at that year (though the exact 
initial count is numerically irrelevant and can be scaled without affecting the 
computation).  
 
For comparison, the Kajstura turnover estimation using the adjusting turnover definition 
is also shown in Figure 3.17 with variations to its key parameters.  Variation in apoptosis 
frequency rate affects turnover conclusions primarily in aged subjects with little influence 
in youth (Figure 3.18).  Alternatively, variation in expansion exponent affects turnover 
conclusions primarily in youthful subjects and does not influence turnover conclusions at 
old age (Figure 3.19); while the expansion exponent drastically affects CM formation at 
all ages, particularly in old age (Figure 3.5), this effect is roughly offset by cumulative CM 
count changes (Figure 3.6) yielding little impact on turnover.  While Figures 3.18 and 
3.19 explore the variable sensitivity in a gender-specific manner, Figure 3.17 displays a 
gender-composite computation for comparison to the Bergmann simulations. As the 
original Bergmann manuscript amalgamated data from 9 males and 3 females, the 
Kajstura best estimate trajectory shown in Figure 3.17 is also computed as the weighted 
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composite of the male (75% weight) and female (25% weight) turnover trajectories (red 
solid line) with variations in parameters also plotted. 
 
When both models incorporate reasonable estimates for variations in their primary 
parameters (CM Apoptosis Rate and Expansion Exponent for Kajstura, Initial C14 
parameter for Bergmann), a region of agreement emerges.  Figure 3.17 suggests that 
initial turnover levels of 4-6%, increasing with age to 15-22%, are compatible with both 
datasets.  
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Figure 3.17.  Impact of Assumptions and Parameter Measurement Uncertainty on Two 
Independent Models of CM Turnover.  Turnover rates derived from Kajstura data plotted (red 
solid) with a range of reasonable uncertainty created by varying the primary model variables (CM 
Apoptosis Frequency “A” and Expansion Exponent, “E”) simultaneously by ±20% (red dashed) 
under the adjusting CM count scenario (wherein the number of CM cells varies in time according 
to the computed CM formation/destruction rates) with gender weighting as equivalent to the 
gender-weighting of the Bergmann dataset (75% male, 25% female).  Turnover rates derived 
from Bergmann data, when conclusions from the TVB-TVDR model, parameterized by optimum 
fit to the 12 Bergmann subjects ΔC14 data, are shown (blue solid) with a range of reasonable 
uncertainty created by performing the TVB-TVDR global fit function with initial C14 levels either 
set to the lowest or highest within 1 year of each subject’s birth (blue dashed).  A region of 
overlap, indicating turnover levels consistent with both the Bergmann and Kajstura datasets, is 
indicated in purple. 
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Figure 3.18.  Sensitivity of the Kajstura Analysis Estimate of CM Turnover to the Apoptosis 
Fraction Variable.  The Apoptosis Fraction is the measured percent of CM observed to be 
undergoing apoptosis at any given point in time. The hybrid model, under the adjusting turnover 
definition, was tested with the value of the fraction (which changes with subject age and is 
gender-specific) decreased by 20% (A=80%) or increased by 20% (A=120%).  Sensitivity to the 
parameter A seems to be greatest when considering subjects of advanced age.  Simulations 
were run for A) Male and B) Female.   
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Figure 3.19.  Sensitivity of the Kajstura Analysis Estimate of CM Turnover to the 
Expansion Exponent Variable. The Expansion Exponent is the number of divisions that a 
Cardiac Stem Cell is expected to undergo before becoming senescent (non-replicative). The 
hybrid model, under the adjusting turnover definition, was tested with the value of the fraction 
(which changes with subject age and is gender-specific) decreased by 20% (E=80%) or 
increased by 20% (E=120%).  Sensitivity to the parameter E seems to be greatest when 
considering subjects of youthful age whereas in advanced age, changes in CM formation are 
roughly compensated for by changes in cumulative cell count. Simulations were run for A) Male 
and B) Female.   
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3.4 Discussion 
Kajstura et al concluded that younger subjects experience turnover of approximately 5-
8% (with no statement about turnover during childhood up to 20 years of age).  
Bergmann et al concluded a turnover rate of 1-2% for these younger subjects, a result 
not far removed from Kajstura when consideration of axioms, methods, and parameter 
sensitivity are included (Figures 3.5-3.10, 3.13, 3.14).   
 
Discrepancy arises primarily in the older subjects, where Kajstura concludes age-
increasing turnover (approximately 20% in aged males, higher in females), Bergmann 
concludes age-decreasing turnover (approximately 0.5%).  The definition of the turnover 
formula itself is open to interpretation.  In the Kajstura paper, a constant baseline value 
of CM content (which becomes the denominator in the formula “Turnover = CM 
Formation/CM Content)” is used for subjects of all ages thus allowing turnover plots to 
be wholly dictated by CM formation rates.  However this constant value is inconsistent 
with the measured CM formation and destruction parameters obtained by the Kajstura 
experiments.  When the heart CM content is allowed to fluctuate as dictated by the 
Kajstura parameter measurements, apoptosis enters into the turnover computation 
(Figures 3.9, 3.10).  Moreover, though the Kajstura age-increasing CM apoptosis rates 
are supported by their empirical data, alternative datasets from other laboratories have 
found similar CM apoptotic rate magnitudes with no evidence of age correlation.  When 
such alternative apoptosis rate data sources are substituted into the Kajstura model, 
age-dependent CM depletion does not occur and thus a fluctuating-denominator 
interpretation of turnover indicates age-decreasing turnover down to levels of 
approximately 2%. Notably this circumstance only arises in scenarios where net CM 
count increases dramatically with age, a circumstance uncorroborated in existing 
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literature.  Similarly, peri-mortem increases in apoptosis and imperfect sensitivity of the 
TUNEL staining assay may further have confounded estimations of apoptosis; extreme 
apoptosis over-estimation by Kajstura could potentially have masked lower levels of 
turnover particularly in older subjects.  While the question of proper apoptosis valuation 
persists, this examination demonstrates the strong impact that subtle and often over-
looked differences in definitions of terms and in parameter selection has on iterative 
mathematical models. 
 
Similarly in the Bergmann model, the assumption of instantaneous incorporation of 
atmospheric C14 into human tissue, which is not supported by prior studies [20], may 
have caused an underestimation of turnover in young subjects.  Regarding aged 
subjects, Bergmann makes the logical deduction that end C14 measurements for the 3 
oldest subjects, which are below atmospheric C14 levels at all points after the rise in 
atmospheric C14, implies that a large number of initial CM (created peri-natal) must 
persist to the end of subject life.  Bergmann goes on to deduce that a large number of 
initial CM surviving to death implies low turnover rates throughout life; however a linear 
model that allows high and age-increasing turnover can also preserve peri-natal CMs by 
allowing newly-formed CMs to experience a higher rate of destruction than older CMs.  
Indeed, such a model provides superior fit both globally and for each individual subject in 
the Bergmann dataset than is achieved by constant turnover scenarios, while also 
producing reasonable associated trajectories for total CM count.    
 
An additional insensitivity effect may have contributed to the conclusion of low-turnover 
in advanced age.  The ability of high-turnover scenarios to fit low ΔC14 observations for 
subjects born before the spike in atmospheric C14 may appear paradoxical, but high 
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turnover solutions in general can decrease expected ΔC14 measurements by eliminating 
CMs containing copious amounts of C14 absorbed during the atmospheric C14 peak.  
Such an effect is manifested in Figure 3.15, which shows that annual turnover beginning 
at 4% would generate ΔC14 values that would support two solutions—a low solution and 
a high solution.  Thus, at surprisingly low ΔC14 measurements, the appropriate level of 
turnover to conclude from such measurements exhibits a bifurcation—a radically higher 
solution can be appropriate for a modestly higher ΔC14 measurement.  If the Bergmann 
measurements for the 3 eldest subjects are accurate representations of true CM DNA 
content at time of death, then this high solution is irrelevant as C14 levels never decline 
below the measured ΔC14 values during the lifetimes of these subjects.  However, the 
credibility of these low measurements is made suspect by the fact that ΔC14 
measurements from the younger subjects imply turnover levels that ought to (under a 
low turnover scenario), have produced drastically higher ΔC14 values than were 
observed in these older subjects.   
 
Any statistical variance in either the Bergmann analysis (possibly resulting from the 
widely fluctuating atmospheric C14 levels) or from the Kajstura modeling process (which 
invokes in vitro estimations of cellular proliferation, differentiation, and apoptosis as well 
as a discrete hierarchical progression of CM differentiation, could blur the conclusions of 
turnover magnitude and age-dependence.  Furthermore, inherent model assumptions, 
such as the age at which turnover is assumed to begin, variance of turnover with subject 
age, variance of CM apoptosis likelihood as a function of CM age, and many others can 
dramatically alter model results without being directly testable.   
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Several scenarios achieve similar fit to the Bergmann C14 measurements; however the 
TVB-TVDR model emerges as the best-fitting scenario with global best fit parameters 
fitting the end C14 values of each subject better than either the Bergmann or Kajstura 
models without invoking unreasonable total CM count trajectories (Figure 3.16).  
Notably, the TVB-TVDR model, in many best-fit and near-best-fit parameter solution 
sets, also concurs with the conclusion reported by Kajstura that CMs formed later in life 
experience diminished longevity compared to predecessor CMs, despite the fact that no 
Kajstura data was used to obtain these solutions.   
 
When attempts are made to incorporate reasonable measurement and assumption 
uncertainty into the Bergmann and Kajstura models, a range of turnover parameters 
emerges that are compatible with both datasets—specifically, that turnover in the healthy 
human heart is approximately 4-6% in youth increasing to 15-22% with advancing age.   
 
While the primary objective of the present study is to rigorously investigate the intricacies 
of the mathematical models used in both studies, additional complications regarding the 
biological methodologies have been proposed both by authors affiliated with the 
Bergmann and Kajstura manuscripts [21-23] and also by independent investigators [24, 
25].  These additional factors may further obscure conclusions derived from these 
mathematical models. 
 
Potential underestimation notwithstanding, the exploitation of atmospheric C14 flux to 
permit a novel C14 tracer analysis of the human heart represents a seminal contribution 
to the growing acceptance that some level of effective cardiomyogenesis contributes to 
the homeostasis the nondiseased human heart.  At the same time, studies 
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characterizing the varied progenitor and CM phenotypes within a large number of 
nondiseased of adult human hearts confirm, extend, and refine the evolving conclusions 
about human CM turnover as a function of age.  Both studies rely heavily on 
mathematical models with inherent assumptions in both the model structure and the 
parameter precision.  Our analysis highlights the need to explore these assumptions 
under various axiomatic regimes to evaluate their impact on the final results.  When such 
considerations are applied to these two estimates of cardiomyogenesis, we find a 
reasonable mechanism (“subject-age-at-time-of-formation”-dependent CM death rates) 
capable of reconciling the apparent discrepancies of the turnover estimates.  
Recognizing the ongoing need to investigate assumptions in mathematical models of 
turnover, especially as we examine datasets derived from diseased-hearts, we have 
provided our full Java program in the supplement to facilitate such exploration, with 
coding options present to test various inherent premises. 
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CHAPTER 4 
4.  Injury-Dependent Progenitor Cell Engraftment Mediated by P-selectin 
 
4.1 Introduction 
Prior dogma asserted that the heart is a terminally differentiated organ with no capacity 
for generating new cardiomyocytes.  However, recent evidence indicates that 
cardiomyocyte formation occurs throughout life [1, 2].  Furthermore, fate-mapping 
studies in mice likewise suggest low level cardiac myogenesis at baseline that is 
enhanced following myocardial infarction or sustained pressure overload [3].  In failing 
human hearts, Kubo et al showed that myogenic c-kit+ progenitor cells are enriched 
compared to nonfailing hearts.  Most of these c-kit+ progenitors coexpressed the pan-
leukocyte marker CD45, suggesting a bone marrow origin [4].  However, the typical scar 
formation following MI suggests that this native repair response is largely inadequate. 
 
The realization that myocyte repopulation is possible has prompted a series of clinical 
trials aimed at augmenting the natural repair response in patients with myocardial 
infarction (MI).  Systemic administration of chemokines such as GM-CSF induces 
increases in circulating bone marrow cells (BMCs) that are believed to be a source of 
angiogenic and cardiomyogenic progenitors.  However, GM-CSF alone has not 
improved clinical outcomes following MI.  In some studies, direct delivery of filtered, 
autologous bone marrow cells (BMCs) into the coronary arteries or myocardial wall 
resulted in statistically-significant increases in cardiac performance, but these 
improvements were also inadequate to improve survival.  Low engraftment rates were 
cited as a primary limitation in some of these studies [5].  Indeed, follow-up studies 
determined that 93–98% of bone marrow cells delivered via coronary artery fail to 
engraft and cannot be detected in the heart within 1 h [6, 7]. 
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Although these trials provide encouragement for pursuing progenitor-based therapies, 
full understanding of the engraftment process and the nature of the engrafted progenitor 
cells remain underdeveloped.  In particular, little is understood about the mechanisms 
regulating progenitor cell engraftment immediately after myocardial injury or stress. 
Accordingly, we adapted an isolated-perfused mouse heart (IPMH) model to study BMC 
engraftment dynamics following ischemia–reperfusion injury (IR-injury).  In particular, we 
employed a heterogenous population of unfractionated BMCs so that ischemia-
responsive engraftment would provide unbiased insights into factors affecting this 
process.  Using this model, we identified a subset of BMCs with injury-dependent 
selective engraftment into the heart and also a necessary adhesion molecule that 
facilitates this selectivity.  The mechanism for this preferential engraftment was 
confirmed using an established in vitro model of cell rolling dynamics.  These studies 
provide new insights into endogenous myocardial repair processes and suggest 
potential improvements to future therapies for myocardial infarction. 
 
4.2 Methods 
4.2.1 Isolation of Mouse BMCs  
Adult C57BL/6 mice (18–22 g, 10–12 weeks old) were anesthetized with 100mg/kg 
ketamine and xylazine, and 1000 units/kg of heparin was administered IP.  Bone marrow 
was obtained by removing the femurs, and flushing them with sterile PBS over a 40 μm 
filter.  The cells were pelleted by centrifugation and resuspended in lysis buffer (BD 
Biosciences) for 1 min to lyse red blood cells.  Cells were again pelleted and 
resuspended in 1 mL PBS to remove remaining lysis buffer.  Cells were counted using a 
hemocytometer on an aliquotted sample, and 12±3 million viable (trypan blue exclusion) 
BMCs were obtained to perform infusions. 
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4.2.2 Isolated Perfused Mouse Heart for Ischemia–Reperfusion Studies 
Following anesthesia and heparization, the heart was rapidly excised, the ascending 
aorta was cannulated and perfusion was initiated with a modified Krebs bicarbonate 
buffer, as previously described [8].  Perfusion was restored within 1 min of excision and 
maintained at 37 °C and 2 mL/min. The perfusion solution was aerated with 95% O2, 5% 
CO2 in order to maintain a pH of 7.4.  A side arm in the perfusion line proximal to the 
heart inflow cannula allowed for entrainment of labeled BMCs along with the oxygenated 
perfusate. 
 
In all experiments, the perfused hearts underwent 10 min of equilibration time at a flow 
rate of 2 mL/min at 37 °C.  After equilibration, the trial cohort underwent no-flow 
ischemia for 15min (i.e. buffer pump flow was entirely halted), whereas a control group 
(sham ischemia) received normal flow of buffer for 15 min.  For all experiments, the 
ischemia or sham ischemia was followed by reperfusion of plain buffer for 0, 15, 30, 45, 
or 60 min.  Effects of this injury model (among others) are reviewed by Murphy and 
Steenbergen [9].  After this reperfusion with plain buffer, 15 min of reperfusion with 
freshly-harvested, PKH26GL-labeled (Sigma Aldrich, MO) BMCs occurred.  At the 
completion of cell infusion, plain buffer was administered for 15 min to clear the 
circulation of non-engrafted BMCs.  Most hearts were then perfusion digested with 
collagenase (180 unit/mL for 15 min) followed by filtration for flow cytometry.  A subset of 
hearts evaluated by histology was not perfused with collagenase. 
 
4.2.3 Flow Cytometry for IPMH Ischemia–Reperfusion Studies 
The heart digest was pelleted by centrifugation and resuspended in 1 mL PBS.  A 
representative sample (0.1 mL) of the heart tissue digest and the infused BMC aliquot 
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were stained with the viability dye DAPI (4′,6-diamidino-2-phenylindole dihydrochloride, 
Invitrogen, CA), an anti-CD117 (c-kit) antibody conjugated to AF-488 (Biolegend, CA) 
and an anti-CD45 antibody conjugated to PE-Texas Red (Abcam Inc., MA). 
 
After excluding dead cells (DAPI+) along with cell fragments and aggregates, gating 
based on PKH26GL fluorescence was employed to identify the infused BMCs.  
DAPI−/PKH26GL+, size/granularity-gated cells from both the perfusate aliquot and heart 
digests were evaluated for c-kit and CD45 expression.  Demarcation intensities for each 
fluorochrome were determined using the Fluorescence Minus One (FMO) technique 
(Figure 4.1).  For each immunophenotypic subtype, the percent representation in the 
retained cells was divided by original percent representation in the perfusate aliquot to 
determine a ‘selectivity ratio’ of engraftment: a ratio of 1 reflects non-selective 
engraftment while a ratio significantly greater than 1 indicates preferential engraftment. 
Figure 4.1. c-kit FMO on Filtered, RBC-Depleted Bone Marrow Cells. The fluorescence 
intensity cutoff between negative and positive cells is determined by comparison of fully-stained 
sample to a sample missing only 1 fluorophore. A) BMCs stained with all fluorophores except AF-
488 c-kit, the chosen delineation intensity is the intensity at which false positives are 0.05%, 
which is in good agreement with visual assessment. B) The fully stained BMC sample with the 
gate from FMO c-kit sample drawn. This cutoff point is used for all samples (perfusate and heart 
digest) to which the AF-488 c-kit antibody has been applied. 
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4.2.4 Selectin Neutralization Studies in Isolated–Perfused Hearts 
IPMHs were prepared as described above with the exception that, prior to BMC infusion, 
PKHGL26-labeled BMCs were incubated for 15 min with 30 μg neutralizing antibody for 
either P-selectin (BD Pharmingen CD62P) or L-selectin (BD Pharmingen CD62L) 
immediately prior to infusion.  Additionally, during the final 5 min of the 30 min 
reperfusion, buffer flow to the heart was supplemented with 80 μg neutralizing antibody 
for either P-selectin or L-selectin.  Hearts were then rinsed with plain buffer for 15 min 
and prepared for histology or flow cytometry as described above. 
 
4.2.5 Histologic Analysis for IPMH Ischemia–Reperfusion Studies 
Cryosectioning was used to visualize infused (PKH26GL or PKH67GL-labeled) cells 
retained in the heart.  Following the cell infusion protocol and rinse protocol, hearts were 
embedded in Tissue-Tek O.C.T compound and snap frozen in liquid nitrogen.  Frozen 
samples were stored at −20°C before sectioning.  In various preparations, sections were 
analyzed following exposure to antibodies for c-kit (PE conjugated CD117, Abcam, or 
FITC conjugated, Biolegend), CD45 (PE-Texas Red conjugated, Abcam), and/or P-
selectin (FITC conjugated, BD Pharmingen).  Sections were stained with                 
DAPI-containing ProLong Gold (Invitrogen, CA) and visualized with a Nikon light 
microscope with DAPI, FITC, and TRITC filters. 
 
4.2.6 Sorting of c-kit+ Cells from Mouse BMCs for Parallel Plate Flow Chamber Studies 
Once isolated, mouse BMCs were stained with DAPI and an anti-CD117 (c-kit) antibody 
conjugated to PE (Abcam).  DAPI-/c-kit+ and DAPI-/c-kit- populations were isolated by 
FACS.  Sorted c-kit− cells were always >95% purity, and c-kit+ cells were >85% purity.  
Based on the c-kit+ cell recovery rate, equal concentrations of c-kit− and c-kit+ cell 
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suspensions of approximately 50,000 cells/mL were used in the flow chamber 
experiment. 
 
4.2.7 Parallel Plate Flow Chamber Studies 
Recombinant P- and L-selectin-IgG chimeras were purchased from R&D Systems. 
Modified flexiPERM wells (Sigma Aldrich, MO) were attached to 35 mm Corning non-
treated culture dishes. To immobilize adhesion molecules, the surface was first 
incubated with recombinant protein A/G (Thermo Scientific, MA) at 4 °C on a rocker 
overnight. 
 
The surface was then washed with a blocking solution (1% BSA in sterile PBS) 3 times 
and the surface was coated with 0.5 μg/mL of P-selectin and incubated at 4 °C on a 
rocker for 5 h. The surface was again washed 3 times with blocking solution and 
incubated in flowing buffer (HBSS, 2mM Ca2+, 2mM Mg2+, 10 mM HEPES+ 0.5% 
BSA), until used for the flow chamber experiment.  For L-selectin, which has a histidine 
tag on the C-terminus, the protocol was changed to include an overnight incubation with 
an anti-polyhistidine antibody (R&D Systems, MN), between the protein A/G and selectin 
coating steps. The apparatus was set up as previously described [10]. 
 
4.2.8 Data Analysis for Parallel Plate Flow Chamber Studies 
A video of rolling and adhered cells was recorded over the same area for both c-kit− and 
c-kit+ cell populations, and later processed using ImageJ software with the MTrack2 
plug-in for calculating rolling velocity and a cell counter for tracking the number of 
adhered cells.  Rolling velocity (μm/s) was calculated by marking the change in position 
of the cell at every frame.  Rolling flux (rolling cells/mm2/min) indicates the number of 
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rolling cells, and rolling concentration (rolling flux/rolling velocity) measures rolling 
efficiency (slow and steady rolling indicates higher efficiency).  The number of adhered 
cells was counted by scanning the same area for both c-kit+ and c-kit− cells and is 
expressed as a percent of the total cells that entered the flow chamber.  A cell was 
considered firmly attached if it did not move for more than 30 s.  Each experiment was 
done in triplicate (n=3). 
 
4.3 Results 
4.3.1 Histological Evidence Infused Cell Engraftment 
Frozen IPMH tissue sections subjected to the ischemia–reperfusion protocol (15 min 
ischemia or sham ischemia, 30 min cell-free reperfusion, 15-min cell infusion with 
PKH26GL-labeled BMCs, and 15 min buffer-only wash) revealed that retained BMCs 
(PKH26GL+) were distributed uniformly within the tissue, with most in the left ventricular 
free wall. Cell clumping and occlusion of coronary vasculature was rarely observed 
(Figure 4.2). Costaining for the myocardial marker α-actinin is shown in Figure 4.3. 
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Figure 4.2. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH ) Infused 
with PKH26GL+ BMCs. Histological visualization of hearts having undergone either 15 min 
sham ischemia (left) or ischemia (right) followed by 30 min reperfusion, 15 min PKH26GL-labeled 
BMC infusion, 15 min buffer-only rinse, and preparation for histology. 10 μm slices are shown as 
merged images of TRITC filter (infused PKH26GL-labeled BMCs appear orange) and DAPI 
(blue), which represents nuclei. A) 10x of sham ischemic lateral free wall. B) 10x of ischemic 
lateral free wall. C) 40x of sham ischemic lateral free wall. D) 40x of ischemic lateral free wall. 
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Figure 4.3.  Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH ) Infused 
with PKH67GL+ BMCs and Co-staining for α-actinin and DAPI. Histological visualization of 
heart having undergone 15 min ischemia followed by 30 min reperfusion, 15 min PKH67GL-
labeled BMC infusion, 15 min buffer-only rinse, and preparation for histology. A representative 10 
µm section stained and filtered for DAPI, PKH67GL (green), α-actinin (red) shown at 40X. 
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4.3.2 Identification of Engrafted Cells in Non-ischemia Control Experiments 
The goal of these experiments was to demonstrate the ability to identify infused BMCs in 
the IPMH and distinguish them from native heart cells.  After serial gating is used to 
exclude dead cells and cell fragments or aggregates, flow cytometric analysis 
demonstrates high efficiency PKH26GL labeling of the infused BMCs, as shown in 
Figure 4.4 (A-D). After identical gating, the smaller proportion of cells identified as 
PKH26GL+ in the heart digest represents infused BMCs that have been engrafted while 
the PKH26GL− cells represent nonengrafted heart-derived cells (Figure 4.4, E-H). 
 
When identically-gated BMCs from the perfusate and heart digest are characterized 
based on biomarker expression (c-kit and CD45), the selectivity of retention, or lack 
thereof, is demonstrated.  One such comparison derived from a sham ischemia 
experiment reveals that the four possible biomarker combinations (c-kit+/CD45+, c-
kit+/CD45−, c-kit−/CD45+, c-kit−/CD45−) are similarly represented in both the sham 
ischemic heart and the bone marrow perfusate aliquot, suggesting that perfusate cell 
retention in the heart is essentially random (nonselective) in the absence of antecedent 
ischemia–reperfusion injury (Figure 4.4 D&H). 
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Figure 4.4. Serial Gating to Identify Retained BMCs in Heart Digest. Perfusate aliquots (A-D) 
and heart samples (E-H) were serially gated to isolate the population of viable BMCs.  DAPI+ 
cells were excluded as dead (A & E).  Gating on forward scatter (FSC, size), side scatter (SSC, 
cellular granularity), and removed non-cellular material (B & F).  PKH26GL positivity was used to 
isolate retained BMCs in heart digests (C & G) for further analysis with biomarker antibodies (D & 
H).  Data from a representative sham-ischemic heart is shown in this figure.  
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4.3.3 Injury-Dependent Engraftment Selectivity for c-kit+/CD45+ Autologous BMCs 
In contrast to sham ischemia, stop-flow ischemia for 15 min followed by cell-free 
reperfusion and then BMC infusion significantly altered the pattern of retained cells 
compared with the infused cells.  As the representative sample in Figure 4.5 shows, c-
kit+/CD45+ and c-kit+/CD45− cells comprise a far greater fraction of the retained cells in 
IR-injured hearts than in the sham ischemic hearts at a reperfusion duration of 30 min. 
Based on a series of experiments of this type, the observed proportion of ckit+/CD45+ 
cells increased from 3±1% in sham ischemia heart to 25±7% in the stop-flow ischemia 
heart after reperfusion duration of 30 min (Figure 4.6, n=3).  These results confirm that c-
kit expression by BMCs is associated with selective retention irrespective of CD45 
expression.  We also examined the preferential retention of c-kit+ BMCs as a function of 
the duration of cell-free reperfusion prior to initiation of BMC administration.  
78 
 
 
Figure 4.5. Biomarker Expression of Retained BMCs Following Sham-Ischemic and 
Ischemic Protocol.  Bone marrow perfusate aliquots and heart digests were serially gated as 
described in Figure 4.4 (FSC: Forward Scatter, SSC: Side Scatter). A) Aliquot from BMCs infused 
into a sham ischemic heart (results of corresponding heart digest displayed in graph C below). B) 
Aliquot from BMCs infused into an ischemic heart (results of corresponding heart digest displayed 
in graph D below). C-kit+ BMCs made up a greater percentage of retained BMCs in ischemia-
reperfusion injured hearts than in sham-ischemic hearts despite similar c-kit+ representation in 
infused BMCs. 
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Figure 4.6. Cell Subtype Distribution in Bone Marrow, Sham-Ischemic Hearts, and Ischemic 
Hearts. For each cell subtype, the percent composition of viable, infused cells (DAPI-, 
FSC&SSC-gated, PKH26GL+) isolated from bone marrow, sham-ischemic hearts, and ischemic 
hearts are displayed as histograms.  A histogram set for each possible reperfusion duration (0, 
15, 30, 45, 60 min) was computed; the histogram set for reperfusion time of 30 min (n=3) is 
shown as an example.  The c-kit+/CD45+ subpopulation is more strongly represented in heart 
than in bone marrow and is considered to be preferentially recruited. 
 
 
 
As shown in Table 4.1, c-kit+ cells were found at significantly higher concentrations in 
ischemic hearts than in sham-ischemic hearts at reperfusion durations of 30, 45, and 60 
min of reperfusion but not at reperfusion durations of 0 and 15 min.  Control experiments 
performed without PKH26GL labeling determined that the contribution of native heart 
cells to the PKH26GL+ recorded event count was less than 11% (see Inset 4.1). 
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Table 4.1 Selective Retention of c-kit+ Subsets at Various Reperfusion Durations 
Table 4.1.  Preferential Retention of c-kit+ BMCs as a Function of Reperfusion Duration.  
Table 4.1 shows a compiled sample BMC subtype compositions for all tested reperfusion 
timepoints of 0-60 min (n=3 for each data point). *C-kit data is aggregated from the c-kit+/CD45+ 
and c-kit+/CD45- entries in the lower 2 rows.  †Standard deviation for sham-ischemic and 
ischemic hearts was very low for reperfusion time of 60 min.  The p-value comparing c-kit+ at 
reperfusion time of 60 min to c-kit+ at reperfusion time of 15 min = 0.4. ‡This population is difficult 
to study due to its rarity, comprising only 0.14%±0.4% of the bone marrow and is variably 
discernible among experiments.  
 
 
Cell Type Reperfusion 
Duration 
(min) 
Fraction of 
Retained BMCs in 
Sham-Ischemic 
Heart (%) 
Fraction of 
Retained BMCs in 
Ischemic Heart (%) 
P-value 
c-kit+* 0 9 ± 2 11 ± 7 0.73 
15 4 ± 2 10 ± 1 0.22 
30 3 ± 1 26 ± 7 0.036 
45 3 ± 1 25 ± 5 0.013 
60 6.9 ± 0.6 10.8 ± 0.3 0.005† 
c-kit+/CD45+ 0 8 ± 2 11 ± 7 0.67 
15 4 ± 2 9 ± 1 0.053 
30 3 ± 1 25 ± 7 0.036 
45 3 ± 1 24 ± 5 0.012 
60 6.6 ± 0.5 10.5 ± 0.3 0.004† 
c-kit+/CD45- ‡ 0 0.9 ± 0.1 0.2 ± 0.1 0.018 
15 0.2 ± 0.1 0.3 ± 0.1 0.54 
30 0.29 ± 0.03 1.0 ± 0.4 0.15 
45 0.27 ± 0.07 0.8± 0.5 0.30 
60 0.3 ± 0.1 0.4 ± 0.2 0.90 
Inset 4.1 Derivation of False PKH26GL Contribution to Engrafted Cell Counts 
Negative controls (Infused BMCs were not labeled with PKH26GL) experiments were used to 
analyze the contribution of native heart cells to the PKH26GL+ recorded events.  Antibody 
staining of heart and aliquot occurred identically to trials that used PKH26GL.  Of 2.5 million 
recorded events, native heart was capable of producing only 140 ± 60 false PKH26GL+ events 
and only 16 ± 1 PKH26GL+/c-kit+ events (n=4).  Of 2.5 million recorded events for each trial 
(PKH26GL-labeled BMCs infused) heart, 2000 ± 300 PKH26GL+ events were recorded (n=30), 
suggesting that only 7% of PKH26GL+ events can be attributed to native heart false positives. 
The average number of PKH26GL+/c-kit+ cells in 2.5 million heart digest events was 200 ± 50 
for ischemic hearts and 140 ± 40 for sham-ischemic hearts, suggesting that only 8% of 
PKH26GL+/c-kit+ cells in ischemic hearts, and 11% of PKH26GL+/c-kit+ cells in sham-
ischemic hearts can be explained as false positives from the native heart.  Thus, native heart 
PKH26GL false positives are insufficient to explain the observed selectivity.  
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Direct comparison for selective retention between c-kit+/CD45+ and c-kit+/CD45− 
populations requires the comparison of selectivity ratios (defined as the fraction in 
engrafted BMCs divided by the fraction in the BMC perfusate for each 
immunophenotypic subclass).  Using this approach, the selectivity ratios for each 
phenotypic subtype are shown as a function of reperfusion time in Figure 4.7. These 
data reveal that the presence of c-kit positivity alone results in average selectivity ratios 
that peak above 15 after 30 min of reperfusion and remain above 10 when cells are 
infused after 60 min of reperfusion.  When the analysis focuses on both c-kit and CD45 
immunophenotypes, the selectivity ratios are even higher for the subset of c-kit+ cells 
that are also CD45+ (Figure 4.7). 
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Figure 4.7. Engraftment Ratios for Various BMC Subtypes at Reperfusion Durations of 0, 
15, 30, 45, and 60 min.  The ordinate plots the percent composition of the retained BMCs found 
in the heart (DAPI-, FSC&SSC-gated, PKH26GL+) divided by the percent composition of that 
BMC subtype in the perfusate (i.e. the BMC subtype’s Selectivity Ratio).  Thus comparisons 
between selective engraftment of different BMC subtypes can be drawn even when the absolute 
percent representation of these subtypes in the bone marrow are highly disparate. (n=3 for each 
data point) 
 
 
 
In order to visualize the expression of CD45 and c-kit biomarkers on infused cells, a 
subset of hearts underwent 15 min of ischemia (or sham ischemia) followed by 30 min of 
reperfusion and then infusion with labeled BMCs (PKH67GL, a green dye), was 
substituted for PKH26GL, an orange dye, to further minimize spectral overlap with the 
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other fluorophores and improve image clarity.  As expected from the flow cytometric 
analyses, nearly all PKH67GL-labeled cells in heart sections stained positively for CD45 
in ischemic and sham ischemic hearts, while approximately 25% stained positively for c-
kit in the ischemic hearts and very little c-kit staining was observed in sham ischemic 
hearts (representative cell images shown in Figure 4.8 and Figure 4.9).  Representative 
cell images co-stained with CD45 and c-kit in combination are shown in Figure 4.10. 
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Figure 4.8.  Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused 
with PKH67GL+ BMCs and Co-staining for CD45.  Histological visualization of heart having 
undergone 15 min ischemia followed by 30 min reperfusion, 15 min PKH67GL-labeled BMC 
infusion, 15 min buffer-only rinse, and preparation for histology.  Representative 10 µm sections 
are shown at 40X (A-D) and 20X (E-H) stained and filtered for DAPI (A&E), PKH67GL (B&F), 
CD45 (C&G), and merged (D&H) are shown.  
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Figure 4.9.  Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused 
with PKH67GL+ BMCs and Co-staining for c-kit.  Histological visualization of heart having 
undergone 15 min ischemia followed by 30 min reperfusion, 15 min PKH67GL-labeled BMC 
infusion, 15 min buffer-only rinse, and preparation for histology.  Representative 10 µm sections 
are shown at 40X (A-D) and 20X (E-H) stained and filtered for DAPI (A&E), PKH67GL (B&F), c-kit 
(C&G), and merged (D&H) are shown.  
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Figure 4.10.  Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused 
with unlabeled BMCs and Co-stained for c-kit and CD45.  Histological visualization of heart 
having undergone 15 min ischemia followed by 30 min reperfusion, 15 min unlabeled BMC 
infusion, 15 min buffer-only rinse, and preparation for histology.  Representative 10 µm sections 
are shown at 40X (A-D) and 20X (E-H) stained and filtered for DAPI (A&E), CD45 (B&F), c-kit 
(C&G), and merged (D&H) are shown.  
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4.3.4 Inhibition of P-selectin or L-selectin in Ischemic Conditions 
In several hearts undergoing 15 min ischemia and 30 min reperfusion, the final 5 min of 
reperfusion were supplemented with soluble P-selectin or L-selectin neutralizing 
antibodies (80 μg). Additionally, PKH26GL-labeled BMCs were incubated with the same 
blocking antibody (5×106 BMCs with 30 μg antibody in 0.5 mL) for 15 min prior to being 
infused to IPMHs.  As shown in Figure 4.11A, P-selectin inhibition reduced the selectivity 
ratio for c-kit+/CD45+ BMCs in ischemic hearts to 2±1 (compared to 18±2without 
neutralization, p=0.002), a result equivalent to unblocked sham ischemia trials.  L-
selectin inhibition in ischemic hearts produced a c-kit+/CD45+ selectivity ratio of 10±4, 
which was significantly greater than observed in unblocked sham ischemic trials 
(selectivity ratio of 2±1, p=0.03) and not significantly below unblocked ischemic trials, 
though a downward trend is observed.  For BMC subtypes besides c-kit+/CD45+, no 
significant differences were found between any of the 4 protocols (unblocked sham 
ischemia, unblocked ischemia, or ischemia with either L-selectin or P-selectin blockage).  
To further confirm the interaction of c-kit+ BMCs with endothelial P-selectin, histological 
sections of a representative ischemic IPMH (15 min ischemia followed by 30 min 
reperfusion and then BMC infusion) were produced with co-staining for c-kit and 
endothelial P-selectin.  P-selectin is observed only in ischemic, but not sham ischemic, 
hearts and c-kit+ BMCs are frequently found adjacent to regions of P-selectin (Figures 
4.11B, 4.11C, and 4.12). 
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Figure 4.11. Neutralizing Antibodies and Co-localization Implicate P-selectin in c-kit 
Selective Cell  Engraftment. A) Ischemia induces strong selective retention of c-kit+/CD45+ 
BMCs compared to sham ischemic trials.  Concomitant incubation of infused BMCs with and 
infusion of neutralizing antibodies for P-selectin eliminates ischemia-induced selective 
engraftment.  Identical treatment with L-selectin neutralizing antibodies in ischemic hearts fails to 
significantly eliminate selectivity (although a trend towards reduction is observed). (n=3 for each 
data point). (* p<0.05, ** p<0.01).  B&C) Histological visualization of heart having undergone 15 
min sham ischemia (B) or ischemia (C) followed by 30 min reperfusion with out neutralizing 
antibodies, 15 min PKH67GL-labeled BMC infusion, 15 min buffer-only rinse, and preparation for 
histology.  P-selectin (green) is not observed in sham ischemic hearts but is co-localized with c-kit 
(orange) cells in ischemic hearts. 
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Figure 4.12.  Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused 
with PKH67GL+ BMCs and Co-staining for P-selectin and c-kit.  Histological visualization of 
heart having undergone 15 min sham ischemia (A-D) or ischemia (E-H) followed by 30 min 
reperfusion, 15 min PKH67GL-labeled BMC infusion, 15 min buffer-only rinse, and preparation for 
histology.  Sections are 10 µm thick, visualized at 40X, and stained/filtered for DAPI (A&E), P-
selectin (B&F), c-kit (C&G), and merged (D&H).  
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To assess potential coexpression of c-kit and the primary P-selectin ligand (PSGL-1) on 
BMCs, BMCs were stained with anti-c-kit (AF700-conjugated) and anti-PSGL-1 (PE-
conjugated) fluorochromes.  The odds ratio of PSGL-1 positivity among c-kit+ BMCs was 
computed as the fraction of c-kit+/PSGL-1+ BMCs divided by the fraction of c-kit+/PSGL-
1− BMCs. The odds ratio of PSGL-1 positivity among c-kit− BMCs was computed as the 
fraction of c-kit−/PSGL-1+ BMCs divided by the fraction of c-kit-/PSGL-1− BMCs. The 
relative quotient of these ratios was 16±4, indicating that c-kit+ BMCs are 16±4 times 
more likely to be PSGL-1+ than are c-kit− BMCs (Figure 4.13). 
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Figure 4.13. Coexpression of PSGL-1 and c-kit in Bone Marrow Cells. Mouse BMCs were 
harvested as described in Methods 4.2.1 and stained with anti-c-kit (AF700-conjugated) and anti-
PSGL-1 (PE-conjugated) fluorescent antibodies.  The FMO technique (see Figure 4.1) was used 
to delineate positive versus negative expression levels.  A representative trial is shown here.  The 
odds ratio of PSGL-1 positivity among c-kit+ BMCs for this sample was computed as (c-
kit+/PSGL-1+)/(c-kit+/PSGL-1-) and equals 17.3 in this trial.  The odds ratio of PSGL-1 positivity 
among c-kit- BMCs for this sample was computed as (c-kit-/PSGL-1+)/(c-kit-/PSGL-1-) and 
equaled 1.05 in this sample.  The relative quotient for this sample is 16.3, meaning that c-kit+ 
BMCs are 16.3X more likely to be PSGL-1+ than are c-kit- BMCs.  A) Fully stained BMC sample.  
B) Fully stained BMC sample with PSGL-1 shown against SSC.  C) Fully stained BMC sample 
with c-kit shown against SSC.  D) FMO for PSGL-1.  E) FMO for c-kit. (n=3) 
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4.3.5 Rolling and Adhesion of c-kit+ Versus c-kit- BMCs on Selectins 
To further define the interaction between c-kit+ cells and cell adhesion molecules, fresh 
BMCs were FACS sorted to obtain purified samples of c-kit+ and c-kit− (50,000 cells/mL 
in 3 mL each).  Using the parallel-plate flow chamber, cells were flowed over substrates 
coated with 0.5 μg/mL of either P-selectin or L-selectin with a shear stress of 1 dyn/cm2 
in the flow chamber.  After a known volume of the cell suspension had run through the 
flow chamber, a fixed region was scanned for firmly adhered cells.  A cell was 
considered firmly attached if it remained stationary for more than 30 s.  The adherence 
of c-kit- BMCs was minimally affected by the substrate (0.18±0.04% adhered on L-
selectin versus 0.17±0.04% adhered on P-selectin).  In contrast, c-kit+ BMCs adhered 
poorly to L-selectin and showed an approximately 9-fold increase in percentage adhered 
on P-selectin (0.03±0.01% adhered on L-selectin versus 0.28±0.04% adhered on P-
selectin).  Rolling velocities were similar for all combinations of substrate and BMC type 
with velocities on P-selectin (23±7 μm/s for c-kit−, 19±1 μm/s for c-kit+) and tended to be 
lower than velocities on L-selectin (39±14 μm/s for c-kit−, 64±11 μm/s for c-kit+).  The 
percentage of adhered cells and rolling velocity results are summarized in Figure 4.14.  
Rolling flux, a manual count of the number of rolling cells observed over a fixed area for 
a known period of time, was similar between all substrate/cell type combinations.  
Rolling concentration (rolling flux divided by rolling velocity) was also similar between all 
substrate/cell type combinations.  Rolling flux and rolling concentration data are 
available as Figure 4.15. 
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Figure 4.14. Rolling and Adhesion Dynamics of c-kit- and c-kit+ cells on P-Selectin and L-
Selectin.   A) The number of cells found to be adhered to a substrate coated with either L-
selectin or P-selectin is graphed for a perfusate sample containing either c-kit- or c-kit+ BMCs.  
While the adherence percentage for c-kit- cells does not vary with substrate, c-kit+ BMC 
demonstrate significantly stronger adherence to P-selectin than to L-selectin.  B) Rolling velocities 
are graphed for c-kit- and c-kit+ BMCs over L-selectin or P-selectin.  Rolling velocities for both 
cell types trend lower for L-selectin than P-selectin and c-kit+ BMCs show a stronger sensitivity to 
choice of selectin (* p < 0.05 between marked groups, one-way ANOVA, student’s t-test). (n=3 for 
each data point) 
 
 
Figure 4.15. Rolling Flux and Rolling Concentration for c-kit- and c-kit+ BMCs over L-
selectin and P-selectin Substrates.  A) Rolling flux was computed as the manual count of the 
number of rolling cells observed over a fixed area for a known period of time.  B) Rolling 
concentration was computed as rolling flux divided by rolling velocity.  No statistically significant 
variations were found between cell type (c-kit- versus c-kit+) or between selectin molecules (L-
selectin versus P-selectin). (n=3) 
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4.4 Discussion 
These studies demonstrate, for the first time, that BMCs expressing the c-kit are 
preferably retained in the heart following ischemia–reperfusion injury.  This selectivity 
varies in time following the ischemic insult with a delay in the onset of selectivity and 
greatest selectivity seen after 30 min of reperfusion.  The optimum engraftment time of 
30 min reperfusion also corresponds with the post-ischemia time required for type 1 
activation of the endothelium, during which P-selectin molecules surface from 
intracellular Weibel-Palade bodies [11].  In contrast, type II activation, which requires 
transcription, generally requires hours [12] and is likely not responsible for the results we 
report.  Our results are also in excellent temporal agreement with in vivo P-selectin 
dependent increases in overall leukocyte rolling following activation of cremaster 
endothelium conducted by Ley et al [13].  P-selectin is further implicated as the 
mediating mechanism for this selective retention by our antibody neutralization 
experiments, which found that P-selectin, but not L-selectin, was required to produce 
selective engraftment of c-kit+ BMCs.  P-selectin is additionally implicated by histological 
demonstration that engrafted c-kit+ cells are usually found adjacent to cells expressing 
P-selectin.  Our analysis of the BMCs further demonstrated that c-kit+ BMCs are 
generally positive for PSGL-1, the primary P-selectin ligand in leukocytes, while only 
about half of c-kit- BMCs express this adhesion molecule.  Together, these results 
indicate that P-selectin/PSGL-1 mediate selective engraftment of c-kit+ cells to the heart 
early after ischemia–reperfusion stress. 
 
Complementing the ex-vivo studies, in vitro exploration of P and L-selectins, which have 
been shown to play a part in the inflammatory cell adhesion process [14], showed a 
strong selective interaction of c-kit+ BMCs with P-selectin.  While c-kit+ cells 
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demonstrated a statistically-significant decrease in rolling velocity along with a 9-fold 
increase in firm adhesion from L- to P-selectin, c-kit− BMCs showed nearly identical 
dynamics regardless of the selectin substrate. 
 
As P-selectin is not highly expressed on resting endothelium but is known to surface 
when the endothelium is activated [15,16], the enhanced P-selectin interaction for c-kit+ 
BMCs supports the mechanistic hypothesis that ischemia-induced activation of the 
coronary endothelium results in P-selectin-mediated selective retention of c-kit+ BMCs. 
 
Although the in vivo regenerative capacity of c-kit+ BMCs remains controversial, these 
cells have been shown to differentiate into cardiomyocytes in vivo [17,18]. Additional 
angiogenic paracrine signaling effects have been identified for c-kit+ BMCs in the injured 
heart [19]. 
 
Thus, the strong retention for these cells in response to injury (selectivity ratio of 18±2) 
may indicate initiation of a repair response.  Together, these findings provide new 
insights into the dynamics of cell recruitment to the injured heart while highlighting the 
utility and versatility of the IPMH model for mechanistic studies focusing on endogenous 
repair and translational studies aimed at developing or refining new therapeutic 
strategies. 
 
The features of preferential engraftment of c-kit+ BMCs to the heart following ischemia–
reperfusion stress in these studies provide clues to the mechanisms of this dynamic 
process.  Most importantly, the preferential recruitment in an IPMH model obviates a 
requirement for systemic hemodynamic, neural, or biochemical triggers for preferential 
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engraftment.  However, an auxillary role for such extracardiac factors is not excluded by 
these studies.  Additional factors may be causally related to the selective retention we 
have described.  For example, because ischemia durations of 10 and 30 min release a 
burst of reactive oxygen species (ROS) in isolated-perfused rabbit hearts upon 
reperfusion, the 15 min ischemia duration utilized in these studies is expected to 
produce a significant ROS burst that could activate the coronary endothelium [20].  
These factors may be causally related to cell engraftment and should be further 
elucidated to complete our understanding of the mechanistic pathway. 
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CHAPTER 5 
5. Local Chemokine Environment Modification Enhances Progenitor Cell Homing 
5.1 Introduction 
5.1.1 Rationale for Modification of the Injury-Site Chemokine Concentrations 
Low retention rates diminish the effectiveness of progenitor cell therapy, as the majority 
of infused cells are immediately lost to the systemic circulation [1, 2].  Many progenitor 
cells types such as Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells 
(HSCs), and Endothelial Progenitor Cells (EPCs) are motile and can navigate the blood 
stream using concentration gradients of chemotactic proteins such as Stromal Derived 
Factor 1 (SDF-1) and Vascular Endothelial Growth Factor (VEGF) [3-5].  Chemokines 
such as SDF-1 and Monocyte Chemotactic Protein-3 (MCP-3) are released from 
infarcted myocardium and encourage stem cell homing to the injured tissue; however 
this release is temporary and insufficient to repair the damaged heart [6, 7]. 
 
Chemokines such as Granulocyte-Colony Stimulating Factor (G-CSF) have been 
intraveneously delivered to the systemic circulation to encourage migration of stem cells 
from the bone marrow to the circulation, but a series of clinical trials demonstrated that 
this technique was ultimately ineffective at improving myocardial repair [8, 9].  One 
limitation of systemic chemokine application is a lack of site specificity and an inability to 
encourage migration from the blood stream to the injured heart.   
 
Direct myocardial injection of pro-angiogenic chemoattractant cytokines to the 
chronically ischemic hearts (which, like infarcted hearts, exhibit compromised ejection 
fraction, exercise tolerance, and coronary perfusion), have been attempted clinically in 
randomized, placebo-controlled trials.  The VIVA trial delivered recombinant Vascular 
99 
 
Endothelial Growth Factor (VEGF) as a single intramyocardial dose (followed by 3 
intravenous doses over the following 9 days), but equivalent functional improvement in 
both treatment and placebo group resulted in premature study termination [10].  
Similarly, the FIRST trial employed a single dose of Fibroblast Growth Factor 2 (FGF2) 
but failed to demonstrate functional benefit at 180 days [11].  Given that an alternative 
trial delivering FGF2 encapsulated in extended release heparin-alginate microspheres, 
performed by the same group, maintained perfusion quality (while placebo-receiving 
patients exhibited worsening perfusion) [12], evidence exists for the importance of long-
term, site-specific chemokine release rather than short-term or systemic chemokine 
delivery. 
 
5.1.2 Hydrogel Delivery Systems for Extended Release of Chemokines: 
Hydrogels are biocompatible materials that, once implanted, are naturally degraded over 
an extended period of time.  Typical hydrogels may be delivered to a specified location 
in liquid phase and then solidified in situ.  Pharmaceutical agents, including chemokines, 
can be mixed with the liquid phase hydrogel solution prior to gelation and released in a 
controlled manner over extended time.  Thus, hydrogels offer a mechanism for sustained 
chemokine delivery to encourage site-specific homing of progenitor cells (either 
delivered or endogenous) from the circulation directly to the site of injury [13].   
 
5.1.3 Stromal Derived Factor 1α and Progenitor Cell Chemotaxis: 
Many chemotactic factors are known.  Specifically, SDF-1a is a well-studied chemokine 
with a known ability to attract bone marrow-derived progenitor cells, including 
mesenchymal stem cells (MSCs), in vitro and in vivo. In particular, SDF-1α expression is 
upregulated in the myocardium during ischemia and occurs concomitantly with increase 
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in circulating bone marrow cells displaying the SDF-1α receptor CXCR4, suggesting that 
myocardial SDF-1α mobilizes these cells [14, 15].  However, despite evidence that the 
mobilized BMCs home to the myocardium via SDF-1 and contribute to tissue repair 
[16-19], the extent of this brief endogenous response is insufficient to prevent the 
eventual onset of heart failure following MI.   
 
Theoretically, longer-term delivery of SDF-1a could increase the extent of myocardial 
repair.  However, SDF-1a, due to its strong positive charge, low molecular weight, and 
proteolytic susceptibility, is difficult to sequester in a hydrogel.  Inspiration for SDF-1α 
manipulation can be found in other components of the bone marrow niche (a repository 
of CXCR4+ cells), such as interactions with glycosaminoglycans (GAGs).  Cationic SDF-
1 binds to GAGs through ionic interactions between basic amino acid residues and 
acidic groups along the disaccharide backbone [20-23].  The affinity between SDF-1 
and GAGs plays an important role in localizing SDF-1 on the endothelium to direct cell 
homing [24, 25] and sustaining SDF-1 activity in the presence of proteases [26].   In 
addition to their roles in chemokine presentation, some GAGs play a more direct role in 
BMC homing through receptor interactions.  For example, hyaluronic acid (HA) is 
abundant in the bone marrow, where it serves as an anchoring molecule for BMC 
homing through binding to the CD44 receptor [27-29].  Interestingly, HA is localized to 
regions of SDF-1α expression in the bone marrow and HA via CD44 mediate cell 
responsiveness to SDF-1α during cell migration in vitro and cell homing in vivo [28].  
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5.1.4 Summary of Work 
The degradation rates and chemotactic properties (regarding BMCs and MSCs) of this 
hydrogel formulation composed of SDF-1a stabilized by polymerized HA monomers 
have been studied in vitro [30], but the present work is the first in vivo evaluation.  
Results show that both the SDF-1a and hyaluronic acid have chemotactic abilities 
towards unfractionated bone marrow cells (BMCs) in vivo, but that combination of these 
into a single hydrogel provides synergistic chemotactic abilities.  Furthermore, flow 
cytometry is leveraged to quantitatively evaluate the effects of this hydrogel on stem cell 
retention in the circulation and heart over a 7-day period in an in vivo model of 
myocardial infarction. 
 
5.2. Materials and Methods 
5.2.1 Animals 
Adult BALB/CAnNHsd mice (Charles River, Production) were housed in a dedicated 
vivarium under conventional conditions.  Mice received a standard diet (LabDiet 5010) 
and water ad libitum.  All experimental procedure were performed according to the NIH 
Guide for Care and Use of Laboratory Animals and approved by the Institutional Animal 
Care and Use Committee (IACUC) at the University of Pennsylvania. 
 
5.2.2 Macromer Synthesis  
A degradable HA macromer with methacrylate functionality was synthesized through 
hydroxyethyl methacrylate (HEMA) modification of the HA backbone in a three step 
process. (1) Sodium hyaluronate (74 kDa, Lifecore) was converted to a 
tetrabutylammonium (TBA) salt by acidic ion exchange with Dowex resin (50W×8–200, 
Sigma), followed by neutralization with TBA-OH, and lyophilization.  (2) 2-hydroxyethyl 
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methacrylate was reacted with succinic anhydride in dichloroethane (DCE) via a ring 
opening polymerization (65C, 16hrs) in the presence of N-methylimidazole to obtain 
HEMA-COOH.  HEMA-COOH was purified via hydrochloric acid wash, DI H2O wash, 
and DCE evaporation with a rotary evaporator. (3) HEMA-COOH was coupled to HA-
TBA in anhydrous dimethyl sulfoxide through an esterification reaction in the presence of 
4-dimethylaminopyridine (DMAP) and di-tert-butyl dicarbonate (BOC2O) activating 
agents (45C, 20hrs).   The following molar ratios of reactants were used: HA-TBA (1), 
HEMA-COOH (1.4), BOC2O (1.2), DMAP (0.1).  The modified HEMA-HA macromer was 
purified via overnight dialysis in DI H2O at 4°C, acetone precipitation, another 5 days of 
dialysis in DI H2O at 4°C, followed by lyophilization.  
1H NMR was used to determine the 
degree of modification and purity of the HEMA-HA. 
 
5.2.3 Hydrogel Formation   
Hydrogels were formed upon visible light exposure using a previously established 
initiator system consisting of eosin Y, triethanolamine (TEOA), 1-vinyl-2-pyrrolidinone 
(VP), and a halogen curing light (Elipar 2500, 3M, MN) [31].  50 μL hydrogel precursor 
solutions were prepared by mixing HEMA-HA and initiators in PBS at final 
concentrations of: 6 wt% HEMA-HA, 0.02 wt% eosin Y, 225 mM TEOA, and 37 mM VP.  
200 ng rSDF-1α was mixed into the 50 μL hydrogel precursor solution for HA Gel/rSDF-
1α groups.  Hydrogels were formed in cylindrical molds upon light exposure for 90 
seconds.   
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5.2.4 BMC Isolation 
Adult BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were anesthetized with 100 
mg/kg ketamine and 20 mg/kg xylazine.  Unfractionated BMCs were obtained by 
removing the femurs, and flushing the marrow cavity with sterile PBS over a 40 μm filter.  
The cells were pelleted by centrifugation and resuspended in lysis buffer (BD 
Biosciences, NJ) for 1 min to lyse red blood cells. Cells were again pelleted and 
resuspended in 1 mL PBS to remove remaining lysis buffer.  To visualize the cells in 
vitro and in vivo, PKH fluorescent linker kits were employed (Sigma, MO).   
 
5.2.5 Experimental MyocardiaI Infarction (MI) 
A cryoinjury model of MI was used to initiate MI remodeling [32, 33].  Adult 
BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were anesthetized with 20 mg/kg 
ketamine and 4 mg/kg xylazine, shaved and disinfected with alcohol.  The mice were 
kept under anesthesia (1.5% isoflurane), incubated and ventilated with 95% O2 using a 
mechanical ventilator (MiniVent, Harvard Apparatus, MA).  The heart was exposed 
through a left lateral thoracotomy and cryoinjury was introduced by applying a round 2 
mm diameter stainless steel probe frozen with liquid nitrogen to the epicardial surface of 
the ventricle for 10 sec.  After removing the probe, the cryoinjured area was confirmed 
by observation of a white disk-shaped region.  For mice receiving hydrogels, 25 μL of the 
liquid hydrogel precursor solutions (same as section 5.2.4) were applied to the surface of 
the injured ventricle through a 27G syringe in the presence of curing lamp exposure.  For 
mice receiving SDF-1α only, 10 μL of a 10 μg/mL rSDF-1α solution was injected into the 
ventricle wall using a 30G syringe.  The order of therapeutic intervention was rotated 
from animal to animal.  Following manipulations to the heart, the intercostal space and 
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skin were closed with sutures.  Mice received 100% oxygen until responding to 
interdigital pinch, after which the endotracheal tube was withdrawn.  Mice were kept 
warm with a heating blanket during recovery.  Meloxicam (5 mg/kg) was administered 
via intraperitoneal injection 1 hr after surgery and once a day for 1 week following 
surgery to minimize pain.  
 
5.2.6 In vivo BMC Homing  
After a recovery period of 3 hrs following MI induction, mice were anesthetized with 20 
mg/kg ketamine and 5 mg/kg xylazine.  Freshly isolated BMCs from a donor mouse were 
fluorescently tagged with PKH linker kit, counted on a Vi-CELL (Beckman Coulter, CA), 
and 9x106 cells in 300 μL sterile PBS were injected into the femoral vein of the MI 
mouse.  Blood samples were collected 1 day after BMC injection via retro orbital bleed, 
treated for RBC lysis, and analyzed for PKH+ cells using flow cytometry.  Briefly, cells 
were gated for viability using 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen, CA), size 
and granularity using characteristic BMC distributions of forward scatter (FSC) and size 
scatter (SSC), respectively, and fluorescent intensity using appropriate controls (Figure 
5.1) [34].   
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Figure 5.1. PKH- BMC Negative Controls for Flow Cytometry Gating.  After gating for viability 
with DAPI, BMCs in the blood (A) and the heart (C) were gated based on the typical size of 
freshly isolated BMCs (A, inset).  The cells within this size range were then analyzed for PKH 
fluorescence (C and D).  This gating strategy minimized PKH false-positive counts in the blood 
and heart to less than 1 per 10
6
 events (D). Abbreviations: SSC – side scatter, FSC – forward 
scatter.     
 
 
 
PKH+ cells in the blood were reported as a percentage of total cells in the blood within 
the characteristic BMC size distribution.  Mice were anesthetized 7 days after 
experimental MI with 100 mg/mL ketamine and xylazine, blood samples were collected 
from the abdomen, and hearts were excised and either perfusion digested with 
collagenase (150 U/mL type 2 collagenase in Krebs buffer, Worthington, NJ) for PKH+ 
cell quantification using flow cytometry [34] or flash frozen in embedding medium for 
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PKH+ cell visualization using histology.  Quantified PKH+ cells in the blood were again 
reported as a percentage of total BMCs in the blood, while quantified PKH+ cells in the 
heart were reported as a total number of cells/heart.  Embedded hearts were sectioned 
at a 12 μm thickness and imaged immediately upon thawing at room temperature.  
 
5.2.7 Statistical Analysis 
Values are reported as mean ± standard error of the mean.  Statistical differences 
between groups were determined using ANOVA in conjunction with a student’s two-
tailed t-test (Microsoft Excel), with P < *0.05, **0.01, and ***0.001 considered as 
significant. 
 
5.3 Results: BMC Homing to the Remodeling Heart 
In order to quantify BMC homing in vivo, fluorescently tagged BMCs were infused into 
the circulation following experimental MI in mice and tracked in the blood and the heart 
using flow cytometry (Figure 5.2).  
 
Figure 5.2 In vivo model to quantify BMC homing. HA Gels were applied to the heart 
immediately following experimental MI.  Freshly isolated BMCs were fluorescently tagged with 
PKH linker dyes and infused into the circulation via a femoral vein injection 3 hrs after MI.  Blood 
samples were collected 1 and 7 days following MI and hearts were digested 7 days following MI 
to quantify PKH+ BMCs. 
 
 
 
Myocardial delivery of homing factors (HA and rSDF-1α) from hydrogels (formed on 
heart using blue light, Figure 5.3) was assessed for the ability to enhance BMC homing 
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to the heart and compared to controls of MI-only and MI with intramyocardial injection of 
rSDF-1α.  Hydrogels were localized to the injury site and adhered to the myocardium for 
sustained delivery of homing molecules (Figure 5.3).   
 
Figure 5.3 Hydrogel Placement in situ.  A) Hydrogels formed in situ by applying a liquid 
precursor solution to the epicardial surface of the ventricle under blue light exposure. B) This 
technique allowed the hydrogels to be localized on the injured myocardium for localized molecule 
delivery. C) The hydrogels adhered to the myocardium (H&E staining shown). 
 
 
 
The circulating PKH+ BMCs were readily quantified in the blood and heart using flow 
cytometry (Figure 5.4).  The fluorescent intensity of the cells varied over a wide range, 
so a PKH+/PKH- threshold was chosen to quantify PKH+ BMCs while minimizing PKH- 
false-positive events in the blood and the heart.  Using this threshold, we observed a 
decrease in fluorescence intensity of the PKH+ BMCs in the blood from day 1 to day 7 
(Figure 5.4).  Considering that the PKH linker dyes are stable in vivo for weeks [35], the 
decrease in fluorescent intensity could be due to cell proliferation, or simply due to 
preferential retaining of cell types in the blood that do not uptake PKH dyes as effectively 
as others.  Interestingly, BMCs quantified in the blood on day 1 were primarily larger 
cells around the size and granularity of granulocytes, while the BMCs quantified in the 
blood on day 7 were primarily smaller cells around the size and granularity of 
lymphocytes (Figure 5.5); however, both size phenotypes show similar ranges of PKH 
staining intensity immediately after exposure to the PKH linker dye.  
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Figure 5.4 Progenitor Cell Retention in vivo.  Representative flow cytometry with constant 
threshold to quantify PKH+ BMCs in the blood and heart.  
 
 
Figure 5.5. Size of PKH+ BMCs in the Blood.  Circulating PKH+ BMCs exhibited a larger 
diameter characteristic of granulocytes 1 day after infusion (A), while PKH+ BMCs exhibited a 
smaller diameter characteristic of lymphocytes/monocytes at 7 days after infusion (B).  Both cell 
size phenotypes were increased to the same extent in the blood after rSDF-1α delivery to the 
heart. Abbreviations: SSC – side scatter, FSC – forward scatter. 
 
 
Delivery of the HA Gel with encapsulated rSDF-1α and delivery of rSDF-1α as a bolus 
injection significantly increased the number of infused BMCs circulating in the blood 1 
day after infusion (Figure 5.6A, ***P < 0.001 and *P = 0.01, respectively).  Both rSDF-1α 
delivery groups more than doubled the number of circulating BMCs on day 1 from 1% to 
2% of native BMCs; however, only the HA Gel with encapsulated rSDF-1α increased 
circulating BMCs on day 7, although this effect was not statistically significant (Figure 
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5.6B).  All intervention groups significantly increased the number of BMCs engrafted in 
the heart compared to MI-only, and the HA Gel with encapsulated rSDF-1α significantly 
increased BMC engraftment compared to rSDF-1α alone and the HA Gel alone (Figure 
5.6C, #P = 0.01 and 0.047, respectively), indicating synergy between the released rSDF-
1α and HA.  When normalized to the percentage of BMCs circulating in the blood, the 
HA Gel (with and without rSDF-1α) enhanced myocardial engraftment of circulating 
BMCs at a significantly improved rate, over 3-fold greater than the bolus rSDF-1α 
injection and MI control, which showed the same engraftment rate (Figure 5.6D).  While 
both the HA Gel/rSDF-1α and bolus rSDF-1α injection groups had the same effect on 
circulating BMCs 1 day after infusion (2.2 ± 0.2 and 2.2 ± 0.3% native BMCs, 
respectively), they had significantly different effects on enhancing BMC engraftment in 
hearts 7 days after infusion, 570 ± 130 and 170 ± 40 BMCs per heart, respectively.    
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Figure 5.6. Quantification of BMC Homing with Molecule Delivery to the Heart. A) rSDF-1α 
delivery to the heart significantly increased the number of circulating PKH+ BMCs 1 day after 
infusion.  B) This effect was sustained, although not statistically significant, 7 days after infusion 
when rSDF-1α was delivered from the HA Gel. PKH+ BMCs in the blood are reported as a 
percentage of total cells in the blood within the BMC size and granularity gating.  C) 
Intramyocardial injection of rSDF-1α and application of the HA Gel alone following MI significantly 
enhanced the number of PKH+ BMCs in the heart compared to MI only 7 days after MI and cell 
infusion.  Application of the HA Gel with encapsulated rSDF-1α further enhanced PKH+ BMC 
engraftment in the heart compared to delivering rSDF-1α or the HA gel individually.  D) When 
normalized to the percent of PKH+ BMCs in the blood 1 day after infusion (“engraftment 
efficiency”), the HA Gel enhances engraftment of circulating PKH+ BMCs.  Values reported are 
mean ± SEM, n = 7 animals for all groups except for MI-only, n = 6. 
 
Engrafted BMCs localized to the infarct region (IR) and border region (BR) in the heart 
following MI (Figure 5.7), while PKH+ BMCs in other regions of the myocardium were 
very rare.  The infarct region was characterized by dense collagen staining with 
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Masson’s Trichrome (Figure 5.7A and 5.7B).  This collagen scar tissue autofluoresced, 
allowing the infarct region to be easily identified for characterizing engrafted BMC 
locations within the heart, and PKH+ BMC fluorescence was bright enough to distinguish 
the BMCs against the tissue background as indicated by white arrows (Figure 5.7C). 
PKH+ BMCs were identified in the infarct region in all groups, but were rare in the border 
region for all groups except for the HA Gel/rSDF-1α group.  Border region BMCs in this 
group were commonly localized within and around vascular structures (Figure 5.7D).  
Some cells also appeared to integrate into the tissue and align with the native tissue 
morphology (Figure 5.7E). 
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Figure 5.7. Visualization of PKH+ BMCs in the Myocardium 7 Days after Systemic Infusion. 
A) The cryoinjury resulted in the formation of a nontransmural collagen rich scar tissue (blue 
region) 7 days following MI as visualized with Masson’s Trichrome.  An infarct region (IR) and 
border region (BR) were defined to assess PKH+ BMC locations within the heart.  B) Vasculature 
in the IR and BR remained intact following the cryoinjury.  C) PKH+ BMCs were identified in the 
IR of all groups, while PKH+ BMCs in the BR were rare except in the HA Gel/rSDF-1α group.  
PKH+ BMCs were not found in remote regions of the myocardium for all groups. White 
arrowheads indicate PKH+ BMCs.  D) PKH+ BMCs in the BR were often localized in and around 
vascular structures.  E) In addition, cells in the BR appeared to align with the myocardial tissue 
structure. Scale bars: A-500 μm; B-50 μm; C-100 μm; D and E-50 μm. 
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5.4 Discussion 
These experiments demonstrate that alterations in the myocardial chemokine milieu can 
enhance progenitor cell engraftment.  Specifically, the combination of SDF-1a extended 
release and hyaluronic acid degradable polymer synergistically augments myocardial 
homing and engraftment of infused labeled BMCs.  Furthermore, differences between 
short and long-term chemokine delivery are exposed as direct myocardial injection of 
SDF-1a had no effect on myocardial engraftment at Day 7 but did reduce clearance of 
infused BMCs from the circulation at Day 1; whereas the same mass of SDF-1a, when 
contained in the heart and released over time, enhanced engraftment.   
 
Interestingly, the HA gel sans SDF-1a caused some increase in BMC engraftment at 
Day 7.  As unfractionated BMCs may contain progenitor and inflammatory cells [36], it is 
difficult to determine what portion, if any, of the enhanced engraftment represents a 
foreign body immune response rather than pure progenitor cell recruitment.  Prior work 
on this material shows that both MSCs (presumably non-immunoresponsive) and BMCs 
migrate towards the hyaluronic acid component of this hydrogel in vitro [30].   However, 
phenotyping of engrafted cells will be required to fully understand the nature of this 
recruitment.  In either case, some participation by the inflammatory response may be 
beneficial as blockade of inflammation after infarction has mixed results—both a 
beneficial reduction in apoptosis [37-40] and a deleterious delay of scarification resulting 
in increased infarct size [41-47].   
 
The use of fresh unfractionated BMCs for these studies directly suggests a potential 
method for increasing the effectiveness of delivered BMCs (proven myocardial repair 
agents, but hindered in effectiveness by low retention rates) [1, 48] while avoiding 
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culturing techniques that can alter cell chemokine responsiveness [49, 50].  Additionally, 
the labeled BMCs may serve as tracers for natural circulating progenitors, which could 
also be drawn to the heart via hydrogel but could not be detected in these studies.  The 
extent to which endogenous circulating cells (which are derived from but may not 
respond similarly to BMCs) can be recruited via SDF-eluting HA hydrogels remains to be 
determined but could theoretically provide a substantial repair mechanism.  Speculation 
aside, the present in work conducted in vivo using a model of myocardial infarction 
presents compelling evidence for the therapeutic potential of SDF-eluting HA hydrogels 
specifically and myocardial chemokine milieu modification in general. 
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CHAPTER 6 
6.  Adjuvant Therapy for Artificial Enhancement of Progenitor Cell Engraftment 
 
6.1 Introduction 
Delivery of bone marrow cell-derived progenitor cells to infarcted myocardium appears to 
improve outcomes [1].  Additionally, a subset of preclinical and clinical studies 
comparing various dosages (number of therapeutic cells delivered) found that higher 
dosages are generally more reparative than lower cell dosages [2].  Indeed, one in vivo 
rodent study showed that engraftment success was a prognostic indicator of cardiac 
function preservation after AMI [3].   
 
Under the hypothesis that increased stem cell presence improves repair, several 
strategies have been employed to increase the effective dosage of delivered stem cells.  
Attempts to prevent stem cell apoptosis or increase stem cell proliferation once 
engrafted have shown some positive results in rodents [4, 5].  However, the vast majority 
of delivered progenitor cells fails to engraft to the injured myocardium and are 
immediately swept into the systemic circulation [6-8], where proliferation and improved 
survival have no benefit.  Accordingly, attempts to modify the delivered cells prior to 
infusion using chemokine stimulation, genetic overexpression of adhesion molecules, 
and hypoxic environments have been tested [9-12].  While these strategies 
demonstrated incremental benefit, evidence that activated endothelium following 
ischemia-reperfusion injury rapidly inactivates (within one hour of injury) may limit the 
potential of any delivered-cell modification to improve engraftment [13]. 
 
As achieving stem cell delivery within the brief window of endothelial cell activation is 
logistically difficult, applying adjuvant stimulants to pre-condition and re-activate the 
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endothelium immediately prior to stem cell infusion could be used to enhance stem cell 
engraftment and thus endothelial repair even after the endothelium has inactivated.   
 
Various methods of stimulating endothelium are known from early studies (circa 1990s) 
of inflammation.  A wide range of chemokine stimulants are known to enact both short-
term activation as well as long term pro-inflammatory alterations to endothelial cell 
transcription.  One source postulates the use of some of these chemokines or related 
polypeptides (specifically SDF1, IL-6, CCL2, SelE, ICAM-1, VCAM-1, Fibronectin, 
Laminin, or Tenascin C) as a stem cell therapeutic adjuvant [14].  However, pro-
inflammatory chemokines may carry unwanted side effects due to long persistence times 
in the circulation, unwanted potency at low concentrations, and their function to initiate 
long-term endothelial changes in transcription.     
 
Alternatively, short term endothelial activation may provide the benefits of enhanced 
stem cell engraftment without substantial systemic effects or long-term local 
inflammation.  Endothelial application of small molecules such as histamine have been 
shown to temporarily (5-30 min post-application) increase the adhesion of mature 
neutrophils to HUVECs [15], but have not previously been described as stem cell 
adjuvants.  Reactive oxygen species (ROS) such as superoxide anions, hydroxyl 
radicals, and hydrogen peroxide also induce rapid endothelial activation [16, 17].  These 
chemicals, at low concentrations, are used as endogenous messengers for endothelial 
injury [18] and are thus natural adjuvant candidates.  Though toxic at high 
concentrations, modest concentrations are well-tolerated [19, 20].  Furthermore, these 
molecules operate in narrow concentration windows [21] and thus, if delivered at 
optimum concentrations, will be rapidly neutralized below effective dosage, limiting off-
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target reactions [22].  ROS have not been previously proposed as adjuvants for stem cell 
therapies.   
 
The purpose of this work is to demonstrate a proof of concept that ROS can be used as 
adjuvants to stem cell therapy via endothelial stimulation.  Peroxide (H2O2) is a ROS with 
several known effects such as vasodilation [23], endothelial cell proliferation [24], and 
induced endothelial secretion of VEGF [20]—all of which may be beneficial to the 
infarcted heart.  Additionally, peroxide is particularly well-suited to such proof concept 
experimentation due to its quick (15 min) and long-lasting (45 min) activation [25], which 
reduces assay dependence on delivery timing (however, alternative ROS adjuvants with 
shorter effect duration may ultimately prove more clinically-desirable to prevent 
endogenous inflammatory recruitment).   
 
6.2 Methods 
6.2.1 Isolation of Mouse BMCs  
Adult Balb/C mice (20–24 g, 10–12 weeks old) were anesthetized with 100mg/kg 
ketamine and xylazine, 1000 units/kg of heparin was administered IP, and hearts were 
immediately excised as described below.  Bone marrow was then obtained by removing 
the femurs, and flushing them with sterile PBS over a 40 μm filter. The cells were 
pelleted by centrifugation and resuspended in lysis buffer (BD Biosciences, NJ) for 1 min 
to lyse red blood cells. Cells were again pelleted and resuspended in 1 mL PBS to 
remove remaining lysis buffer.  Cells were then stained with the fluorescent general 
membrane labeling dye PKH26GL (Sigma Aldrich, MO).  Stained cells in suspension 
were counted and analyzed using a Vicell XR 2.03 automated cell counter (Beckman 
Coulter, CA) for concentration and viability (trypan blue exclusion, automated).  Viable 
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concentrations were used to ensure accurate delivery of the correct number of BMCs for 
each experimental protocol. 
 
 
6.2.2 Isolated Perfused Mouse Heart (IPMH) for Ischemia–Reperfusion Studies 
Adult Balb/C mice (20–24 g, 10–12 weeks old) were anesthetized with 100mg/kg 
ketamine and xylazine, and 1000 units/kg of heparin was administered IP.  Following 
anesthesia and heparization, the heart was rapidly excised, the ascending aorta was 
cannulated and perfusion was initiated with a modified Krebs bicarbonate buffer, as 
previously described [26].  Perfusion was restored within 1 min of excision and 
maintained at 37 °C and 2 mL/min.  The perfusion solution was aerated with 95% O2, 
5% CO2 in order to maintain a pH of 7.4.  A side arm in the perfusion line proximal to the 
heart inflow cannula allowed for entrainment of labeled autologous BMCs (isolation, 
performed simultaneously with heart IPMH procedure, described above) along with the 
oxygenated perfusate. 
 
In all experiments, the perfused hearts underwent 10 min of equilibration time at a flow 
rate of 2 mL/min at 37 °C.  After equilibration, the trial cohort underwent no-flow 
ischemia for 15 min (i.e. buffer pump flow was entirely halted), whereas a control group 
(sham ischemia) received normal flow of buffer for 15 min.  For all experiments, the 
ischemia or sham ischemia was followed by reperfusion of plain buffer for 45 min.  
Effects of this injury model (among others) are reviewed by Murphy and Steenbergen 
[27].  In some sham ischemia experiments, the initial 10 min of reperfusion included 1 
mM, 3 mM, or 10 mM hydrogen peroxide (CVS Pharmacy, RI).  After this reperfusion 
with plain buffer, 15 min of reperfusion with freshly-harvested, autologous PKH26GL-
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labeled (Sigma Aldrich, MO) BMCs occurred.  At the completion of cell infusion, plain 
buffer was administered for 15 min to clear the circulation of non-engrafted BMCs. 
Hearts were then perfusion digested with collagenase (180 unit/mL for 15 min) followed 
by filtration (40 µm nylon filer, Becton Dickenson, NJ) for flow cytometry.  
 
6.2.3 Flow Cytometry for Total BMC Retention Rate in Ischemia–Reperfusion Studies 
The heart digest was pelleted by centrifugation and resuspended in 0.5 mL PBS and 
stained with the viability dye DAPI (4′,6-diamidino-2-phenylindole dihydrochloride, 
Invitrogen, CA) at 1.6 µg/mL and immediately analyzed via flow cytometry (BD 
Biosciences LSR, NJ). 
 
After excluding dead cells (DAPI+) along with cell fragments and aggregates (gated 
based on forward scatter and side scatter to metrics consistent with BMCs, see Figure 
6.1), gating based on PKH26GL fluorescence was employed to identify the infused 
BMCs. The entire heart was scanned to determine the number of recovered BMCs. 
 
Figure 6.1.  Flow Cytometry Gating Strategy for Heart Digest.  IPMHs infused with PKH26GL-
labeled BMCs were digested with collagenase and stained with DAPI, a DNA-binding fluorescent 
molecule that cannot permeate the membrane of intact (viable) cells.  DAPI negative events (as 
determined by FMO), were then gated for forward scatter (FSC) and side scatter (SSC), which 
represent cell size and granularity respectively.  The FSC/SSC gatings were chosen to match the 
metrics of the infused BMCs (not shown, see Fig 6.2).  DAPI-/FSC-SSC-gated events were 
evaluated for PKH26GL fluorescence via the FMO technique; the absolute number of PKH26GL 
events was recorded and either reported in absolute form or divided by the number of infused 
labeled BMCs to determine a recovery rate. 
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6.2.4 Flow cytometry for Analysis of Biomarkers in IPMH Ischemia–Reperfusion Studies 
Aliquots of PKH26GL-labeled and unlabeled BMCs were reserved for analysis via flow 
cytometry.  One aliquot was used to determine the prevalence of c-kit+ and CD45+ 
BMCs in the perfusate; this aliquot received staining with an anti-CD117 (c-kit) antibody 
conjugated to AF-488 (Biolegend, CA) and an anti-CD45 antibody conjugated to PE-
Texas Red (Abcam, MA).  Additional aliquots were stained with only one fluorochrome 
(either c-kit antibody, CD45 antibody, PKH26GL-labeling, or DAPI) to serve as 
compensation tubes for the automated flow cytometer algorithm for spectral overlap 
compensation.   
 
Similarly, the heart digest was pelleted by centrifugation and resuspended in 0.8 mL 
PBS. The heart was divided into 4 aliquots of 0.2 mL each.  A primary aliquot received 
staining with an anti-CD117 (c-kit) antibody conjugated to AF-488 (Biolegend, CA) and 
an anti-CD45 antibody conjugated to PE-Texas Red (Abcam, MA), while one control 
aliquot received only the c-kit antibody, one control aliquot received only the CD45 
antibody, and one control aliquot received no antibodies—these controls, all of which 
received DAPI, are used for comparison to determine the effect of fluorescent 
interference when these antibodies are applied to heart digest. 
 
In the fully stained perfusate and heart aliquots, after excluding dead cells (DAPI+) along 
with cell fragments and aggregates, forward scatter (a measure of cell size) and side 
scatter (a measure of intracellular complexity) gating was performed to exclude cell 
fragments and aggregates (Figure 6.2).  Then, DAPI-, size/granularity-gated cells from 
both the perfusate aliquot and heart digests were evaluated for c-kit and CD45 
expression.  Demarcation intensities for each fluorochrome were determined using the 
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Fluorescence Minus One (FMO) technique (Fig 6.3).  For each immunophenotypic 
subtype, the percent representation in the retained cells was divided by original percent 
representation in the perfusate aliquot to determine a ‘selectivity ratio’ of engraftment: a 
ratio of 1 reflects non-selective engraftment while a ratio significantly greater than 1 
indicates preferential engraftment. 
Figure 6.2.  Flow Cytometry Gating Strategy for Biomarker Evaluation.  A representative 
experiment is shown (15 min sham ischemia, 45 min reperfusion with 3 mM peroxide for the initial 
10 min) with flow cytometric serial gating analysis of the perfusate aliquot (A-C) and heart digest 
(D-F).  DAPI negative events (not shown, see Fig 6.1), were then gated for forward scatter (FSC) 
and side scatter (SSC), which represent cell size and granularity respectively (A&D).  The 
FSC/SSC gatings were chosen to match the metrics of the infused BMCs.  DAPI-/FSC&SSC-
gated events were evaluated for PKH26GL fluorescence via the FMO technique (B&E).  Serially 
gated PKH26GL+ events were evaluated for c-kit and CD45 fluorescent intensity via FMO 
technique (see Fig 6.3).  Selectivity ratios were determined for the 4 possible combinations of c-
kit and CD45 staining, where a selectivity ratio is equal to the percentage representation of that 
phenotype in the heart digest divided by the representation in the perfusate.  
126 
 
Figure 6.3. c-kit FMO on Filtered, RBC-Depleted Bone Marrow Cells. The fluorescence 
intensity cutoff between negative and positive cells is determined by comparison of fully-stained 
sample to a sample missing only 1 fluorophore.  A) BMCs stained with all fluorophores except 
AF-488 c-kit, the chosen delineation intensity is the intensity at which false positives are 0.05%, 
which is in good agreement with visual assessment.  B) The fully stained BMC sample with the 
gate from FMO c-kit sample drawn. This cutoff point is used for all samples (perfusate and heart 
digest) to which the AF-488 c-kit antibody has been applied. 
 
 
 
6.2.5 Statistical Analysis 
The primary comparison criteria for these experiments was the heteroscedastic t-Test 
(rationale provided by Ruxton [28]).  An Absolute Recovery Rate (ARR) was determined 
for each experiment by dividing the number of BMCs recovered from the heart divided 
by the number of BMCs infused into the heart.  Heteroscedastic t-Tests assuming 
unequal variance were used to compare ARRs between experimental protocols (n=4).  
Viability measurements of native heart cells in heart digests for each experiment were 
also compared between protocols by heteroscedastic t-Tests (n=4).  Phenotypic 
distributions for each sample (heart and BMC perfusate) were recorded and also 
compared between protocols (for heart digests) or between type (for heart digest of each 
protocol compared to BMC perfusate) via heteroscedastic t-Tests (n=4).   
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To compute phenotypic ARRs within a protocol, the absolute counts for total BMC 
retention (performed without biomarker staining) were weighted by phenotypic 
distributions of heart digest and perfusate aliquot for that protocol (obtained in separate 
experiments using antibody marker staining), as specified in the following formula: 
    
               
             
 
                         
                           
.  Fractional standard error in the ARR 
measurements was calculated as the sum of the fractional errors of the two component 
random variables: (1) Selectivity Ratio  
           
               
 and (2) Absolute Recovery Level 
 
             
           
.  Heteroscedastic t-Tests were used to determine significance protocols 
for phenotype ARR (n=4).   
 
6.3 Results 
6.3.1 Validation of BMC Recruitment Assay 
The following experiments use flow cytometry to quantify the absolute number of cells 
retained in the ischemia-reperfused heart.  To demonstrate the repeatability and 
sensitivity of this assay, IPMHs were produced, underwent 15 min of ischemia followed 
by 45 min of reperfusion, and were then perfused with buffer supplemented with 0, 1, 3, 
or 9 million viable, PKH26GL-labeled BMCs.  After 15 min buffer-only rinse and 
collagenase digestion, the number of recovered BMCs for each trial was plotted (Figure 
6.4, n=4).  As expected, a roughly linear relationship between recovered BMCs and 
number of infused BMCs is obtained.  The invulnerability of the assay to PKH26GL false 
positives (which could stem from the abundance of native heart cells) is demonstrated, 
as IPMHs infused with zero PKH26GL-labeled BMCs are almost entirely devoid of 
PKH26GL+ events.   
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Figure 6.4.  IPMH/Flow Cytometry Assay is Sensitive and Linear.  IPMHs underwent no-flow 
ischemia for 15 min followed by 30 min reperfusion.  After reperfusion, either 0, 1, 3, or 9 million 
viable, PKH26GL-labeled BMCs were infused.  After rinse and collagenase digestion, the 
absolute number of DAPI-, forward scatter/side scatter-gated (size and granularity respecitively), 
PKH26GL+ events was recorded from the heart digest via flow cytometry.  Cell recovery counts 
were largely linearly related with infused cell number.  Infusion of 3 million versus 1 million BMCs 
resulted in greater cell recovery (p<0.05, n=4), however the difference between 3 million and 9 
million BMC infusion was not statistically significant at 4 replicates.  Importantly, when 0 labeled 
BMCs were infused, the number of recovered PKH26GL+ events (false positives) was 19±3 
events amongst 1.6±4 million total heart events, suggesting an extremely low false positive rate 
stemming from native heart cells.  Some evidence of saturation or may be seen in the deviation 
from linearity; best fit linear regression lines (green=intercept nonspecified, red = intercept set to 
0) are shown for illustration. 
 
 
 
6.3.2 Peroxide Increases Engraftment of Bone Marrow Cells 
IPMHs were produced undergoing either sham ischemia or no-flow ischemia for 15 min 
followed by 45 min reperfusion and infusion with 1 million PKH26GL-labeled viable 
(trypan exclusion, automated cell counter) BMCs.  After 15 min buffer-only rinse and 
collagenase digestion, retained BMCs were quantified by flow cytometry.  In a subset of 
experiments, the initial 10 min of reperfusion ischemia (following sham ischemia) was 
supplemented with 1 mM, 3 mM, or 10 mM hydrogen peroxide (H2O2).  The number of 
recovered BMCs for each protocol, shown as a percentage retention (recovered BMCs 
divided by the 1 million infused BMCs) are plotted in Fig 6.5.  Ischemic IPMHs tended to 
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retain slightly more BMCs than sham ischemic IPMHs, but this difference could not be 
detected to statistical significance with this assay after 4 replicates (1.1%±0.1% 
ischemic, 1.3±0.4% sham ischemic).  Similarly, IPMH exposed to 1 mM peroxide yielded 
1.4%±0.4% retention.  However, exposure to 3 mM peroxide yielded 3.6%±0.3% 
retention, which was significantly higher than all lower dosages of peroxide and the 
sham and ischemic protocols (p<0.01).  Exposure to 10 mM peroxide resulted in highly 
variable engraftment, with both the lowest and highest retained values occurring for this 
protocol, and also caused noticeable blanching of the IPMH preparation; the average 
retention rate for this protocol was 3%±1%. 
 
Figure 6.5.  BMC Retention Rates are Enhanced by 3 mM Peroxide Exposure.  IPMHs 
underwent either sham ischemia or no-flow ischemia for 15 min followed by 45 min reperfusion.  
In some trials, the initial 10 min of reperfusion were supplemented with 1, 3, or 10 mM peroxide.  
After reperfusion, 1 million viable, PKH26GL-labeled BMCs were infused.  After rinse and 
collagenase digestion, BMC retention rates (#BMCs Recovered/1 Million BMCs infused) were 
recorded.  Engraftment following 10 mM peroxide exposure was highly variable. 3 mM peroxide 
exhibited enhanced engraftment (n=4, p<0.01) over all lower dosages.   
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6.3.3 Viability of Heart Cells Post-Exposure to Peroxide 
The relative toxicity of various peroxide dosages was estimated by examining the degree 
of DAPI (non-viability) staining on native heart (PKH26GL negative) events.  After gating 
for size and granularity (forward scatter and side scatter, respectively), the percentage of 
DAPI+ events was recorded and plotted (Figure 6.6).  While 10 mM peroxide was found 
to have significantly more native heart DAPI staining than all other protocols (p<0.05), 3 
mM peroxide (which achieved the highest improvement in retention) did not result in 
increased native heart DAPI staining. 
 
Figure 6.6.  Native Heart Non-Viability is Unaffected by Peroxide Dosages Up to 3 mM.  
IPMHs underwent either sham ischemia or no-flow ischemia for 15 min followed by 45 min 
reperfusion.  In some trials, the initial 10 min of reperfusion were supplemented with 1, 3, or 10 
mM peroxide.  After reperfusion, 1 million viable, PKH26GL-labeled BMCs were infused.  After 
rinse and collagenase digestion, native heart events (gated on size/granularity, by forward scatter 
and side scatter respectively, and for PKH26GL negativity) were evaluated for DAPI (non-
viability) staining.  Sham ischemia, stop-flow ischemia, and sham ischemia followed by 1 or 3 mM 
peroxide showed no difference in native heart non-viability, while 10 mM peroxide resulted in 
significantly lower viability (n=4, p<0.05). 
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6.3.4 Retention Selectivity Favors c-kit+ BMCs  
IPMHs underwent either 15 min of sham ischemia or stop-flow ischemia followed by 45 
min of reperfusion.  In a subset of the sham ischemic hearts, the first 10 min of 
reperfusion was supplemented with 3 mM peroxide.  In all trials, 3 million viable, 
PKH26GL-labeled BMCs were infused after reperfusion.  After BMC infusion, IPMHs 
underwent 15 min buffer only rinse followed by collagenase digestion.  Perfusate 
aliquots and heart digests were incubated with fluorescent antibodies for c-kit and CD45 
and stained with the viability dye DAPI.  For each experiment, a selectivity ratio for each 
of the 4 possible phenotypes (c-kit+/CD45+, c-kit+/CD45-, c-kit-/CD45+, c-kit-/CD45-) 
was computed.  A representative phenotypic analysis of each protocol (sham ischemia, 
no flow ischemia, and sham ischemia + 3 mM peroxide) is shown in Figure 6.7.  For 
each phenotype, if the percent representation of retained (PKH26GL+) BMCs in the 
heart is substantially greater than the representation of the same phenotype in the BMC 
perfusate, then BMCs of that phenotype are considered to engraft preferentially under 
the given protocol conditions.  For example, though c-kit+/CD45+ BMCs comprise 
approximately 2% of the perfusate BMCs in all shown representative trials (Fig 6.7), in 
the sham ischemia example, c-kit+/CD45+ BMCs comprise 3.87% of the retained BMCs 
compared to 27.70% in the ischemic heart and 17.86% in the sham ischemic heart 
receiving 3 mM peroxide during reperfusion.   
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Figure 6.7.  Representative Biomarker Staining for BMC Perfusate and BMCs Retained in 
Heart for Various Protocols.  Representative experiments for each of 3 protocols are shown.  
IPMHs underwent either sham ischemia (A&B), no-flow ischemia (C&D), or sham ischemia in 
which the initial 10 min of reperfusion was supplemented with 3 mM peroxide (E&F).  After 45 min 
reperfusion, 3 million viable PKH26GL-labeled BMCs were infused.  Perfusate aliquots and heart 
digests were stained with fluorescent antibodies for c-kit and CD45 and gated as described in 
Figure 6.2 to identify PKH26GL+ BMCs (in heart digests, these represent cells retained from the 
perfusate).  BMCs retained in sham ischemic hearts are roughly equal in phenotypic distribution 
to perfusate aliquots, while ischemic hearts and sham ischemic hearts receiving peroxide (to a 
lesser degree) preferentially retain c-kit+/CD45+ BMCs.  
 
 
 
After a series of 4 replicates for each protocol, compiled summary statistics were 
computed (Figure 6.8).  Figure 6.8 confirms that c-kit+/CD45+ BMCs are preferentially 
retained in ischemic and sham ischemic protocols when peroxide is used as an 
adjuvant, compared with sham ischemic hearts without peroxide treatment.   
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Figure 6.8. Cell Subtype Distribution in Bone Marrow, Sham-ischemic Hearts, Ischemic 
Hearts, and Sham-ischemic Hearts Receiving 3 mM Peroxide during the First 10 min of 
Reperfusion.  For each cell subtype, the percent composition of viable, infused cells 
(DAPI−,FSC&SSC-gated, PKH26GL+) isolated from bone marrow, sham-ischemic hearts, 
ischemic hearts, and sham ischemic hearts receiving 3 mM peroxide during the first 10 min of 
reperfusion are displayed as histograms.  The c-kit+/CD45+ subpopulation is more strongly 
represented in ischemic and, to a lesser degree, sham ischemic+peroxide heart than in bone 
marrow and are considered to be preferentially recruited. 
 
 
 
Combining the results of Figure 6.5 regarding absolute BMC recovery rates and the 
results of Fig 6.8 regarding ratiometric phenotypic distributions, recovery rates for each 
phenotype under each protocol were computed.  Thus, the Absolute Recovery Rates 
(ARR), defined as     
               
             
 
                         
                           
  
for each phenotype as shown in Table 6.1, n=4. 
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Table 6.1:  Absolute Recovery Rates for Various Phenotypes 
Protocol c-kit+/CD45+ c-kit+/CD45- * c-kit-/CD45+ c-kit-/CD45- 
Sham Ischemia 3% ± 2% 6% ± 5% 
 
1.2% ± 0.5% 
 
3% ± 2% 
No-Flow Ischemia 23% ± 6% 
 
11% ± 6% 
 
1.2% ± 0.4% 
 
0.8% ± 0.2% 
 
Sham Ischemia + 3 
mM Peroxide 
27% ± 7% 
 
28% ± 18% 
 
2.8% ± 0.4% 
 
10% ± 5% 
 
*This population is rare in the bone marrow (0.3%±0.1%) and difficult to quantify 
consistently. 
 
Table 6.1 displays that antecedent no-flow ischemia increases the ARR of c-kit+/CD45+ 
BMCs relative to sham ischemic protocols (p<0.05), but has no detectable effect on 
other phenotypes.  Alternatively, sham ischemia followed by 3 mM peroxide also 
increases the ARR for c-kit+/CD45+ BMCs compared to sham ischemia alone (p<0.05) 
and the ARR of c-kit-/CD45+ BMCs.  The effect on c-kit-/CD45+ BMCs, though small, 
has a large effect on total number of retained BMCs due to the high prevalence of this 
phenotype in BMC perfusate) with p<0.05 when compared to sham ischemia and no-
flow ischemia. 
 
6.4 Discussion 
Previous work in Chapter 4 demonstrated that the IPMH model, combined with flow 
cytometry, provides a sensitive assay to evaluate comparative engraftment rates of 
various cells in a heterogeneous mixture [29].  However, evaluation of myocardial 
interventions requires the ability to compare retention rates between IPMH preparations 
rather than merely within a single preparation as there is no internal control or 
normalization mechanism for these conditions.  Chapter 6 now shows that the IPMH/flow 
cytometry assay is sufficiently sensitive and repeatable to detect differences in absolute 
(i.e. not merely relative) retention rates for various BMC phenotypes.  
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This assay is then used to demonstrate that adjuvant delivery, hydrogen peroxide 
specifically, can be used to enhance progenitor cell engraftment in an intact organ.  Brief 
stimulation with low-dose hydrogen peroxide could potentially be used to stimulate 
endothelium immediately prior to progenitor cell infusion.  As the engraftment 
enhancement achieved by low-dose peroxide stimulation occurred in sham ischemia 
hearts, which are considered to exhibit non-stimulated endothelium [30, 31], low-dose 
peroxide could be used as an adjuvant for stem cell delivery long after initial ischemia-
dependent endothelial activation (from myocardial infarction) has subsided.  Because 
endothelial activation following reperfusion injury has been shown to diminish in under 1 
hour in vivo [32], low-dose peroxide therapy could achieve the engraftment yield 
associated with quick delivery but may be more feasible clinically.  While peroxide is 
toxic at high dosages, lower dosages are well tolerated and serve as natural endothelial 
mediators; indeed our preliminary exploration of toxicity suggest that 3 mM peroxide 
exposure for 10 min is both a safe and effective stimulant.  While many studies have 
explored the effect of peroxide on signaling in endothelial monolayers (usually 100 µM – 
1 mM) [33, 34], apparently higher dosages are needed to achieve stimulation in an intact 
organ which may have additional catalases and dismutases that reduce the effective 
peroxide dose.  Still higher dosages may be required in vivo, depending on the 
concentration of reducing agents in the blood [35].   
 
While peroxide may have potential as a therapeutic stem cell adjuvant, it also serves as 
proof of concept for additional stimulatory mechanisms such as alternative reactive 
oxygen species (superoxide radicals, hydroxyl anions, and others), inhibitors of 
catalases and dismutases that destroy naturally or artificially produced ROS, and 
proteins or chemokines associated with inflammation.  Similarly, these adjuvants could 
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be used in combination with each other or in conjugation with additional compounds.  
For example, adjuvant and stem cell delivery could be chased with anti-inflammatory 
molecules to reduce unwanted lingering inflammatory effects.  Additionally, the stem 
cells could be modified (either by co-culturing with chemical stimulants or altered genetic 
expression) to be more responsive to activated endothelium; such modifications could 
aim to increase relevant adhesion molecules such as PSGL1, CD24, or VCAM, among 
many others.   
 
Individually or in combination, these therapies could be used to augment progenitor cell 
engraftment in a wide range of diseases where cell depletion has occurred.  Because 
stem cell therapy, with unfractionated BMCs and also with specific subtypes of bone 
marrow-derived cells, has proven effective even with very low retention rates (and in a 
dose-dependent manner in some analyses [36]), the 3-fold improvement shown here 
with peroxide can be expected to provide additional benefit.  The increase is especially 
encouraging with regards to the much stronger (15-fold) impact on c-kit+ BMCs, which 
are known to have superior ability to stimulate new cardiomyocyte formation post-injury 
in vivo [37].         
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CHAPTER 7 
7.  Summary, Conclusions, and Future Work 
 
7.1 Summary 
Ideally, the heart would regenerate healthy myocardium to replace cells and restore 
normal tissue architecture and function following an injury such as acute myocardial 
infarction (AMI).  Prior dogma asserted that the human heart is a terminally differentiated 
organ with no capacity for generating new cardiomyocytes (CMs); however, recent 
evidence indicates that CM formation occurs throughout life, though the magnitude is 
disputed, and increases briefly post-injury.  Controversy over the exact degree of CM 
formation rates is especially discordant for older patients, the primary demographic for 
AMI.   
 
In Chapter 3, we scrutinized two prominent studies of CM turnover in aging human 
hearts.  Both the study by Bergmann et al, which favored low age-decreasing turnover 
(1% declining to 0.5% with advancing age), and the study by Kajstura et al, which 
favored high, age-increasing turnover (4% increasing to 20%), were highly dependent on 
complex mathematical models.  Both papers were found to be exquisitely sensitive to 
variance in primary measured parameters despite limited ability to assess the precision 
of these measurements.  In particular, the Kajstura study was supra-linearly sensitive to 
a parameter describing the number of divisions undergone by cardiac stem cells prior to 
senescence, while the Bergmann paper was especially sensitive to assumptions about 
the corporeal incorporation of atmospheric C14 levels.  Furthermore, the candidate 
turnover scenarios tested by Bergmann did not include an option for time-varying 
turnover where the attrition rates of CMs could be a function of the patient-age at which 
they were formed.  In fact, a scenario of age-increasing turnover with new CMs 
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experiencing higher rates of attrition than predecessors fit the Bergmann data far better 
than all models favored by Bergmann.  Interestingly, this solution largely agreed with the 
conclusions drawn by Kajstura.    
 
This age-increasing solution, in addition to achieving superior fit, also explains a 
discrepancy in the Bergmann turnover conclusions between subjects born prior versus 
after the initiation of atomic weapons testing.  The relatively insubstantial amount of C14 
incorporated by subjects born prior to the atmospheric C14 spike is not consistent with 
the higher levels of C14 that would have been incorporated by these older subjects 
assuming that, in youth, they experienced cycling rates similar to those of the dataset’s 
younger subjects.  We observe that, for these pre-spike subjects, two numeric solutions 
are possible to compute a turnover level from observed ΔC14 measurements.  Pre-spike 
subjects can gain C14 content either by slow, steady accumulation or alternatively by 
rapid CM formation during the highest levels of atmospheric C14 followed by rapid 
replacement of those newly-formed CMs with successor CMs formed at time of 
diminished atmospheric C14—thus creating two numerical solutions.  Selection of the 
low solution, as favored by Bergmann, yields an unreasonable discontinuity in turnover 
estimates at the onset of atomic weapons testing, whereas the high solution readily 
explains the discontinuity.   
 
All things considered, a scenario of roughly 4% turnover in youth increasing to 15-22% in 
old age seems compatible with all known data.  This finding implies that the baseline 
level of turnover is much higher than is previously thought and that the rates of new CM 
formation may be frequent in victims of AMI (who are generally elderly).  Such findings 
suggest that that the persistent scarring following myocardial infarction may not be due 
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to inadequate myogenic capacity, but rather to high rates of new CM destruction and/or 
a loss of normal tissue architecture that compromises the ultimate efficacy of native 
myogenic processes.   
 
In an attempt to augment endogenous cardiac repair post-AMI, cardiologists have tested 
delivery of various bone marrow-derived cells to the injured heart.  While the culmination 
of a large number of randomized, placebo-controlled clinical trials have demonstrated a 
modest improvement in cardiac performance metrics associated with these therapies, 
the overall magnitude is too limited to cause an improvement in patient outcomes.   
 
In studies that have measured the degree of cardiac retention of infused cells after 
delivery, most find that nearly all of the infused cells are lost to the systemic circulation 
within an hour.  Given that several studies now implicate paracrine signaling as the 
primary mechanism by which cell therapy stimulates cardiac repair, and also that cell 
therapy benefits appear to be dose-dependent, improvement of cell engraftment 
efficiency would be expected to augment the repair effect of cell therapy. 
 
In Chapter 4, we identified engraftment mechanisms used by bone marrow-derived 
progenitor cells with the anticipation that knowledge of these mechanisms would yield an 
actionable strategy to improve engraftment in cell therapy.  To achieve this end, we 
recognized that, within a heterogenous bone marrow source, some phenotypic cell 
subsets are likely to have superior engraftment capability relative to others.  We 
identified strongly-engrafting subsets by comparing the phenotypic composition bone 
marrow cells (BMCs) prior to infusion into injured mouse hearts with the composition of 
labeled BMCs retained within the heart.  We found that, after antecedent ischemia-
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reperfusion injury, c-kit+/CD45+ bone marrow cells were preferentially retained in the 
heart by approximately 15-fold (relative to non-selective retention), but that this effect 
does not fully occur until 30 min post-injury.  Subsequent studies using P-selectin 
neutralization techniques, parallel plate flow chamber dynamics, and PSGL1/c-kit co-
expression assays indicated that interaction with endothelial P-selectin is required to 
achieve engraftment by c-kit+ BMCs. 
 
After studying the natural phenomena of cardiac regeneration and stem cell engraftment, 
we attempted to manipulate engraftment via two distinct approaches.  In Chapter 5, we 
manipulated the local concentration of chemotactic factors at the site of cardiac injury.  
The chemokine Stromal Derived Factor 1α (SDF), encapsulated in a hydrogel comprised 
of polymerized hyaluronic acid (HA), was deployed on the epicardial surface of a 
cryoinjury in an in vivo mouse model.  We observed that labeled BMCs, infused into the 
femoral vein after injury, were more prevalent in the blood at day 1 post-injury and nearly 
8-fold more likely to home to the heart when the SDF-containing HA-hydrogel was 
applied.  Interestingly, we also observed effects in some of the control cohorts; 
intramyocardial injection of soluble SDF resulted in higher relative abundance of labeled 
cells in the blood at 1 day post injury (though no impact on cardiac retention at day 7 
was observed) whereas the addition of the carrier hydrogel alone (sans SDF) had no 
effect on day 1 blood but increased retention in the heart at day 7.  As BMCs respond to 
SDF gradients, it is likely that altering the SDF balance prevented homing of the labeled 
cells to natural BMC repositories (such as the bone marrow) and allowed continued 
BMC presence in the blood.  Hyaluronic acid is also a chemotactic factor, thus 
explaining the increased cardiac homing when it was applied.  The strongest 
engraftment was seen for the SDF-impregnated hyaluronic acid hydrogel suggesting that 
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this method is a viable strategy for increasing stem cell homing by retrieving infused 
cells lost to the circulation.  
 
Building on results from Chapter 4 and the recognition that endothelial P-selectin 
activation may be short-lived, we attempted to artificially induce endothelial activation 
prior to BMC infusion in a model of quiescent endothelium.  Though several molecules 
are capable of inducing endothelial activation via injury, we selected Reactive Oxygen 
Species (ROS) as a prime agent due to its ability to stimulate short-term inflammation 
and its brief half-life in circulation (both reducing likelihood of off-target effects and 
toxicity).  In particular, we selected peroxide which, though toxic at high doses, is a 
natural paracrine signaling molecule and well tolerated at low dosages.  Using pre-
stimulation with 3 mM peroxide, we achieved a 3-fold increase in total BMC engraftment.  
Importantly, engraftment rates c-kit+/CD45+ BMCs were 10-fold higher than in untreated 
hearts, similar to the engraftment rates seen for this subtype after ischemia-reperfusion 
injury.  As infused c-kit+ BMCs are known to be a particularly potent stimulant of new 
CM formation, the impact of enhancing engraftment of these specific BMCs may be 
particularly beneficial.  Though higher dosage (10 mM) peroxide caused hyper-variable 
overall retention and high toxicity, preliminary tests using DAPI as a viability dye for 
native heart showed no overt toxicity at 3 mM.  As peroxide is a vasodilator, a stimulator 
of endothelial VEGF release, and a stimulator of endothelial proliferation, additional 
benefits may result from use of this adjuvant in addition to a boost in engraftment 
efficiency. 
 
Thus the attempts to manipulate engraftment have yielded two complementary 
strategies for enhanced cell therapy that could be used separately or in tandem.  Pre-
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stimulation with an endothelial activator, such as peroxide, could be used to increase the 
first-pass retention of infused progenitor cells while the application of a chemokine-
eluting hydrogel patch could encourage homing of both endogenous and delivered cells 
from the systemic circulation back to the site of cardiac injury. 
 
7.2 Limitations 
While many conclusions can be drawn from the presented studies, a few limitations 
deserve mention.  For example, in Chapter 3, an analysis is performed using the two 
most prominent manuscripts investigating turnover in healthy human hearts.  While 
these papers are particularly targeted to the scientific question, other studies involving 
animals or other patient populations (particularly those with relevant morbidities) exist 
but were excluded from the current analysis due to possible confounding variables.  
While many statements regarding proper mathematical modeling in biomedical studies 
will transcend the underlying manuscripts, the specific turnover conclusions are 
beholden to the quality and completeness of the input data.  The analysis discovered 
turnover ranges compatible with both datasets but does not formally exclude all other 
possible turnover scenarios, for which future data will be required.  Additionally, the 
effect of pathological conditions on these turnover levels is not investigated in Chapter 3.   
 
In Chapter 4, we explored aspects of BMC engraftment using an in-tact organ model; 
however as with all experiments, the model system was chosen to achieve balance 
between physiological relevance (to human stem cell trials) and controllability, which 
generally requires more reductionist methods.  For example, we directly infused filtered, 
labeled bone marrow constituents into the Isolated Perfused Mouse Heart (IPMH) while 
the in vivo setting involves an indirect interaction in which marrow-derived cells are 
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released into the circulation and the circulation, in turn, perfuses the myocardium.  While 
our procedure may have allowed some marrow-derived populations greater access of to 
the heart than occurs in vivo, this realization does not diminish the validity of injury-
triggered engraftment cues and preferential engraftment dynamics revealed by these 
studies.  
 
Similarly, though the IPMH model has been shown to exhibit contractile impairment 
following ischemia-reperfusion injury (and also similar Reactive Oxygen Species 
release) that is similar to the injury’s effect in vivo, the IPMH undergoes a traumatic 
injury, separation from the nervous system, and a transition from blood to crystalloid 
buffer.  Given that the observed P-selectin-mediated selective engraftment parallels 
results from systemic circulation and the fact that this selectivity was not seen in control 
IPMHs, the results are likely representative of true physiology.   
 
The utility of the IPMH model is likely greatest for studying early engraftment dynamics 
before deterioration of contractile performance and edema of the IPMH reduce its 
reproducibility and relevance to in vivo dynamics.  Additionally, this model is critically 
dependent on rapid cannulation of the mouse heart since delay will induce ischemic 
insults that would confound the interpretation of protocol-driven ischemia–reperfusion 
stress.  To address this concern, we routinely aborted experiments if the heart 
cannulation and initiation of perfusion takes more than two minutes. 
 
In Chapter 5, we utilized a rodent model to test a chemokine-eluting hydrogel patch.  
Application to a rodent heart required topical delivery to the epicardial surface.  
However, as human AMI patients are generally catheterized, a more translatable 
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delivery method may involve infusing the SDF-laced hydrogel as a solution via catheter 
and then using chemical initiators, rather than photo-initiation, to form the hydrogel.  
While other work using intravascular polymerization of hydrogels has shown a strong 
safety record, concentrations and cross-linking density will have to be optimized to 
ensure that no obstruction of blood flow occurs in this process.  Furthermore, our 
presented experiments show an increase in homing for peripherally-infused BMCs (i.e. 
BMCs delivered as an intervention), however the hydrogel formulation may also 
encourage homing of native BMCs cells to the heart, which is a much more abundant 
cell source.  While such stimulation of endogenous BMCs is an attractive possibility, our 
experiments were not designed to evaluate this potential effect. 
 
In Chapter 6, we return to the IPMH model to study direct engraftment of BMCs flowing 
over the coronary endothelium.  The peroxide results show that it is possible to increase 
engraftment of infused BMCs, particularly for c-kit+/CD45+ BMCs.  The optimum dosage 
was 3 mM peroxide infused for 10 min for these experiments.  However, in vitro cell 
culture experiments show endothelial effects occurring at lower dosages (under 1 mM) 
with toxicity beyond these levels.  Differences in optimum and toxic dosages could result 
from the model system used, where the differential concentration of reducing agents 
may alter the effective ROS dose.  Similarly, the optimum dose for use in patients, where 
blood is present rather than crystalloid buffer, may also be different and require re-
optimization.  While preliminary viability dye staining of native heart cells indicated a 
narrow therapeutic range around 3 mM peroxide that is both safe and effective, full 
toxicology studies assessing the long-term effects of peroxide dosing have not been 
performed.  Follow-up therapy with anti-inflammatory agents or possibly substitution of 
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peroxide for less toxic molecules in the ROS family may reduce adverse reactions to the 
therapy. 
 
7.3 Future Work 
The results of these experiments suggest many avenues for new explorations and 
continued translation to the clinic.  The computer model (full code provided in the 
Appendix) is intended to accommodate future fate-mapping and cell dynamics studies 
for both physiological and pathophysiological subject sets.  Regarding the specific 
question of endogenous CM turnover in healthy human hearts, definitive testing of the 
emergent theory (from the two studied papers) of age-increasing turnover with 
progressively inferior CMs should be performed.  Debate over the causes for 
discrepancy between subjects born prior to and after the onset of atomic weapons 
testing could be clarified by repeating the Bergmann studies using subject hearts 
obtained from autopsies over the next few decades (such that subjects of longer 
lifespans will contribute to the set of individuals born after the atmospheric C14 spike).  
The use of multiple pulse-chase markers in addition to or instead of C14 may be needed 
to definitively demonstrate the proposed inferiority of CMs made late in life, and in vitro 
testing of biopsied samples or evaluation of CM characteristics dated by surrogate age 
markers (such as telomere length) may support more conclusive experiments. 
 
Myocardial ischemia–reperfusion stress is here shown to provoke time-dependent and 
highly selective engraftment of c-kit+ cells included in the perfusate via a P-selectin-
dependent mechanism.  In this context, additional applications of this model might 
include more extensive examinations how the type of ischemia (demand vs. supply), 
duration of ischemia or alternative local cytokine manipulations might alter engraftment 
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dynamics.  More detailed profiling of selectively retained cells via further 
immunophenotyping, sorting with gene expression studies, and/or characterization of the 
IPMH effluent should provide additional insights into the precise sequence of events 
responsible for the highly selective engraftment dynamics we observed.  Refined 
mechanistic hypotheses raised by such studies could be tested by gain- and loss-of-
function studies enabled by altering the myocardial cytokine milieu, exploiting 
genetically-manipulated mouse models and/or the varying the composition of the infused 
cells.  For example, manipulations of the infused cell populations via sorting 
and/recombination could permit unique opportunities to examine whether there are 
cooperative or inhibitory interactions among infused cells that affect overall engraftment 
dynamics. 
 
Two therapeutic strategies— (1) SDF-eluting hydrogels and (2) peroxide adjuvants--
have been proposed in this work to enhance the effectiveness of cell therapies for AMI 
patients.  The specific cell types recruited by the two therapies may offer more benefit to 
regeneration than would be expected by simply evaluating the increase in overall BMC 
presence.  For example, the SDF-hydrogel may preferentially attract Mesenchymal Stem 
Cells (MSCs), which are known to release pro-angiogenic chemokines when deployed to 
the heart and are strongly attracted to SDF-gradients.  Because MSCs may represent a 
disproportionate fraction of the cells homing to the heart in response to our hydrogel 
therapy, phenotyping the recruited cells would be of great value to these studies.  
Regarding the peroxide therapy, c-kit+ BMCs are known to be especially effective at 
increasing the formation of new CM when infused into the injured heart; however the 
true impact of increasing c-kit- BMCs will require additional studies using measures of 
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regional myocardial function, infarct size, and labeling techniques that can define the 
ultimate fates of engrafted cells.   
 
The mouse models used provided an expedient method to demonstrate proof of concept 
for these candidate procedures.  However, these approaches operate under the 
assumption that increased BMC retention will ultimately improve repair and patient 
outcomes.  This assumption is supported by dose-dependent cardiac performance 
benefit observed in some cell infusion studies.  However, studies of cardiac performance 
metrics in vivo would greatly promote translation of both strategies, particularly in larger 
animals where more physiologically-relevant injuries can be reliably produced.  In each 
of these studies, therapeutic agent concentrations and timing deliveries will likely have to 
be re-optimized to maximize benefit and minimize adverse reactions. 
 
Though these proof-of-concept studies evaluate the proposed therapies in isolation, they 
could also be combined with other therapeutics (including each other).  For example, the 
peroxide therapy may be combined with anti-inflammatories to avoid exacerbating 
damage to the heart after cell infusion is complete.  While a multi-faceted approach may 
ultimately yield the best results, the complexity of proving additive or synergistic effects 
suggests that the direct benefits of therapies suggested by this work are most likely to 
have near-term impact.   
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APPENDIX - Hybrid Model JAVA Code 
 
package turnovermodel; 
 
import java.io.BufferedReader; 
import java.io.BufferedWriter; 
import java.io.FileNotFoundException; 
import java.io.FileReader; 
import java.io.FileWriter; 
import java.io.IOException; 
import java.util.StringTokenizer; 
import java.util.logging.Level; 
import java.util.logging.Logger; 
import org.jdesktop.application.Application; 
import org.jdesktop.application.SingleFrameApplication; 
 
 
 
public class TurnoverModelApp extends SingleFrameApplication { 
 
    /*Read Me 
    Thank You for Studying Our Paper! 
    The complete code to run our model heart and regenerate our results is divided into two Java classes 
(TurnoverModelView and TurnoverModel) 
    TurnoverModel contains methods for basic tasks such as loading datapoints from databases, also contains global 
variables 
    TurnoverModelView contains a list of high-level methods (top of the class) that produce excel files (.csv) for output 
data/figures 
    TurnoverModelView contains lower level methods (middle of class) that perform basic model tasks that feed into the 
upper level methods 
    TurnoverModelView contains data retrieval methods (end of class) that return age and gender dependent parameters 
from published data 
 
    This program has no graphical user interface and is intended to be run from within an IDE such as Netbeans 
    This program requires 2 folders to exist in the working directory, so please create them manually when you 
download the program:  IndividC14, RawDatabase 
    The RawDatabase folder requires the 9 .txt data files found in the supplement 
    If this setup has not been performed, the program will not run and you will not receive an error message 
 
    A method will fail to run if the .csv file it is intended to write to is open by the user.  You will not receive an error 
message.  Close the .csv file and re-run. 
 
    When the program has completed all scheduled runtime tasks, a generic window will popup.  If this window does not 
pop up, the program is either still running or an error has occurred 
 
    Be aware of the output format of the .csv files.  Data matrix structure is annotated in the individual methods that 
create the .csv of interest.  Charts are not automatically generated from these .csv files. 
 
    We would like to acknowledge 3 primary sources of data for this program. 
     Kajstura J, Gurusamy N, Ogorek B, Goichberg P, Clavo-Rondon C, Hosoda T, D'Amario D, Bardelli S, Beltrami 
AP, Cesselli D, Bussani R, del Monte F, Quaini F, Rota M, Beltrami CA, Buchholz BA, Leri A, Anvera P, "Myocyte 
Turnover in the Aging Human Heart," Circ Res 2010, 107:1374-1386 
     Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, 
Druid H, Jovinge S, Frisen J, "Evidence for Cardiomyocyte Renewal in Humans, Science 2009, 324,5923:98-102 
     Atmospheric Carbon14 over Time:  CALIbomb web site (http://calib.qub.ac.uk/CALIBomb/frameset.html) 
   */ 
 
 
    @Override protected void startup() {try { 
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            show(new TurnoverModelView(this)); 
        } catch (IOException ex) { 
            Logger.getLogger(TurnoverModelApp.class.getName()).log(Level.SEVERE, null, ex); 
        } 
 } 
    @Override protected void configureWindow(java.awt.Window root) { } 
    public static TurnoverModelApp getApplication() { return Application.getInstance(TurnoverModelApp.class); } 
    public static void main(String[] args) { 
        launch(TurnoverModelApp.class, args); 
 
    } 
 
    public static String workingfold = "C:/Documents and Settings/jelser/Desktop/"; 
    public static double cyclelengthhours = 26; //26 in paper 
    public static double cyclelengthhoursStdErr = 4; 
    public static double num20yroldMaleCM = 6*Math.pow(10,9); 
    public static double num20yroldFemaleCM=4*Math.pow(10,9); 
 
    public static double num20yroldMaleCM10g = 500*Math.pow(10,6); 
    public static double num20yroldFemaleCM10g = 500*Math.pow(10,6); 
 
    public static int numC14points=0; 
    public static double[][] C14points; 
    public static double scaleinterceptC14=1.0; 
    public static double scalemultiplierC14=1000; 
    public static double maxC14raw=1.92035; 
    public static int numBergmann=12; 
    public static double[][] Bergmann; 
    public static double delay=0; 
 
    public static int startage=19; 
    public static int Agerepetitions = 82; 
 
    public static double apopdurationhours = 4;//4 in paper 
 
    public static double CMvolume = 40000; //cubic microns, Not found in Kajstura. 20x20x100 
    public static double gramsperheart = 300; 
 
    public static double male5percAge = 0; 
    public static double female5percAge = 0; 
 
    public static double[][] holddata = new double[1][1]; 
    public static int holdnumrows = 0; 
    public static int holdnumcol = 0; 
 
    public static double[][] holddata2=new double[1][1]; 
    public static int holdnumrows2=0; 
    public static int holdnumcol2=0; 
 
    public static double[][] holddata3 = new double[1][1]; 
    public static int holdnumrows3=0; 
    public static int holdnumcol3=0; 
 
    public static double[][] KajsturaFig7Histos; 
    public static int numKajsturaFig7; 
 
    public static int[] optimumMaleHistogramAges = {40,55,70}; 
    public static int[] optimumFemaleHistogramAges = {49,69,85}; 
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    public static double initguess=0.001;//0.001 finds lowest for pre-bomb, 0.6 finds highest (For Scenario A, around 
150%) 
    public static int counter =0; public static boolean applysubtract = true; public static double partialploidy=1.0;public 
static double addtoC14=0; 
    public static double modelerror=0;public static double[] modelparams; 
 
    public static double holddouble=0;public static double holddouble2=-1;public static double holddouble3=-1; 
    public static String curmethod = "None"; 
 
 
    public static double[][] convertHistotoRiemannSum(double[][] data, int numyears){ 
        //Assumes #CM of Age 0 = EndCount 
        double endcount = 0; 
        //Assumes Increment of 1 Year Between Rows 
        //Need numyears rows of data[i][0]=ageofCM and data[i][3] = % 
         
        double[][] riemannsum = new double[numyears+1][2]; //CM age and Riemann Sum % 
         
        for (int i=0;i<numyears-1;i++){ 
            riemannsum[i][0]=data[i][0]; 
            riemannsum[i][1]=(data[i][3]+data[i+1][3])/(2*1); 
        } 
        riemannsum[numyears-1][0]=1; 
        riemannsum[numyears-1][1]=(data[numyears-1][3]+endcount)/(2*1); 
 
        double cellcount=0; 
        for (int j=0;j<=numyears;j++){cellcount=cellcount+riemannsum[j][1];} 
        for (int j=0;j<=numyears;j++){riemannsum[j][1]=100*riemannsum[j][1]/cellcount;} 
 
        return riemannsum; 
    } 
 
    public static void fileWriter(double[][] data,int rows,int col, String dataname) throws IOException{ 
        BufferedWriter OUT = new BufferedWriter(new 
FileWriter(TurnoverModelApp.workingfold+"/ApopModel/"+dataname+".csv")); 
        for (int i=0;i<rows;i++){ 
           for (int j=0;j<col;j++){ 
               OUT.write(data[i][j]+","); 
           } 
           OUT.write('\r'); 
        } 
        OUT.close(); 
    } 
 
 
 
    public static FileReader getfile(String unique) throws FileNotFoundException{ 
      String filetype = ".txt";String preface = workingfold+"/ApopModel/"; 
      FileReader r =new FileReader(preface+unique+filetype); 
    return r; 
} 
 
 public static void BuildC14bybirthyear() throws IOException{ 
        TurnoverModelApp.numC14points=914; 
        TurnoverModelApp.C14points=new double[TurnoverModelApp.numC14points][2]; 
 
        BufferedReader compIN = null; 
          try{ compIN = new BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawBombYears"));} 
          catch(FileNotFoundException a){System.out.println("RawBombYears Not Found");} 
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          String bombline = compIN.readLine(); 
 
          for (int q=0;q<TurnoverModelApp.numC14points;q++){ 
          StringTokenizer bombtok = new StringTokenizer(bombline," "); 
          TurnoverModelApp.C14points[q][0]=Double.parseDouble(bombtok.nextToken()); 
          bombline = compIN.readLine(); 
          } 
 
          compIN.close(); 
 
          try{ compIN = new BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawBombC14"));} 
          catch(FileNotFoundException a){} 
 
          bombline = compIN.readLine(); 
 
          for (int q=0;q<TurnoverModelApp.numC14points;q++){ 
          StringTokenizer bombtok = new StringTokenizer(bombline," "); 
          TurnoverModelApp.C14points[q][1]=Double.parseDouble(bombtok.nextToken()); 
          bombline = compIN.readLine(); 
          } 
 
          //scale to Bergmann 
          for (int i=0;i<TurnoverModelApp.numC14points;i++){ 
              TurnoverModelApp.C14points[i][1]=TurnoverModelApp.C14points[i][1]-
TurnoverModelApp.scaleinterceptC14; 
              
TurnoverModelApp.C14points[i][1]=TurnoverModelApp.C14points[i][1]*TurnoverModelApp.scalemultiplierC14/(Tu
rnoverModelApp.maxC14raw-TurnoverModelApp.scaleinterceptC14); 
          } 
 
 
          compIN.close(); 
 
          //Add In Pre-1959 data 
          double[][] holdC14points = new double[TurnoverModelApp.numC14points+(1959-1930)][2]; 
          for (int i=0;i<1959-1930;i++){ 
 
              holdC14points[i][0]=1930+i; 
              if (1930+i<1955){holdC14points[i][1]=-2;} 
              
if(1930+i==1955){holdC14points[i][1]=0;}if(1930+i==1956){holdC14points[i][1]=25;}if(1930+i==1957){holdC14po
ints[i][1]=80;} 
              if(1930+i==1958){holdC14points[i][1]=100;} 
          } 
          for (int i=0;i<TurnoverModelApp.numC14points;i++){ 
              holdC14points[i+1959-1930][0]=TurnoverModelApp.C14points[i][0]; 
              holdC14points[i+1959-1930][1]=TurnoverModelApp.C14points[i][1]; 
          } 
          
TurnoverModelApp.C14points=holdC14points;TurnoverModelApp.numC14points=TurnoverModelApp.numC14point
s+1959-1930; 
    } 
 
    public static double getinitialbergmannpatientC14level(int id){ 
        double init=0; 
 
      if(TurnoverModelApp.delay==0){ 
        //Standard Bomb Curve Response 
       // if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if 
(id==4){init=25;}else if (id==5){init=847;} 
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      //  else if (id==6){init=689;}else if (id==7){init=667;}else if (id==8){init=426;}else if (id==9){init=248;}else if 
(id==10){init=239;}else if (id==11){init=184;} 
 
        //Adjusted 
        if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if (id==4){init=-
2;}else if (id==5){init=835;} 
        else if (id==6){init=647;}else if (id==7){init=653;}else if (id==8){init=417;}else if (id==9){init=238;}else if 
(id==10){init=236;}else if (id==11){init=178;} 
      } 
 
     /* else if (TurnoverModelApp.delay==2){ 
        if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if (id==4){init=-
2;}else if (id==5){init=313;} 
        else if (id==6){init=884;}else if (id==7){init=792;}else if (id==8){init=570;}else if (id==9){init=300;}else if 
(id==10){init=270;}else if (id==11){init=217;} 
      }*/ 
 
      //To use lowest C14 values in same year 
      //if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if 
(id==4){init=0;}else if (id==5){init=809;} 
      //else if (id==6){init=639;}else if (id==7){init=639;}else if (id==8){init=402;}else if (id==9){init=230;}else if 
(id==10){init=230;}else if (id==11){init=211;} 
 
      //To use highest C14 values in same year 
      //if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if 
(id==4){init=25;}else if (id==5){init=1000;} 
      //else if (id==6){init=701;}else if (id==7){init=701;}else if (id==8){init=485;}else if (id==9){init=268;}else if 
(id==10){init=272;}else if (id==11){init=176;} 
 
        return init; 
 
    } 
 
 
 
     public static void ProduceBergmannData(){ 
    //Use Figure 3d in Bergmann.  Best Fit for Scenario A.  Continuous Ploidy for Both Delta C14 (Fig 3d) and 
Turnover (Supp Tab 1) 
 
 
        double[][] bergmann = new double[12][10]; 
        //0=ID, 1=gender(1=male,0=female), 2=birthyear, 3=ageatdeath, 4=Post-ploidcorrect dC14 (final, measured) from 
Bergmann Fig 3d, 
        //5=AveTurnover%PerYear pre-ploidy correction, AveTurnover(ContinuousPloidization)%PerYear, [7]=Pre-
PloidyCorrected dC14 (Fig 3d, Table S1), 
        //8=k(DNA synthesis), 9=Pre-ploidcorrect dC14 (final, measured) from Bergmann Fig 3a/3b 
        
bergmann[0][0]=1;bergmann[0][1]=1;bergmann[0][2]=1933.7;bergmann[0][3]=73.25;bergmann[0][4]=21.3;bergmann[
0][5]=0.095;bergmann[0][6]=0.095;bergmann[0][7]=21.3-getinitialbergmannpatientC14level(0);   
bergmann[0][8]=79.5;bergmann[0][9]=21.3; 
        
bergmann[1][0]=2;bergmann[1][1]=1;bergmann[1][2]=1939.6;bergmann[1][3]=67.58;bergmann[1][4]=18.84;bergman
n[1][5]=0.085;bergmann[1][6]=0.085;bergmann[1][7]=18.84-getinitialbergmannpatientC14level(1); 
bergmann[1][8]=58.7;bergmann[1][9]=18.84; 
        
bergmann[2][0]=3;bergmann[2][1]=1;bergmann[2][2]=1944.6;bergmann[2][3]=62.67;bergmann[2][4]=3.65;bergmann[
2][5]=0.0049;bergmann[2][6]=0.0049;bergmann[2][7]=3.65-getinitialbergmannpatientC14level(2);  
bergmann[2][8]=72.2;bergmann[2][9]=3.65; 
        
bergmann[3][0]=4;bergmann[3][1]=1;bergmann[3][2]=1948.6;bergmann[3][3]=58.42;bergmann[3][4]=60;bergmann[3
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][5]=0.54;bergmann[3][6]=0.42;bergmann[3][7]=69.45-getinitialbergmannpatientC14level(3);     
bergmann[3][8]=101.5;bergmann[3][9]=80; 
        
bergmann[4][0]=5;bergmann[4][1]=1;bergmann[4][2]=1955.9;bergmann[4][3]=50.83;bergmann[4][4]=40;bergmann[4
][5]=0.79;bergmann[4][6]=0.40;bergmann[4][7]=194.6-getinitialbergmannpatientC14level(4);     
bergmann[4][8]=57.4;bergmann[4][9]=185; 
        
bergmann[5][0]=6;bergmann[5][1]=1;bergmann[5][2]=1964.1;bergmann[5][3]=42.75;bergmann[5][4]=515;bergmann[
5][5]=1.58;bergmann[5][6]=1.53;bergmann[5][7]=443.24-getinitialbergmannpatientC14level(5);   
bergmann[5][8]=74.0;bergmann[5][9]=455; 
        
bergmann[6][0]=7;bergmann[6][1]=1;bergmann[6][2]=1967.4;bergmann[6][3]=39.83;bergmann[6][4]=455;bergmann[
6][5]=1.36;bergmann[6][6]=1.14;bergmann[6][7]=403.08-getinitialbergmannpatientC14level(6);   
bergmann[6][8]=52.7;bergmann[6][9]=405; 
        
bergmann[7][0]=8;bergmann[7][1]=0;bergmann[7][2]=1967.7;bergmann[7][3]=39.00;bergmann[7][4]=405;bergmann[
7][5]=1.65;bergmann[7][6]=1.63;bergmann[7][7]=355.7-getinitialbergmannpatientC14level(7);    
bergmann[7][8]=83.1;bergmann[7][9]=360; 
        
bergmann[8][0]=9;bergmann[8][1]=1;bergmann[8][2]=1973.5;bergmann[8][3]=33.75;bergmann[8][4]=330;bergmann[
8][5]=1.48;bergmann[8][6]=1.36;bergmann[8][7]=279.94-getinitialbergmannpatientC14level(8);   
bergmann[8][8]=64.5;bergmann[8][9]=280; 
        
bergmann[9][0]=10;bergmann[9][1]=1;bergmann[9][2]=1983.5;bergmann[9][3]=23.75;bergmann[9][4]=200;bergmann
[9][5]=0.90;bergmann[9][6]=0.93;bergmann[9][7]=178.4-getinitialbergmannpatientC14level(9);   
bergmann[9][8]=74.5;bergmann[9][9]=180; 
       
bergmann[10][0]=11;bergmann[10][1]=0;bergmann[10][2]=1983.8;bergmann[10][3]=23.00;bergmann[10][4]=195;ber
gmann[10][5]=1.51;bergmann[10][6]=1.48;bergmann[10][7]=167.38-
getinitialbergmannpatientC14level(10);bergmann[10][8]=68.5;bergmann[10][9]=170; 
       
bergmann[11][0]=12;bergmann[11][1]=0;bergmann[11][2]=1987.2;bergmann[11][3]=20;bergmann[11][4]=155;bergm
ann[11][5]=1.86;bergmann[11][6]=1.87;bergmann[11][7]=141.2-
getinitialbergmannpatientC14level(11);bergmann[11][8]=67.8;bergmann[11][9]=140; 
       TurnoverModelApp.Bergmann=bergmann; TurnoverModelApp.numBergmann=12; 
    } 
 
 
 
    public static void LoadFig7Histograms() throws IOException{ 
        int maxAnversaAge = 20; 
        double[][] Histos = new double[maxAnversaAge][7];//0=AgeofCM, 1=M-Yng(%),2=M-Mid(%),3=M-
Old(%),4=F-Yng(%),5=F-Mid(%),6=F-Old(%) 
 
        BufferedReader compIN = null; 
          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFig7Years"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][0]=Double.parseDouble(compIN.readLine());} 
 
          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawMYoungFig7"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][1]=Double.parseDouble(compIN.readLine());} 
 
          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawMMiddleFig7"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][2]=Double.parseDouble(compIN.readLine());} 
 
          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawMOldFig7"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][3]=Double.parseDouble(compIN.readLine());} 
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          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFYoungFig7"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][4]=Double.parseDouble(compIN.readLine());} 
 
          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFMiddleFig7"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][5]=Double.parseDouble(compIN.readLine());} 
 
          try{ compIN = new 
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFOldFig7"));}catch(FileNotFoundException a){} 
          for (int q=0;q<maxAnversaAge;q++){Histos[q][6]=Double.parseDouble(compIN.readLine());} 
 
          compIN.close(); 
 
          TurnoverModelApp.KajsturaFig7Histos=Histos; 
          TurnoverModelApp.numKajsturaFig7=maxAnversaAge; 
 
      } 
 
    public static void printpercDC14attributedtoploidybybergmann(){ 
        for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
            double p = 1-TurnoverModelApp.Bergmann[i][4]/TurnoverModelApp.Bergmann[i][7]; 
 
            System.out.println(p); 
        } 
    } 
 
    public static int findpatientindex(int lifespan){ 
        int index=-1; 
        for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
            if (lifespan==(int)TurnoverModelApp.Bergmann[i][3]){ 
                index=i; 
            } 
        } 
        return index; 
    } 
 
     public static double getTakamatsuPloidy(int age){ 
         double fa =0; 
         if (age<22){ //all patient deaths are over age 9 
             fa=113.6+((135.4-113.6)/(22-9))*(age-9); 
         } 
         else if (age>22){ 
             fa=135.4+((148.8-135.4)/(75-22))*(age-22); 
         } 
         return fa; 
    } 
 
} 
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package turnovermodel; 
 
import java.io.IOException; 
import org.jdesktop.application.Action; 
import org.jdesktop.application.ResourceMap; 
import org.jdesktop.application.SingleFrameApplication; 
import org.jdesktop.application.FrameView; 
import org.jdesktop.application.TaskMonitor; 
import java.awt.event.ActionEvent; 
import java.awt.event.ActionListener; 
import java.io.BufferedReader; 
import java.io.FileNotFoundException; 
import java.util.NoSuchElementException; 
import java.util.StringTokenizer; 
import javax.swing.Timer; 
import javax.swing.Icon; 
import javax.swing.JDialog; 
import javax.swing.JFrame; 
 
 
public class TurnoverModelView extends FrameView { 
 
 
    public TurnoverModelView(SingleFrameApplication app) throws IOException { 
        super(app); 
 
     //Do Not Comment-Out the Following Block of Programs, They are Required to Run the Program 
 
        initComponents(); 
        TurnoverModelApp.ProduceBergmannData(); 
        TurnoverModelApp.BuildC14bybirthyear(); 
        TurnoverModelApp.LoadFig7Histograms(); 
 
 
    //You May Comment-Out These Programs or Erase Comments to Activate the Script for Runtime 
 
      //Reproduction of Kajstura Results Using Automaton Model 
        //ProduceFig1Ecmdepletion(); //Demonstrates Model Apoptosis Module Ability to Reproduce Kajstura 
Publication Figure1E (Also Prints Year of 95% Reduction of CM for Comparison to Kajstura) 
        //HierarchModel10gCompareOnlyApop();  //Shows Apoptosis Module Agreement with Kajstura Publication for 
Both Male and Female 
        //HierarchModel10gCompareOnlyBirthRateFig6b();  //Shows Myocyte Formation with Age for Both Genders 
(Compare to Kajstura Figure6b) 
        //ProduceAnnTurnoverFig6c();  //Shows Turnover (Derived from Myocyte Formation) with Age for Both Genders 
(Compare to Kajstura Figure6c) 
        //GetKajsturaTurnoverDenominatorinHeart(); 
        //ProduceKajsturaModelCMoverTime(); 
 
      //Vary Kajstura Parameters and View Effect on Kajstura Outputs 
        //VaryBirthCycleDuration();  //Creates Myocyte Formation Over Patient Age for Both Genders for Various Stem 
Cell Progenitor Turnover Levels 
       // KajsturaModelTurnover(); //Creates Turnover Rates Over Patient Age for Both Genders with Total CM Count 
Allowed to Vary (Compares to Reported (Fixed CM) Kajstura Results) 
        //VaryApopRateforHistograms(); //Creates Myocyte-Age Histograms at Time of Death for Young, Middle-Aged, 
and Old Patients (Both Genders) for Various Apoptosis Rates 
        //VaryHalfLifeforHistograms(); //Creates Myocyte-Age Histograms at Time of Death for Young, Middle-Aged, 
and Old Patients (Both Genders) for Various Half-Life Parameters 
        //VaryExpansionExponentforTurnover();  //Creates Myocyte Formation Over Patient Age for Both Genders for 
Various Stem Cell Progenitor Turnover Levels Varying Gt Exponent 
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      //Reproduce Bergmann Results 
        //PrintBombFunction();  //Displays Atmospheric C14 Data, CALIbomb website accessed 3/28/2011 
(http://calib.qub.ac.uk/CALIBomb/frameset.html). 1-Year Smoothing of Levin Dataset. 
        //TestHybridModelforBergmann(); 
        //TestScenarioA(); //Converts Published DeltaC14 Values for 12 Patients to Published Scenario A Turnover Rates 
        //IdentifyBifurcation(); 
 
      //Evaluate Bergmann 
        //BergmannSensitivityToTrueTurnover(); 
        //TestPloidy();  //Tests effect of Ploidization Variation 
        //GlobalFit(); 
        GetC14forScenarioE2(); 
        //GetCMAgeHistogramwithGlobal(); //Manually set turnover parameters of interest 
 
 
 
      //Combine Bergmann and Kajstura Model Results 
        //AnversaAgeHistogramforBergmannPatients(); //Generates an Age Histogram for Each of the 12 Bergmann 
Patients Based on Their Lifespans 
        //CompareAversaBergmannPercent(); //Generates a Comparison of Bergmann Ploidy-Corrected Turnover Rates 
for the 12 Bergmann Patients and Compares to Modeled (Kajstura Parameterized) Hearts of Same Simulated Birthdates 
and Lifespans 
        //VaryHalfLifeforC14andPerc(); //Computes Annual Turnover Rates for the 12 Bergmann Patients, Modeled by 
Automaton with Kajstura Parameters for Various Halflife Parameter Values 
 
         
 
       
 
 
        // status bar initialization - message timeout, idle icon and busy animation, etc 
        ResourceMap resourceMap = getResourceMap(); 
        int messageTimeout = resourceMap.getInteger("StatusBar.messageTimeout"); 
        messageTimer = new Timer(messageTimeout, new ActionListener() { 
            public void actionPerformed(ActionEvent e) { 
                statusMessageLabel.setText(""); 
            } 
        }); 
        messageTimer.setRepeats(false); 
        int busyAnimationRate = resourceMap.getInteger("StatusBar.busyAnimationRate"); 
        for (int i = 0; i < busyIcons.length; i++) { 
            busyIcons[i] = resourceMap.getIcon("StatusBar.busyIcons[" + i + "]"); 
        } 
        busyIconTimer = new Timer(busyAnimationRate, new ActionListener() { 
            public void actionPerformed(ActionEvent e) { 
                busyIconIndex = (busyIconIndex + 1) % busyIcons.length; 
                statusAnimationLabel.setIcon(busyIcons[busyIconIndex]); 
            } 
        }); 
        idleIcon = resourceMap.getIcon("StatusBar.idleIcon"); 
        statusAnimationLabel.setIcon(idleIcon); 
        progressBar.setVisible(false); 
 
        // connecting action tasks to status bar via TaskMonitor 
        TaskMonitor taskMonitor = new TaskMonitor(getApplication().getContext()); 
        taskMonitor.addPropertyChangeListener(new java.beans.PropertyChangeListener() { 
            public void propertyChange(java.beans.PropertyChangeEvent evt) { 
                String propertyName = evt.getPropertyName(); 
                if ("started".equals(propertyName)) { 
                    if (!busyIconTimer.isRunning()) { 
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                        statusAnimationLabel.setIcon(busyIcons[0]); 
                        busyIconIndex = 0; 
                        busyIconTimer.start(); 
                    } 
                    //progressBar.setVisible(true); 
                    progressBar.setIndeterminate(true); 
                } else if ("done".equals(propertyName)) { 
                    busyIconTimer.stop(); 
                    statusAnimationLabel.setIcon(idleIcon); 
                    progressBar.setVisible(false); 
                    progressBar.setValue(0); 
                } else if ("message".equals(propertyName)) { 
                    String text = (String)(evt.getNewValue()); 
                    statusMessageLabel.setText((text == null) ? "" : text); 
                    messageTimer.restart(); 
                } else if ("progress".equals(propertyName)) { 
                    int value = (Integer)(evt.getNewValue()); 
                   // progressBar.setVisible(true); 
                    progressBar.setIndeterminate(false); 
                    progressBar.setValue(value); 
                } 
            } 
        }); 
    } 
 
    public void ProduceFig1Ecmdepletion() throws IOException{ 
       int agerep = TurnoverModelApp.Agerepetitions; 
       int startage = TurnoverModelApp.startage+1; 
 
 
        boolean hasbeenfoundmale=false;boolean hasbeenfoundfemale=false; 
 
        double[][] maleCMaliveMillion = new double[agerep][2]; 
        maleCMaliveMillion[0][0]=startage; 
        maleCMaliveMillion[0][1]=TurnoverModelApp.num20yroldMaleCM; 
        int age=startage;int repetitions = agerep; 
        for (int i=1;i<repetitions;i++){ 
            maleCMaliveMillion[i][0]=age+1; 
 
            double startyearCM = maleCMaliveMillion[i-1][1]; 
            int numAnnualCycles = (int) Math.rint(365*24/TurnoverModelApp.apopdurationhours); 
            for (int j=0;j<numAnnualCycles;j++){ 
                double apopLost = ApopCMperMillionCM("Male",age)*(startyearCM/Math.pow(10,6)); 
                startyearCM=startyearCM-apopLost; 
 
            } 
            maleCMaliveMillion[i][1]=startyearCM; 
            if (hasbeenfoundmale==false&&maleCMaliveMillion[i][1]<TurnoverModelApp.num20yroldMaleCM*0.05){ 
                hasbeenfoundmale=true;TurnoverModelApp.male5percAge=maleCMaliveMillion[i][0]; 
            } 
            age++; 
        } 
 
        double[][] femaleCMaliveMillion = new double[agerep][2]; 
        femaleCMaliveMillion[0][0]=startage; 
        femaleCMaliveMillion[0][1]=TurnoverModelApp.num20yroldFemaleCM; 
        age=startage; repetitions = agerep; 
        for (int i=1;i<repetitions;i++){ 
            femaleCMaliveMillion[i][0]=age+1; 
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            double startyearCM = femaleCMaliveMillion[i-1][1]; 
            int numAnnualCycles = (int) Math.rint(365*24/TurnoverModelApp.apopdurationhours); 
            for (int j=0;j<numAnnualCycles;j++){ 
                double apopLost = ApopCMperMillionCM("Female",age)*(startyearCM/Math.pow(10,6)); 
                startyearCM=startyearCM-apopLost; 
            } 
            femaleCMaliveMillion[i][1]=startyearCM; 
             if 
(hasbeenfoundfemale==false&&femaleCMaliveMillion[i][1]<TurnoverModelApp.num20yroldFemaleCM*0.05){ 
                 hasbeenfoundfemale=true;TurnoverModelApp.female5percAge=femaleCMaliveMillion[i][0]; 
             } 
             age++; 
        } 
        System.out.println("Age of 95% Reduction in CM: "+TurnoverModelApp.male5percAge+"-Male, 
"+TurnoverModelApp.female5percAge+"-Female"); 
 
        double[][] combined = new double[repetitions][3]; 
        for (int k=0;k<repetitions;k++){ 
            
combined[k][0]=maleCMaliveMillion[k][0];combined[k][1]=maleCMaliveMillion[k][1];combined[k][2]=femaleCMali
veMillion[k][1]; 
        } 
 
        TurnoverModelApp.holddata=combined; 
        TurnoverModelApp.fileWriter(combined,repetitions , 3, "ApoptosisFig1E"); 
    } 
 
    public void AnversaAgeHistogramforBergmannPatients() throws IOException{ 
          double gtmult=1; 
          int numtoshow = 25; 
          double[][] data = new double[numtoshow][TurnoverModelApp.numBergmann+1]; //columns are age histograms 
(to 25 years) for each patient 
          for (int i=0;i<numtoshow;i++){data[i][0]=numtoshow-i;} 
 
     for (int g=0;g<TurnoverModelApp.numBergmann;g++){ 
        int[] ages = 
{(int)TurnoverModelApp.Bergmann[g][3],(int)TurnoverModelApp.Bergmann[g][3],(int)TurnoverModelApp.Bergman
n[g][3]}; //Dummy ages[] to satisfy CompareHistograms 
 
        String gender = "Male"; if (TurnoverModelApp.Bergmann[g][1]==0){gender = "Female";} 
        CompareHistogramsforVariousPatientAges(gender,ages,1.0,gtmult); 
 
        for (int i=0;i<numtoshow;i++){ 
            data[i][g+1]= 
TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-numtoshow][1]; 
        } 
      } 
      
TurnoverModelApp.fileWriter(data,numtoshow,TurnoverModelApp.numBergmann+1,"BergmannAgeHistosbyAnvers
a"); 
    } 
 
    public double ComputeDeltaC14forConstantTurnover(int patient, double turn, boolean ploidyindependent) throws 
IOException{ 
        turn = turn + 0.0; //must be a decimal (int value will cause error) 
        int birthyear = (int)TurnoverModelApp.Bergmann[patient][2]; int deathyear = 
(int)(TurnoverModelApp.Bergmann[patient][2]+(int)TurnoverModelApp.Bergmann[patient][3]); 
        int lifespan= (int)TurnoverModelApp.Bergmann[patient][3]; 
        double[][] agedist = new double[lifespan][4]; //0=CMage, 3=CMcount at Age 
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        for (int j=0;j<lifespan;j++){ 
                agedist[j][0]=lifespan-j; //CM Age 
 
                if (j>0){agedist[j][3]=turn*Math.pow((1-turn),lifespan-j);} 
                else if (j==0){agedist[j][3]=Math.pow((1-turn),lifespan);} 
         } 
 
        double[][] riemanndata = TurnoverModelApp.convertHistotoRiemannSum(agedist, deathyear-birthyear); 
        //riemanndata = agedist; 
 
        double[][] data = new double[deathyear-birthyear][3]; //0=AgeofCM, 1=#CMProducedofAge, 
2=C14atDateofProduction 
        for (int i=0;i<deathyear-birthyear;i++){ 
            data[i][0]=riemanndata[i][0]; 
            data[i][1]=riemanndata[i][1]; 
            data[i][2]=GetC14atyear(birthyear+i); 
        } 
 
            double[] aveC14postploidy=new double[lifespan];for (int 
w=0;w<lifespan;w++){aveC14postploidy[w]=data[w][2];} 
            if (ploidyindependent==false){ //remove ploidy 
                for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life 
                     double aveC14foragegroup = data[p][2]; 
                    for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p 
                           double percadded = computepersonalizedpolyploidyc14rate(patient, q,1); 
                           aveC14foragegroup = (aveC14foragegroup + percadded*data[q][2])/(1+percadded); 
                    } 
                    data[p][2]=aveC14foragegroup; 
                } 
            } 
 
 
 
        double CMcount=0; double C14count=0; 
        for (int i=0;i<deathyear-birthyear;i++){ 
            CMcount=CMcount+data[i][1];C14count=C14count+data[i][1]*data[i][2]; 
        } 
        double aveC14 = C14count/CMcount; 
 
        //Normalize for PrintOut 
        double c1 = 0;double[][] normdata = data; 
        for (int i=0;i<deathyear-birthyear;i++){c1=c1+normdata[i][1];} 
        for (int i=0;i<deathyear-birthyear;i++){normdata[i][1]=100*normdata[i][1]/c1;} 
 
        TurnoverModelApp.fileWriter(normdata,deathyear-birthyear,3,"/IndividC14/C14"+birthyear+deathyear); 
 
        System.out.println(patient+" AveC14 "+aveC14+", DeltaC14 "+(aveC14-
TurnoverModelApp.getinitialbergmannpatientC14level(patient))); 
        return aveC14-TurnoverModelApp.getinitialbergmannpatientC14level(patient); 
        //return (aveC14-GetC14atyear((double)(birthyear))); 
 
    } 
 
 
 
    public void VaryBirthCycleDuration() throws IOException{ 
        double holdbirthcycle = TurnoverModelApp.cyclelengthhours; 
         
        //Datafile = A=Age, B=CM(CycLengthFactor=1/2), B=CM(CycLengthFactor=1), C=CM(CycLengthFactor=3/2) 
        double[][] data = new double[TurnoverModelApp.Agerepetitions][4]; 
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        for (int p=1;p<=3;p++){ 
            TurnoverModelApp.cyclelengthhours=holdbirthcycle*(0.5*p); 
            HierarchicalModel10g("Male",false,true,false,1,1,1); 
            for (int i=1;i<TurnoverModelApp.Agerepetitions;i++){ 
                data[i][p]=TurnoverModelApp.holddata[i][7];  
                if(p==1){data[i][0]=TurnoverModelApp.holddata[i][0];} 
            }     
        } 
       TurnoverModelApp.fileWriter(data, TurnoverModelApp.Agerepetitions, 4, "VaryBirthRate-M"); 
       TurnoverModelApp.cyclelengthhours=holdbirthcycle; 
 
        data = new double[TurnoverModelApp.Agerepetitions][4]; 
        for (int p=1;p<=3;p++){ 
            TurnoverModelApp.cyclelengthhours=holdbirthcycle*(0.5*p); 
            HierarchicalModel10g("Female",false,true,false,1,1,1); 
            for (int i=1;i<TurnoverModelApp.Agerepetitions;i++){ 
                data[i][p]=TurnoverModelApp.holddata[i][7]; 
                if(p==1){data[i][0]=TurnoverModelApp.holddata[i][0];} 
            } 
        } 
       TurnoverModelApp.fileWriter(data, TurnoverModelApp.Agerepetitions, 4, "VaryBirthRate-F"); 
       TurnoverModelApp.cyclelengthhours=holdbirthcycle; 
 
    } 
 
 
 
    public void ProduceAnnTurnoverFig6c() throws IOException{ 
           //Comparing Kajstura Fig 6 
       boolean allowapop=false; 
 
        TurnoverModelApp.curmethod="AllowNumCellstoFluctuate";allowapop=true; //Comment out if testing Kajstura 
turnover as done in paper (turnover=new cells/constant old cells), allow if testing turnover = new cells/fluctuating old 
cells 
          //Hierchical Model Params: String gender,boolean includeapop,boolean includebirth, boolean 
includeCMsen,double gtmult, double apopfractmult,double apopdurationmult 
 
 
        //Datafile = A=Age, B=M-KajsturaAnnCMTurnover%,C=M-MyModelAnnCMTurnover%,D=F-
KajsturaAnnCMTurnover%,E=F-MyModelAnnCMTurnover% 
        int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5]; 
 
        //Test My Model 
        HierarchicalModel10g("Male",allowapop,true,false,.8,1,1); //GT, Apop Fract, ApopDur 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.holddata[0][6]; 
        for (int 
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0];data[i][2]=TurnoverModelApp.holddata[i][6];} 
 
        HierarchicalModel10g("Female",allowapop,true,false,.8,1,1); 
        data[0][4]=TurnoverModelApp.holddata[0][6]; 
        for (int i=1;i<rep;i++){data[i][4]=TurnoverModelApp.holddata[i][6];} 
 
 
         //Test Kajstura Model 
        for (int i=0;i<rep;i++){ 
            data[i][1]=AnnTurnoverCombinedModel("Male",data[i][0]); 
            data[i][3]=AnnTurnoverCombinedModel("Female",data[i][0]); 
        } 
        TurnoverModelApp.fileWriter(data, rep, 5, "Figure6C"); 
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    } 
 
    public void ProduceKajsturaModelCMoverTime() throws IOException{ 
        //Compare Effect of Apoptosis, Senescence, and Birth  
        //Datafile = A=Age, B=CM(OnlyApop), C=CM(Apop,Birth), D=CM(Apop,Birth,Senescence) 
        int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5]; 
 
        HierarchicalModel10g("Male",true,false,false,1,1,1); 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][1]=TurnoverModelApp.num20yroldMaleCM10g; 
        for (int 
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0]+1;data[i][1]=TurnoverModelApp.holddata[i][5];} 
        HierarchicalModel10g("Male",true,true,false,1,1,1); 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.num20yroldMaleCM10g; 
        for (int i=1;i<rep;i++){data[i][2]=TurnoverModelApp.holddata[i][5];} 
        HierarchicalModel10g("Male",true,true,true,1,1,1); 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][3]=TurnoverModelApp.num20yroldMaleCM10g; 
        for (int i=1;i<rep;i++){data[i][3]=TurnoverModelApp.holddata[i][5];} 
        TurnoverModelApp.fileWriter(data, rep, 4, "KajsturaModel-M"); 
 
        HierarchicalModel10g("Female",true,false,false,1,1,1); 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][1]=TurnoverModelApp.num20yroldFemaleCM10g; 
        for (int 
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0];data[i][1]=TurnoverModelApp.holddata[i][5];} 
        HierarchicalModel10g("Female",true,true,false,1,1,1); 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.num20yroldFemaleCM10g; 
        for (int i=1;i<rep;i++){data[i][2]=TurnoverModelApp.holddata[i][5];} 
        HierarchicalModel10g("Female",true,true,true,1,1,1); 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][3]=TurnoverModelApp.num20yroldFemaleCM10g; 
        for (int i=1;i<rep;i++){data[i][3]=TurnoverModelApp.holddata[i][5];} 
 
        TurnoverModelApp.fileWriter(data, rep, 4, "KajsturaModel-F"); 
    } 
 
    public void HierarchModel10gCompareOnlyApop() throws IOException{ 
        //Comparing Kajstura Fig 1 
 
        //Datafile = A=Age, B=M-KajsturaApopScaled10g,C=M-MyModelApop10g,D=F-KajsturaApopScaled10g,E=F-
MyModelApop10g 
        int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5]; 
 
        double holdnum20yearoldMaleCM=TurnoverModelApp.num20yroldMaleCM; 
        double holdnum20yearoldFemaleCM=TurnoverModelApp.num20yroldFemaleCM; 
 
        //Test Kajstura Models Scaled to 10g 
        TurnoverModelApp.num20yroldMaleCM=TurnoverModelApp.num20yroldMaleCM10g; 
        TurnoverModelApp.num20yroldFemaleCM=TurnoverModelApp.num20yroldFemaleCM10g; 
        ProduceFig1Ecmdepletion();//Holdata COL0=age,COL1=maleWholeHeart,COL2=femaleWholeHeart 
        boolean malefound=false; boolean femalefound=false;double 
malestartCM=TurnoverModelApp.holddata[0][1];double femalestartCM=TurnoverModelApp.holddata[0][2]; 
        for (int i=0;i<rep;i++){ 
            
data[i][0]=TurnoverModelApp.holddata[i][0];data[i][1]=TurnoverModelApp.holddata[i][1];data[i][3]=TurnoverModel
App.holddata[i][2]; 
            if 
(TurnoverModelApp.holddata[i][1]<0.05*malestartCM&&!malefound){malefound=true;System.out.println("Kajstura 
Model Male 5% Year = "+data[i][0]);} 
            if 
(TurnoverModelApp.holddata[i][2]<0.05*femalestartCM&&!femalefound){femalefound=true;System.out.println("Kaj
stura Model Female 5% Year = "+data[i][0]);} 
        } 
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        HierarchicalModel10g("Male",true,false,false,1,1,1); 
        boolean found = false;double startCM = TurnoverModelApp.holddata[0][4]; 
        for (int i=0;i<rep;i++){data[i][2]=TurnoverModelApp.holddata[i][4]; 
          if (TurnoverModelApp.holddata[i][4]<0.05*startCM&&!found){found=true;System.out.println("My Model 
Male 5% Year = "+data[i][0]);} 
        } 
 
        HierarchicalModel10g("Female",true,false,false,1,1,1); 
        found = false; startCM = TurnoverModelApp.holddata[0][4]; 
        for (int i=0;i<rep;i++){data[i][4]=TurnoverModelApp.holddata[i][4]; 
          if (TurnoverModelApp.holddata[i][4]<0.05*startCM&&!found){found=true;System.out.println("My Model 
Female 5% Year = "+data[i][0]);} 
        } 
 
        TurnoverModelApp.fileWriter(data, rep, 5, "CompareModelsofApopAlone"); 
 
        TurnoverModelApp.num20yroldMaleCM=holdnum20yearoldMaleCM; 
        TurnoverModelApp.num20yroldFemaleCM=holdnum20yearoldFemaleCM; 
    } 
 
    public void HierarchModel10gCompareOnlyBirthRateFig6b() throws IOException{ 
        //Comparing Kajstura Fig 6 
 
        //Datafile = A=Age, B=M-KajsturaAnnCMform10g/Million,C=M-MyModelAnnCMform10g/Million,D=F-
KajsturaAnnCMform10g/Million,E=F-MyModelAnnCMform10g/Million 
        int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5]; 
 
        //Test My Model 
        HierarchicalModel10g("Male",false,true,false,1,1,1); 
        double startCM = TurnoverModelApp.holddata[0][4]; 
        data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.holddata[0][4]-startCM; 
        for (int 
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0];data[i][2]=(TurnoverModelApp.holddata[i][3]-
TurnoverModelApp.holddata[i-1][3])/Math.pow(10,6);} 
 
        HierarchicalModel10g("Female",false,true,false,1,1,1); 
        startCM = TurnoverModelApp.holddata[0][4]; 
        data[0][4]=TurnoverModelApp.holddata[0][4]-startCM; 
        for (int i=1;i<rep;i++){data[i][4]=(TurnoverModelApp.holddata[i][3]-TurnoverModelApp.holddata[i-
1][3])/Math.pow(10,6);} 
 
 
         //Test Kajstura Model 
        for (int i=0;i<rep;i++){ 
            data[i][1]=MillionsMyocyteFormationCombinedModelPer10gPerYear("Male",data[i][0]); 
            data[i][3]=MillionsMyocyteFormationCombinedModelPer10gPerYear("Female",data[i][0]); 
        } 
        TurnoverModelApp.fileWriter(data, rep, 5, "CompareModelsofBirthAlone"); 
 
    } 
 
    public void KajsturaModelTurnover() throws IOException{ 
 
        int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][7]; 
        //Datefile = A=age,B=PublishedTurnover,C=BirthRate/MyModelCellsinHeart 
 
        String gender = "Male"; 
        HierarchicalModel10g(gender,true,true,true,1,1,1); 
        for (int i=0;i<rep;i++){ 
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            data[i][0]=TurnoverModelApp.holddata[i][0]; 
            data[i][1]=AnnTurnoverCombinedModel(gender,data[i][0]); 
            data[i][2]=100*TurnoverModelApp.holddata[i][7]/TurnoverModelApp.holddata[i][2]; 
        } 
 
        gender = "Female"; 
        HierarchicalModel10g(gender,true,true,true,1,1,1); 
        for (int i=0;i<rep;i++){ 
            data[i][4]=TurnoverModelApp.holddata[i][0]; 
            data[i][5]=AnnTurnoverCombinedModel(gender,data[i][0]); 
            data[i][6]=100*TurnoverModelApp.holddata[i][7]/TurnoverModelApp.holddata[i][2]; 
        } 
        TurnoverModelApp.fileWriter(data,rep,7,"TurnoverComparison"); 
    } 
 
    public void VaryApopRateforHistograms() throws IOException{ 
        double gtmult=1; 
        int numtoshow = 25;double[][] data = new double[numtoshow][10]; //0=Age(25->1),1=Y-80%,2=Y-100%,3=Y-
120%,4=M-80%,5=M-100%,6=M-120%,7=O-80%,8=O-100%,9=O-120% 
        double holdapop = TurnoverModelApp.apopdurationhours; 
 
        for (int i=0;i<numtoshow;i++){data[i][0]=numtoshow-i;} 
 
      String gender = "Male"; int[] ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=74; 
        TurnoverModelApp.apopdurationhours=holdapop*0.8; 
        CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        TurnoverModelApp.apopdurationhours=holdapop*1.0; 
        CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        TurnoverModelApp.apopdurationhours=holdapop*1.2; 
        CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
        TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryApopHistogram-M"); 
 
        gender = "Female"; ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=80; 
        TurnoverModelApp.apopdurationhours=holdapop*0.8; 
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        CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        TurnoverModelApp.apopdurationhours=holdapop*1.0; 
        CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        TurnoverModelApp.apopdurationhours=holdapop*1.2; 
        CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
        TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryApopHistogram-F"); 
 
 
        TurnoverModelApp.apopdurationhours=holdapop*1.0; 
    } 
 
      public void VaryHalfLifeforHistograms() throws IOException{ 
        double gtmult=1; 
        int numtoshow = 25;double[][] data = new double[numtoshow][10]; //0=Age(25->1),1=Y-80%,2=Y-100%,3=Y-
120%,4=M-80%,5=M-100%,6=M-120%,7=O-80%,8=O-100%,9=O-120% 
 
        for (int i=0;i<numtoshow;i++){data[i][0]=numtoshow-i;} 
 
      String gender = "Male"; int[] ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=74; 
        CompareHistogramsforVariousPatientAges(gender,ages,0.8,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        CompareHistogramsforVariousPatientAges(gender,ages,1.0,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
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            data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        CompareHistogramsforVariousPatientAges(gender,ages,1.2,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
        TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryHLhistogram-M"); 
 
        gender = "Female"; ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=80; 
        CompareHistogramsforVariousPatientAges(gender,ages,0.8,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        CompareHistogramsforVariousPatientAges(gender,ages,1.0,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
 
        CompareHistogramsforVariousPatientAges(gender,ages,1.2,gtmult); 
        for (int i=0;i<numtoshow;i++){ 
            data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][1]; 
            data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][2]; 
            data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-
numtoshow][3]; 
        } 
        TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryHLhistogram-F"); 
 
    } 
 
public void VaryHalfLifeforC14andPerc() throws IOException{ 
 
    double hmult = 1.0;//halflife, 
    double gtmult=1.0;//expansion exponent 
    CompareAversaBergmannPercent(hmult,gtmult);//hmult, gtmult 
    
} 
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    public void CompareHistogramsforVariousPatientAges(String gender,int[] ages,double halflifemultiplier,double 
gtmult) throws IOException{ 
        double[][] data = new double[TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage+50][4]; 
        for (int 
i=0;i<TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage;i++){data[i][0]=TurnoverModelApp.Agerepetit
ions+TurnoverModelApp.startage-i;} 
 
        //Age Selection is Very Critical to Fit with Anversa Figure 7 
 
        int patientage=ages[0]; 
        ComputeAgeHistograms(gender,patientage,halflifemultiplier,gtmult,1,true); 
        int start=TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-patientage; 
        for (int i=start;i<start+patientage;i++){data[i][1]=TurnoverModelApp.holddata[i-start][3];} 
 
        patientage=ages[1]; 
        ComputeAgeHistograms(gender,patientage,halflifemultiplier,gtmult,1,true); 
        start=TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-patientage; 
        for (int i=start;i<start+patientage;i++){data[i][2]=TurnoverModelApp.holddata[i-start][3];} 
 
        patientage=ages[2]; 
        ComputeAgeHistograms(gender,patientage,halflifemultiplier,gtmult,1,true); 
        start=TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-patientage; 
        for (int i=start;i<start+patientage;i++){data[i][3]=TurnoverModelApp.holddata[i-start][3];} 
 
        //Normalize to % 
        double c1 = 0; double c2=0; double c3=0; 
        for (int 
i=0;i<TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage+50;i++){c1=c1+data[i][1];c2=c2+data[i][2];c3
=c3+data[i][3];} 
        for (int 
i=0;i<TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage+50;i++){data[i][1]=100*data[i][1]/c1;data[i][2
]=100*data[i][2]/c2;data[i][3]=100*data[i][3]/c3;} 
 
        
TurnoverModelApp.holddata2=data;TurnoverModelApp.holdnumrows2=TurnoverModelApp.Agerepetitions+Turnove
rModelApp.startage; 
 
        
TurnoverModelApp.fileWriter(data,TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage,4,"HistogrambyP
atientAge"); 
    } 
 
    public double ComputeAveC14atDeath(int patient, String gender, int patientbirthyear,int patientdeathyear,double 
hmult,double gtmult, double apopmultfract,boolean recompute) throws IOException{ 
 
       //Turn on for Anversa Histograms and Off for Bergmann 
       if (recompute){ 
           ComputeAgeHistograms(gender,patientdeathyear-patientbirthyear,hmult,gtmult,apopmultfract,true); 
       } 
 
        double[][] riemanndata = TurnoverModelApp.convertHistotoRiemannSum(TurnoverModelApp.holddata, 
patientdeathyear-patientbirthyear); 
 
 
        double[][] data = new double[patientdeathyear-patientbirthyear][3]; //0=AgeofCM, 1=#CMProducedofAge, 
2=C14atDateofProduction 
        for (int i=0;i<patientdeathyear-patientbirthyear;i++){ 
            data[i][0]=riemanndata[i][0]; 
            data[i][1]=riemanndata[i][1]; 
            data[i][2]=GetC14atyear(patientbirthyear+i); 
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        }       
       data[0][2]=TurnoverModelApp.getinitialbergmannpatientC14level(patient); 
 
 
        //TurnoverModelApp.fileWriter(data,patientdeathyear-patientbirthyear,3,"C14forPatient"); 
 
        double CMcount=0; double C14count=0; 
        for (int i=0;i<patientdeathyear-patientbirthyear;i++){ 
            CMcount=CMcount+data[i][1];C14count=C14count+data[i][1]*data[i][2]; 
        } 
        double aveC14 = C14count/CMcount; 
        System.out.println(aveC14); 
        //System.out.println("Delta C14: "+(aveC14-GetC14atyear((double)(patientbirthyear)))); 
 
        //Normalize for PrintOut 
        double c1 = 0;double[][] normdata = data; 
        for (int i=0;i<patientdeathyear-patientbirthyear;i++){c1=c1+normdata[i][1];} 
        for (int i=0;i<patientdeathyear-patientbirthyear;i++){normdata[i][1]=100*normdata[i][1]/c1;} 
 
        TurnoverModelApp.fileWriter(normdata,patientdeathyear-
patientbirthyear,3,"/IndividC14/C14"+patientbirthyear+patientdeathyear); 
 
        return aveC14; 
    } 
 
    public void CompareAnversaBergmannC14(double hmult, double gtmult) throws IOException{ 
        //double hmult=1.0;double gtmult=1.0; 
 
        double[][] patients = new double[12][3]; //Patient,Bergmann Raw Delta C14,AnversaPredictedDeltaC14 
        String gender=""; 
        for (int i=0;i<12;i++){ 
            patients[i][0]=TurnoverModelApp.Bergmann[i][0]; 
            patients[i][1]=TurnoverModelApp.Bergmann[i][7]; 
            if (TurnoverModelApp.Bergmann[i][1]==1){gender="Male";}else if 
(TurnoverModelApp.Bergmann[i][1]==0){gender="Female";}else{System.out.println("Gender 
Error"+TurnoverModelApp.Bergmann[i][2]);} 
            
patients[i][2]=ComputeAveC14atDeath(i,gender,(int)TurnoverModelApp.Bergmann[i][2],(int)(TurnoverModelApp.Be
rgmann[i][2]+TurnoverModelApp.Bergmann[i][3]),hmult,gtmult,1,true); 
             
            patients[i][2]=patients[i][2]-TurnoverModelApp.getinitialbergmannpatientC14level(i); 
 
 
           // patients[i][2]=patients[i][2]-GetC14atyear(TurnoverModelApp.Bergmann[i][2]); 
        } 
 
      TurnoverModelApp.fileWriter(patients,12,3,"BergmannAnversaC14"); 
      TurnoverModelApp.holddata=patients;TurnoverModelApp.holdnumrows=12; 
    } 
 
    public void CompareAversaBergmannPercent(double hmult, double gtmult) throws IOException{ 
 
        CompareAnversaBergmannC14(hmult, gtmult); 
 
       double[][] data = new double[12][3]; //patient, Bergmann Reported %, Anversa-Produced Bergmann 
 
       double C14multiplier=1.0; 
       for (int i=0;i<12;i++){ 
           data[i][0]=TurnoverModelApp.Bergmann[i][0]; 
           data[i][1]=TurnoverModelApp.Bergmann[i][6]; 
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data[i][2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelA
pp.Bergmann[i][3],C14multiplier*TurnoverModelApp.holddata[i][2],TurnoverModelApp.initguess,true,1.0,0); 
       } 
        System.out.println("Finished"); 
       TurnoverModelApp.fileWriter(data,12,3,"BergmannAnversaPerc"); 
    } 
 
 
 
public void ComputeAgeHistograms(String gender, int patientage,double halflifemultiplier,double gtmult,double 
apopfractmult, boolean addploidy) throws IOException{ 
       double BergmannTurnover=0.01;double cellsinheart=500000000; 
       boolean senescencebool = false; //normally true, try false for trajectories 
 
        double[][] CMbyAge = new double[patientage][4];//0=AgeofCM, 1=Number of Age Births,2=N(a) No Apop 
Funct, 3=N(a) 
 
        //false turns off apoptosis so it can be handled with random kill applied to previous cycles below 
        HierarchicalModel10g(gender,false,true,senescencebool,gtmult,1,1); 
        for (int i=0;i<patientage;i++){CMbyAge[i][0]=patientage-i;} 
         
        ///for (int i=0;i<patientage;i++){CMbyAge[i][1]=TurnoverModelApp.holddata[i][7];} //For Kajstura 
        //Make constant to match Bergmann (or age declining) 
        for (int i=0;i<patientage;i++){CMbyAge[i][1]=BergmannTurnover*cellsinheart;} //New CM in Year 
 
       for (int i=0;i<patientage;i++){ 
               double n = 500*Math.pow(10,6); 
               //n = TurnoverModelApp.holddata[i][2];  //Total Myocyte Count Allowed to Vary with Age, Comment Out to 
Fix CM count at 500 Million 
               double a=CMbyAge[i][0];  //a = age of CM at TIME OF DEATH 
               double h; 
 
             h = TimetoSenescence(gender,i)/2; //Variable is required for older patients to have young CM.  Reverse if h is 
constant 
             h = h*halflifemultiplier; //usually 1.0 
 
            CMbyAge[i][2]=n*Math.exp(-1*((Math.pow(a,2))/(2*Math.pow(h,2))));CMbyAge[i][3]=CMbyAge[i][2]; 
 
            for (int j=0;j<=i;j++){ 
               double deathcyclesperyear = 365*24/TurnoverModelApp.apopdurationhours; 
               for (int k=0;k<=deathcyclesperyear;k++){ 
                 CMbyAge[i][3] = CMbyAge[i][3]-
(CMbyAge[j][2])*apopfractmult*ApopCMperMillionCM(gender,i)/Math.pow(10,6); //using i instead of j means i 
takes all death 
               } 
            } 
            if (CMbyAge[i][3]<0){CMbyAge[i][3]=0;} 
        }//patientage for loop 
 
            if (addploidy){ //Worst Case Scenario For Concordance - Adds All Ploidy to End 
                double TetraPerc = AnversaPloidyLinear4n(gender,patientage);double 
OctaPerc=AnversaPloidyLinear8n(gender,patientage); 
                CMbyAge[patientage-1][3]=CMbyAge[patientage-
1][3]+TetraPerc*TurnoverModelApp.holddata[patientage-1][2]+2*OctaPerc*TurnoverModelApp.holddata[patientage-
1][2]; 
            } 
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        TurnoverModelApp.holddata=CMbyAge;TurnoverModelApp.holdnumrows=patientage; 
        TurnoverModelApp.fileWriter(CMbyAge,patientage,4,"AgeHistogram"); 
    } 
 
  public void HierarchicalModel10g(String gender,boolean includeapop,boolean includebirth, boolean 
includeCMsen,double gtmult, double apopfractmult,double apopdurationmult) throws IOException{ 
     // System.out.println("GTmult"+gtmult); 
      int Agerepetitions = TurnoverModelApp.Agerepetitions; 
        int startage = TurnoverModelApp.startage; 
 
        double[][] CellTypesByAge = new double[Agerepetitions][8]; 
//0=Age,1=FunctCompCSCs,2=StartingCM,3=CMafterBirths,4=CMafterapop,5=CMafterCMSenescence(afterApopC
M),6=PercTurnOver,7=NewCMinYear 
 
        double cyclemult = 1; 
 
        CellTypesByAge[0][0]=startage; 
 
        CellTypesByAge[0][1]=CSCper10gram(gender,startage); 
 
 
        if (gender.equals("Male")){CellTypesByAge[0][2] = 
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][2] = 
TurnoverModelApp.num20yroldFemaleCM10g;} 
        if (gender.equals("Male")){CellTypesByAge[0][3] = 
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][3] = 
TurnoverModelApp.num20yroldFemaleCM10g;} 
        if (gender.equals("Male")){CellTypesByAge[0][4] = 
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][4] = 
TurnoverModelApp.num20yroldFemaleCM10g;} 
        if (gender.equals("Male")){CellTypesByAge[0][5] = 
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][5] = 
TurnoverModelApp.num20yroldFemaleCM10g;} 
        startage++; 
 
        double CMbirthsPerCycle=0; double FunctCSCs=0;int deathcyclesperbirthcycle = 
(int)Math.rint((cyclemult*TurnoverModelApp.cyclelengthhours)/(apopdurationmult*TurnoverModelApp.apopduration
hours)); 
        int cyclesperyear=(int) Math.rint(365*24/(cyclemult*TurnoverModelApp.cyclelengthhours)); 
 
        for (int i=1;i<Agerepetitions;i++){ 
            CellTypesByAge[i][7]=0; //NewCMinYear 
 
            CellTypesByAge[i][0]=startage; 
 
            //Starting CM = Last End (After Birth and Apop Removal but BEFORE Senescence BC Senescence is 
Measured Percent Found So Not Iterative) 
            CellTypesByAge[i][2]=CellTypesByAge[i-1][4]; 
 
            //Prior to Birth/Death, Initialize to Start 
            CellTypesByAge[i][3]=CellTypesByAge[i][2]; 
            CellTypesByAge[i][4]=CellTypesByAge[i][3]; //Initialize Prior to Apop 
            CellTypesByAge[i][5]=CellTypesByAge[i][4]*(1-PercP16ink4aPositiveCM(gender,startage)/100);; 
 
            for (int b=0;b<cyclesperyear;b++){ //Assumes CMbirthsPerCycle is constant throughout year 
 
                FunctCSCs=FunctCompCSCsper10g(gender,startage); 
 
                double LCCs = Math.pow(2,0)*FunctCSCs; //Right Now, No Expansion for LCC. All in Gt 
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                double PercCycling = 
(CSCper10gram(gender,startage)*PercOfCSCcycling(gender,startage)/(FunctCompCSCsper10g(gender,startage)))/100
; 
 
                //Don't divide by cycle length since per cycle 
                double gt = GTbyAge(gender,startage)*gtmult; 
 
              CMbirthsPerCycle =PercCycling*LCCs*Math.pow(2,gt); 
                    //System.out.println(gt+" "+CMbirthsPerCycle); 
              //CMafterBirths 
              if (includebirth==true){ 
              CellTypesByAge[i][3]=CellTypesByAge[i][3]+CMbirthsPerCycle; 
              CellTypesByAge[i][4]=CellTypesByAge[i][4]+CMbirthsPerCycle; 
              CellTypesByAge[i][5]=CellTypesByAge[i][5]+CMbirthsPerCycle; 
              CellTypesByAge[i][7]=CellTypesByAge[i][7]+CMbirthsPerCycle;//NewCMinYear Explicitly 
              } 
 
              //Subtract Apoptosis  (Assumes apop cycle < prolif cycle) 
              //Assumes only CM apoptose 
              //Assumes Birth Occurs Before Apoptosis Starts & Newly Born CM Can't be Killed Right Away 
              if (includeapop==true){ 
              for (int p=0;p<deathcyclesperbirthcycle;p++){ 
                 CellTypesByAge[i][4]=CellTypesByAge[i][4]-
(apopfractmult*ApopCMperMillionCM(gender,startage)*(CellTypesByAge[i][4]/Math.pow(10,6))); 
              } 
              } 
 
              //Scale for Senescence of MYOCYTES after Birth and Apoptosis 
              if (includeCMsen==true){ 
              CellTypesByAge[i][5]=CellTypesByAge[i][4]*(1-PercP16ink4aPositiveCM(gender,startage)/100); 
              } 
            } 
 
            //Compute Turnover 
               double CMper10g=0; 
               //If Assumption of Constant Denominator (500 Million CM per 10g) 
               if 
(gender.equals("Male")){CMper10g=TurnoverModelApp.num20yroldMaleCM10g;}else{CMper10g=TurnoverModel
App.num20yroldFemaleCM10g;} 
 
               if (TurnoverModelApp.curmethod.equals("AllowNumCellstoFluctuate")){ 
                   CMper10g =CellTypesByAge[i][2];System.out.println(i+" "+CellTypesByAge[i][7]+" 
"+CellTypesByAge[i][2]+" "+Math.round(100*CellTypesByAge[i][7]/CellTypesByAge[i][2])); 
               } 
 
               CellTypesByAge[i][6]=100*CellTypesByAge[i][7]/CMper10g; 
 
            startage++; 
 
        } 
        
TurnoverModelApp.holddata=CellTypesByAge;TurnoverModelApp.holdnumrows=Agerepetitions;TurnoverModelAp
p.holdnumcol=8; 
 
  } 
 
  
    //Compiled Data Extraction 
    public double PercP16ink4aPositiveCM(String gender,double ageyears){ 
        //From Kajstura Fig 1.  Intercepts Estimated 
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        double perc=0; 
        if (gender.equals("Female")){perc = 0.68*ageyears+0;} 
        else if (gender.equals("Male")){perc = 0.89*ageyears+5;} 
        return perc; 
    } 
 
    public double ApopCMperMillionCM(String gender,double ageyears){ 
        //From Kajstura Fig 1.  Intercepts Estimated 
         
        double apop=0; 
        if (gender.equals("Female")){apop = 1.23*ageyears-18;} 
        else if (gender.equals("Male")){apop = 1.31*ageyears+7;} 
        return apop; 
         
        //From Mallet 
      /*  double apop=0; 
        if (gender.equals("Female")){apop = 42;} 
        else if (gender.equals("Male")){apop = 133;} 
        return apop;*/ 
    } 
 
     public double CSCper10gram(String gender,double ageyears){ 
        //From Kajstura Fig 2.  Intercepts Estimated 
        double CSCs=0; 
        if (gender.equals("Female")){CSCs = 2.344*ageyears - 26;}//CSCs = 2.344*ageyears - 37; 
        else if (gender.equals("Male")){CSCs = 1.44*ageyears - 10;} 
        CSCs = CSCs*1000; 
        return CSCs; 
    } 
 
    public double PercOfCSCcycling(String gender,double ageyears){ 
        //From Kajstura Fig 2.  Intercepts Estimated 
        double perc=0; 
        if (gender.equals("Female")){perc = 0.0514*ageyears + 4.5;}//0.0514*ageyears + 4.1; 
        else if (gender.equals("Male")){perc = 0.0193*ageyears+5;} 
        return perc; 
    } 
 
    public double PercOfCSCsenescent(String gender,double ageyears){ 
        //From Kajstura Fig 3.  Intercepts Estimated 
        double perc=0; 
        if (gender.equals("Female")){perc = 0.59*ageyears - 3.6;} 
        else if (gender.equals("Male")){perc = 0.73*ageyears + 3.6;} 
        return perc; 
    } 
 
    public double FunctCompCSCsper10g(String gender,double ageyears){ 
        //From Kajstura Fig 3.  Intercepts Estimated 
        double CSCs=0; 
        if (gender.equals("Female")){CSCs = 918*ageyears + 0;} 
        else if (gender.equals("Male")){CSCs = 295*ageyears + 20000;} 
        return CSCs; 
    } 
 
    public double GTbyAge(String gender,double ageyears){ 
        //From Kajstura Fig 3.  Intercepts Estimated 
        double GT=0; 
        if (gender.equals("Female")){GT = -0.0091*ageyears + 5.8;}//-0.0086*ageyears + 6; 
        else if (gender.equals("Male")){GT = -0.0036*ageyears + 5.4;} 
        return GT; 
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    } 
 
    public void GetKajsturaTurnoverDenominatorinHeart(){ 
        double ave = 0; double numpoints = 0; double thisyear=0; 
        for (int i=20;i<100;i++){ 
            
thisyear=1000000*MillionsMyocyteFormationCombinedModelPer10gPerYear("Female",i)/AnnTurnoverCombinedMo
del("Female",i); 
            System.out.println(thisyear); 
            ave=ave+thisyear;numpoints++; 
        } 
        ave=ave/numpoints; 
        System.out.println("Ave:  "+ave); 
    } 
 
    public double MillionsMyocyteFormationCombinedModelPer10gPerYear(String gender,double ageyears){ 
        //From Kajstura Fig 6.  Intercepts Estimated 
        double MillionsNewCMPerYear=0; 
        if (gender.equals("Female")){MillionsNewCMPerYear = 2.5*ageyears - 34;} 
        else if (gender.equals("Male")){MillionsNewCMPerYear = 1.0*ageyears + 0;} 
        return MillionsNewCMPerYear; 
    } 
 
    public double AnnTurnoverCombinedModel(String gender,double ageyears){ 
        //From Kajstura Fig 6.  Intercepts Estimated 
        double AnnPerc=0; 
        if (gender.equals("Female")){AnnPerc = 0.434*ageyears - 4;} 
           if(AnnPerc<0){AnnPerc=0;} 
        else if (gender.equals("Male")){AnnPerc = 0.2*ageyears + 0;} 
        return AnnPerc; 
    } 
 
    public double AnversaPloidyLinear4n(String gender, double ageyears){ 
        //From Kajstura Fig 5.  Points Estimated 
        double perc=0; 
        if (gender.equals("Female")){perc = 0.000259*ageyears + 0.001457;} 
        else if (gender.equals("Male")){perc = 0.000176*ageyears + 0.003647;} 
        return perc; 
    } 
 
    public double AnversaPloidyLinear8n(String gender, double ageyears){ 
        //From Kajstura Fig 5.  Points Estimated 
        double perc=0; 
        if (gender.equals("Female")){perc = 0.000063*ageyears + 0.002799;} 
        else if (gender.equals("Male")){perc = 0.000057*ageyears + 0.002910;} 
        return perc; 
    } 
 
    public double TimetoSenescence(String gender, double ageyears){ 
        //From Kajstura Supp. Fig XIV.  Intercepts Estimated 
        double tts=0; 
        if (gender.equals("Female")){tts = -0.16*ageyears + 17.4;} 
        else if (gender.equals("Male")){tts = -0.19*ageyears + 17.4;} 
 
        if (tts<0){tts=0;} 
        return tts; 
    } 
 
     public double PercPostMitNonSenCM(String gender, double ageyears){ 
        //From Kajstura Fig 4.  Intercepts Estimated 
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        double tts=0; 
        if (gender.equals("Female")){tts = -0.69*ageyears + 100;} 
        else if (gender.equals("Male")){tts = -0.89*ageyears + 94;} 
 
        if (tts<0){tts=0;} 
        return tts; 
    } 
 
   
    public static double GetC14atyear(double year){ 
        //Returns first datapoint of that exceeds year (Consider for Rounding) 
        double C14=-100; boolean found=false; 
        for (int i=0;i<TurnoverModelApp.numC14points;i++){ 
            if (!found&&TurnoverModelApp.C14points[i][0]>=year){ 
 
                //Average Over Year 
                int thisyear = (int)TurnoverModelApp.C14points[i][0]; 
                int count=0;double c14=0; 
                for (int j=0;j<TurnoverModelApp.numC14points;j++){ 
                    if ((int)TurnoverModelApp.C14points[j][0]==thisyear){ 
                        c14=c14+TurnoverModelApp.C14points[j][1];count++; 
                    } 
                } 
                C14=c14/count; 
                 
                //Does Not Average Over Year 
                C14=TurnoverModelApp.C14points[i][1]; 
 
                found=true; 
                return C14; 
            } 
        } 
 
        if (C14==-100){C14=TurnoverModelApp.C14points[TurnoverModelApp.numC14points-1][1];} 
        return C14; 
 
    } 
 
    public static void TestPloidy() throws IOException{ 
        int numtotest=20; 
        double[][] data = new double[TurnoverModelApp.numBergmann][numtotest+1]; //each row is a patient, each 
column is i/10% of Bergmann ploidy applied 
 
        double perc=0; 
        for (int j=0;j<=numtotest;j++){ 
            for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
              data[i][j]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2], 
(int)TurnoverModelApp.Bergmann[i][3],TurnoverModelApp.Bergmann[i][7],TurnoverModelApp.initguess,true,.1*j,0)
; 
            } 
        } 
        TurnoverModelApp.fileWriter(data, TurnoverModelApp.numBergmann, numtotest+1, "TestPloidy"); 
    } 
 
 
    public static void TestScenarioA() throws IOException{ 
        double[][] data = new 
double[TurnoverModelApp.numBergmann][3];//Patient,BergmannReported,BergmannScenA 
        double scale=1;double delay=TurnoverModelApp.delay;//Scale controls polyploidy magnitude, delay controls 
delay from C14 atmosphere to body 
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        for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
           double initguess=TurnoverModelApp.initguess; 
           //Use scale*TurnoverModelApp.Bergmann[i][7] for no ploidy correction, [i][4] for correction 
           data[i][2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2], 
(int)TurnoverModelApp.Bergmann[i][3],TurnoverModelApp.Bergmann[i][7],initguess,true,scale,0); 
           data[i][0]=i;data[i][1]=TurnoverModelApp.Bergmann[i][6]; 
        } 
 
        TurnoverModelApp.holddata3=data;TurnoverModelApp.holdnumrows3=TurnoverModelApp.numBergmann; 
TurnoverModelApp.holdnumcol3=3; 
        TurnoverModelApp.fileWriter(data, TurnoverModelApp.numBergmann, 3, "ScenarioA"); 
    } 
 
 
public static void GlobalFit() throws IOException{ 
    String scenario = "E2"; 
 
    //global mode 
    GlobalFitRange(scenario,0,TurnoverModelApp.numBergmann); 
     
    //individual patient list mode 
    //for (int i=0;i<TurnoverModelApp.numBergmann;i++){GlobalFitRange(scenario,i,i+1);  } 
 
    //single patient model 
    //GlobalFitRange(scenario,6,7); 
 
    //GetCMAgeHistogramwithGlobal(); 
} 
 
public static void GlobalFitRange(String scenario,int spatient, int endpatient) throws IOException{ 
   double lowesterr=999999999; double holdbesterr=0; 
 
   if (scenario.equals("A")){ 
       double Aparam = 0; TurnoverModelApp.modelparams = new double[1]; 
       for (int k=0;k<10000;k++){ 
           TurnoverModelApp.modelerror=0; 
           for (int i=spatient;i<endpatient;i++){ 
               
TurnDeltaC14intoScenarioTurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i][3
],Aparam,Aparam); 
         } 
           //System.out.println("B: "+Math.round(10000*Aparam)*0.01+"%, D: "+Math.round(10000*Aparam)*0.01+"%, 
E: "+TurnoverModelApp.modelerror); 
           if 
(TurnoverModelApp.modelerror<lowesterr){lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelpar
ams[0]=Aparam;} 
           Aparam=Aparam+0.0001; 
       } 
   System.out.println("BF Turnover: "+100*TurnoverModelApp.modelparams[0]+"%, SSE="+lowesterr); 
   } 
 
   if (scenario.equals("B")){ 
       double Bbirth = 0; double Bdeath=0; TurnoverModelApp.modelparams = new double[2]; 
       for (int k=0;k<100;k++){ 
          Bdeath=0; 
          for (int d=0;d<10;d++){ 
             TurnoverModelApp.modelerror=0; 
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             for (int i=spatient;i<endpatient;i++){ 
               
TurnDeltaC14intoScenarioTurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i][3
],Bdeath,Bbirth); 
             } 
             if 
(TurnoverModelApp.modelerror<lowesterr){lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelpar
ams[0]=Bbirth;TurnoverModelApp.modelparams[1]=Bdeath;   } 
             //System.out.println("B: "+Math.round(10000*Bbirth)*0.01+"%, D: "+Math.round(10000*Bdeath)*0.01+"%, 
E: "+TurnoverModelApp.modelerror); 
             Bdeath=Bdeath+0.001; 
           } 
           Bbirth=Bbirth+0.001; 
       } 
   System.out.println("BF Turnover: B="+100*TurnoverModelApp.modelparams[0]+"%, 
D="+100*TurnoverModelApp.modelparams[1]+"%, SSE="+lowesterr); 
   } 
 
   if(scenario.equals("E2")){ 
       TurnoverModelApp.modelparams = new double[2]; 
        
       double gamma0low = 0; double gamma0high = .5;double gamma0increment = 0.01; 
       double gamma1low = 0.0; double gamma1high = 2;double gamma1increment = 0.05; 
 
       int gamma0reps = (int) Math.rint((gamma0high - gamma0low)/gamma0increment); 
       int gamma1reps = (int) Math.rint((gamma1high - gamma1low)/gamma1increment); 
 
       if (gamma0reps==0){gamma0reps=1;}if (gamma1reps==0){gamma1reps=1;} 
 
       double gamma0=gamma0low;double gamma1=gamma1low; 
       for (int k=0;k<gamma0reps;k++){ //controls gamma0 
          gamma1=gamma1low; 
          for (int d=0;d<gamma1reps;d++){//controls gamma1 
               TurnoverModelApp.modelerror=0; 
               for (int i=spatient;i<endpatient;i++){ 
                 
TurnDeltaC14intoScenarioE2Turnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i
][3],gamma0,gamma1); 
               } 
               if 
(TurnoverModelApp.modelerror<lowesterr){lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelpar
ams[0]=gamma0;TurnoverModelApp.modelparams[1]=gamma1; holdbesterr= TurnoverModelApp.modelerror; } 
             //System.out.println("G0: "+gamma0+", G1: "+gamma1+", E: "+TurnoverModelApp.modelerror); 
             gamma1=gamma1+gamma1increment; 
         } 
         gamma0=gamma0+gamma0increment; 
 
      } 
      System.out.println("BEST: Gamma0: "+TurnoverModelApp.modelparams[0]+", Gamma1: 
"+TurnoverModelApp.modelparams[1]+", E: "+holdbesterr); 
   } 
    
      if (scenario.equals("TVB-TVDR")){  //Birth increases with patient age, Annual Death rate of CM increases with 
patient age 
          double desiredDINTrange = 0.1; //0.05 = 0->5% 
          int numrepsDINT = 10; 
 
          double desiredBINTrange=0.1; //0.05 = 0->10% 
          int numrepsBINT = 10; 
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          double desiredDSLOPErange=0.01;  //0.005 = -0.005 -> 0.005, in per year 
          int numrepsDSLOPE = 20; 
 
          double desiredBSLOPErnage=0.01;//0.005 = -0.005 -> 0.005, in per year 
           int numrepsBSLOPE = 20; 
 
       double bslope = -1*desiredBSLOPErnage; double bint=0; double dslope=-1*desiredDSLOPErange; double dint=0; 
TurnoverModelApp.modelparams = new double[4]; 
       for (int b0=0;b0<numrepsBSLOPE;b0++){ //controls bslope 
          System.out.println("Progress:"+ (int)(100*b0/numrepsBSLOPE)+"%"); 
          bint=0; 
          for (int b1=0;b1<numrepsBINT;b1++){ //controls bint 
               dslope=-1*desiredDSLOPErange; 
               for(int d0=0;d0<numrepsDSLOPE;d0++){ //controls slope 
               dint=0; 
               for (int d1=0;d1<numrepsDINT;d1++){ //controls dint 
                   TurnoverModelApp.modelerror=0; 
                   for (int i=spatient;i<endpatient;i++){ 
                      
GfitCustomScenVaryDeath(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i][3],bslope,
bint,dslope,dint); 
                   } 
                   if (TurnoverModelApp.modelerror<lowesterr){ 
                       
lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelparams[0]=bslope;TurnoverModelApp.modelpar
ams[1]=bint;TurnoverModelApp.modelparams[2]=dslope;TurnoverModelApp.modelparams[3]=dint; 
                       
TurnoverModelApp.holddouble2=lowesterr;TurnoverModelApp.holddouble3=TurnoverModelApp.holddouble;//Test 
Scenario A 
                   } 
                dint=dint+desiredDINTrange/numrepsDINT;  
TurnoverModelApp.holddouble=TurnoverModelApp.holddouble+0.0001;//Test Scenario A 
               } 
               dslope=dslope+2*desiredDSLOPErange/numrepsDSLOPE; 
             } 
             bint=bint+desiredBINTrange/numrepsBINT; 
           } 
           bslope=bslope+2*desiredBSLOPErnage/numrepsBSLOPE; 
            
       } 
   System.out.println("BF Turnover: Bs="+TurnoverModelApp.modelparams[0]+", Bi= 
"+TurnoverModelApp.modelparams[1]+", Ds: "+TurnoverModelApp.modelparams[2]+", Di: 
"+TurnoverModelApp.modelparams[3]+", SSE= "+lowesterr); 
   } 
   //System.out.println("FINISH A "+TurnoverModelApp.holddouble2+" "+TurnoverModelApp.holddouble3); //Test 
Scenario A 
}//end global method 
 
public static void GetC14forScenarioE2() throws IOException{ 
    double gamma0=0.123;double gamma1=1.42; 
 
     for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
       
TurnDeltaC14intoScenarioE2Turnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i
][3],gamma0,gamma1); 
    } 
} 
 
 
public static void GetCMAgeHistogramwithGlobal() throws IOException{ 
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    double bslope=0.001;double bint=0.03;double dslope = 0.004; double dint=0.02; //bestfit 
    //double bslope=0.0;double bint=0.03;double dslope = 0.004; double dint=0.025; //secondbestfit 
    //double bslope=-0.0004;double bint=0.03;double dslope = 0.002; double dint=0.035; //thirdbestfit 
    //double bslope=0;double bint=0.01;double dslope = 0; double dint=.01; //constant 
 
 
 
    double[] endC14= new double[TurnoverModelApp.numBergmann]; 
    for(int i=0;i<TurnoverModelApp.numBergmann;i++){ 
        
endC14[i]=GfitCustomScenVaryDeath(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i
][3],bslope,bint,dslope,dint); 
        System.out.println(endC14[i]); 
    } 
} 
 
 public static double GfitCustomScenVaryDeath(int patient,int birthyear, int lifespan,double birthslope,double 
birthintercept,double deathslope,double deathintercept) throws IOException{ 
  
 
        double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear 
 
        //assume totally random turnover but variable death rate 
            agedist = new double[lifespan+1][3]; 
            for (int j=0;j<=lifespan;j++){ 
                agedist[j][0]=lifespan-j; //CM Age 
 
                //Allow Constant Birth and Constant Death Rate 
                double deathrate = deathintercept+deathslope*j; 
 
            //deathrate = TurnoverModelApp.holddouble; //Test Scenario A 
                if (j==0){agedist[j][1]=Math.pow((1-deathrate),lifespan);} 
                double birthrate = birthintercept+birthslope*j; 
            //birthrate = deathrate;//Test Scenario A 
                if (j>0){agedist[j][1]=birthrate*Math.pow((1-deathrate),lifespan-j);} 
 
                agedist[j][2]=GetC14atyear(birthyear+j); 
        } 
 
            //agedist[0][2]=TurnoverModelApp.getinitialbergmannpatientC14level(patient); 
 
        //Normalize to cell count 
        double tot=0; 
        for (int j=0;j<=lifespan;j++){tot=tot+agedist[j][1];} 
        for (int j=0;j<=lifespan;j++){agedist[j][1]=agedist[j][1]/tot;} 
 
        double[] aveC14postploidy=new double[lifespan+1];for (int 
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];} 
 
                for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life 
                     double aveC14foragegroup = agedist[p][2]; 
                    for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p 
                           double percadded = computepersonalizedpolyploidyc14rate(patient, q, 1); 
                           aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded); 
                    } 
                    aveC14postploidy[p]=aveC14foragegroup; 
                } 
 
            double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 = 
newaveC14+agedist[k][1]*aveC14postploidy[k];} 
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       double modeldC14 = newaveC14-GetC14atyear(birthyear); 
 
       TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(modeldC14-
TurnoverModelApp.Bergmann[patient][7],2); //SSE 
 
       //System.out.println("TOT: " + tot); 
       TurnoverModelApp.fileWriter(agedist,lifespan+1,3,"/Individual/"+patient); 
       return newaveC14; 
    } 
 
 
 
    public static void TurnDeltaC14intoScenarioTurnover(int patient,int birthyear, int lifespan,double deathrate,double 
birthrate) throws IOException{ 
 
        double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear 
 
        //assume totally random turnover but variable death rate 
            agedist = new double[lifespan+1][3]; 
            for (int j=0;j<=lifespan;j++){ 
                agedist[j][0]=lifespan-j; //CM Age 
 
               //Allow Constant Birth and Constant Death Rate 
                if (j==0){agedist[j][1]=Math.pow((1-deathrate),lifespan);} 
                if (j>0){agedist[j][1]=birthrate*Math.pow((1-deathrate),lifespan-j);} 
 
                agedist[j][2]=GetC14atyear(birthyear+j); 
        } 
             
        //Normalize to cell count 
        double tot=0; 
        for (int j=0;j<=lifespan;j++){tot=tot+agedist[j][1];} 
        for (int j=0;j<=lifespan;j++){agedist[j][1]=agedist[j][1]/tot;} 
 
 
        double[] aveC14postploidy=new double[lifespan+1];for (int 
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];} 
 
                for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life 
                     double aveC14foragegroup = agedist[p][2]; 
                    for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p 
                           double percadded = computepersonalizedpolyploidyc14rate(patient, q, 1); 
                           aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded); 
                    } 
                    aveC14postploidy[p]=aveC14foragegroup; 
                } 
 
            double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 = 
newaveC14+agedist[k][1]*aveC14postploidy[k];} 
 
       double modeldC14 = newaveC14-GetC14atyear(birthyear); 
       //double modeldC14 = newaveC14-TurnoverModelApp.getinitialbergmannpatientC14level(patient); 
   
       TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(modeldC14-
TurnoverModelApp.Bergmann[patient][7],2); //SSE 
    
    } 
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      public static void TurnDeltaC14intoScenarioE2Turnover(int patient,int birthyear, int lifespan,double 
gamma0,double gamma1) throws IOException{ 
 
        double[][] celldist = new double[lifespan+1][3]; //0=CM age at death, 1=%survive till death, 2=%formation 
         
        //compute death 
        for(int a=0;a<=lifespan;a++){ 
            celldist[a][0]=a; 
 
            double deathrate = gamma0*gamma1/(gamma1+a); 
            double liverate = 1-deathrate; 
            for (int j=0;j<a;j++){ 
                liverate=liverate*(1-gamma0*gamma1/(gamma1+j)); 
            } 
            celldist[a][1]=liverate; 
            //System.out.println(liverate); 
        } 
 
       //compute formation 
 
        double[] holdformed = new double[lifespan]; 
       for(int k=0;k<lifespan;k++){ 
            double formed=0; 
            if(k>0){ 
              for (int j=0;j<k;j++){ 
                  int a = j+k; 
                  double newdeath = gamma0*gamma1/(gamma1+a); 
                  formed = formed+holdformed[j]*newdeath; 
              } 
            } 
            else{formed=1;} 
            holdformed[k]=formed; 
            //System.out.println(k+" "+holdformed[k]); 
            celldist[lifespan-k-1][2]=formed; 
       } 
 
        //System.out.println(" A        Live to End     Formed%"); 
        for(int i=0;i<lifespan-1;i++){ 
            //System.out.println(celldist[i][0]+" "+celldist[i][1]+" "+celldist[i][2]); 
        } 
 
 
        double[][] agedist = new double[lifespan+1][3]; 
            for (int j=0;j<=lifespan;j++){ 
                agedist[j][0]=lifespan-j; //CM Age 
                agedist[j][1]=celldist[lifespan-j][1]*celldist[lifespan-j][2]; 
                agedist[j][2]=GetC14atyear(birthyear+j); 
                if(j==1){agedist[j][2]=TurnoverModelApp.getinitialbergmannpatientC14level(patient);} 
            } 
 
            for(int i=0;i<=lifespan;i++){ 
                //System.out.println(agedist[i][0]+" "+agedist[i][1]+" "+agedist[i][2]); 
            } 
 
        //Normalize to cell count 
        double tot=0; 
        for (int j=0;j<=lifespan;j++){tot=tot+agedist[j][1];} 
        //System.out.println("TOT: "+tot); 
        for (int j=0;j<=lifespan;j++){agedist[j][1]=agedist[j][1]/tot;} 
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        double[] aveC14postploidy=new double[lifespan+1];for (int 
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];} 
 
                for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life 
                     double aveC14foragegroup = agedist[p][2]; 
                    for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p 
                           double percadded = computepersonalizedpolyploidyc14rate(patient, q, 1); 
                           aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded); 
                    } 
                    aveC14postploidy[p]=aveC14foragegroup; 
                } 
 
            double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 = 
newaveC14+agedist[k][1]*aveC14postploidy[k];} 
 
       double modeldC14 = newaveC14-GetC14atyear(birthyear); 
       System.out.println(newaveC14); 
       //double modeldC14 = newaveC14-TurnoverModelApp.getinitialbergmannpatientC14level(patient); 
 
       TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(modeldC14-
TurnoverModelApp.Bergmann[patient][7],2); //SSE 
    } 
 
    public  void TestHybridModelforBergmann() throws IOException{ 
        double[][] data = new double[TurnoverModelApp.numBergmann][3]; 
       //int i=4; 
         for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
           data[i][0]=i; 
           data[i][1]=TurnoverModelApp.Bergmann[i][4]-TurnoverModelApp.Bergmann[i][9];  //How much Bergmann 
Corrected for Ploidy 
           data[i][2]=ComputeDeltaC14forConstantTurnover(i,TurnoverModelApp.Bergmann[i][6]/100, true)-
ComputeDeltaC14forConstantTurnover(i, TurnoverModelApp.Bergmann[i][6]/100, false); 
 
           //System.out.println("A "+i+" "+ data[i][1]+" "+data[i][2]); 
        TurnoverModelApp.holddata3=data;TurnoverModelApp.holdnumrows3=TurnoverModelApp.numBergmann; 
TurnoverModelApp.holdnumcol3=3; 
        TurnoverModelApp.fileWriter(data, TurnoverModelApp.numBergmann, 3, "HybridModelPloidyCompProof"); 
      } 
    } 
 
 public static double computepersonalizedpolyploidyc14rate(int patientID, int a, double ploidyscale){ 
    //smooth - break into 10 parts and compute a CAGR 
 
      double d0 = 110.5; double theta = 7; double n=5.4; 
      double k=76;k=TurnoverModelApp.Bergmann[patientID][8]; 
 
      double c14percrate=0; 
 
      //compute f(a) 
      double FofA=0; 
      if (a==0){FofA=d0;} 
      if (a>0){FofA=d0+k/(1+Math.pow((a/theta),-1*n));} 
 
      //compute f(a-1) 
      double FofAminus1=0; 
      if (a>1){FofAminus1=d0+k/(1+Math.pow(((a-1)/theta),-1*n));} 
      if(a==1){FofAminus1=d0;} 
      if(a==0){FofAminus1=d0;} 
 
      c14percrate = ((FofA-FofAminus1)/(FofAminus1));  
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      c14percrate = c14percrate*ploidyscale; 
 
     //System.out.println(patientID+" "+a+" "+c14percrate); 
 
      return c14percrate; 
  } 
 
    public static double TurnDeltaC14intoScenarioATurnover(int patientid, int birthyear, int lifespan, double 
BergmanndeltaC14,double initguess, boolean subtract,double ploidyscale,double delay) throws IOException{ 
 
        double guessturn = initguess;  int numtries = 400; 
        double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear 
 
        //assume totally random turnover 
        double error=0; double lastC14=0; 
     for (int i=0;i<numtries;i++){ 
            //System.out.println("Guess "+guessturn); 
            agedist = new double[lifespan+1][3]; 
            for (int j=0;j<=lifespan;j++){ 
                agedist[j][0]=lifespan-j; //CM Age 
 
                if (j>0){agedist[j][1]=guessturn*Math.pow((1-guessturn),lifespan-j);} 
                else if (j==0){agedist[j][1]=Math.pow((1-guessturn),lifespan);} 
 
                agedist[j][2]=GetC14atyear(birthyear+j); 
                //System.out.println("R " + agedist[j][0]+" "+100*agedist[j][1]+" "+agedist[j][2]); 
            } 
 
            double[] aveC14postploidy=new double[lifespan+1];for (int 
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];} 
            if (subtract==true){ //remove ploidy 
                for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life 
                     double aveC14foragegroup = agedist[p][2]; 
                    for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p 
                           double percadded = computepersonalizedpolyploidyc14rate(patientid, q, ploidyscale); 
                           aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded); 
                    } 
                    aveC14postploidy[p]=aveC14foragegroup; 
                }    
            } 
            double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 = 
newaveC14+agedist[k][1]*aveC14postploidy[k];} 
 
 
           double modeldeltaC14 = newaveC14-GetC14atyear(birthyear);double 
desireddeltaC14=TurnoverModelApp.Bergmann[patientid][7]; 
lastC14=newaveC14; 
            //System.out.println(patientid +", % "+guessturn+", New C14 "+ newaveC14+", ModelDc14 
"+modeldeltaC14+ ", DesiredDC14 "+desireddeltaC14); 
           error = modeldeltaC14-BergmanndeltaC14; 
           TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(error,2); //SSE 
           //System.out.println(guessturn+" "+error+" "+BergmanndeltaC14+ " "+modeldeltaC14); 
 
           double trylower = 
CheckDeltaC14intoScenarioATurnover(patientid,birthyear,lifespan,BergmanndeltaC14,guessturn*.98,subtract,ploidysc
ale,delay); //returns new modeldeltaC14 
           double tryhigher = 
CheckDeltaC14intoScenarioATurnover(patientid,birthyear,lifespan,BergmanndeltaC14,guessturn*1.02,subtract,ploidys
cale,delay); 
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           if (Math.abs(BergmanndeltaC14-trylower)<Math.abs(BergmanndeltaC14-
tryhigher)){guessturn=guessturn*0.98;} 
           else if(Math.abs(BergmanndeltaC14 - trylower)>Math.abs(BergmanndeltaC14 - tryhigher)){guessturn = 
guessturn * 1.02;} 
    } 
 
        //System.out.println(lastC14); 
        return guessturn; 
    } 
 
    public static double CheckDeltaC14intoScenarioATurnover(int patientid,int birthyear, int lifespan, double 
BergmanndeltaC14,double initguess,boolean subtract,double ploidyscale,double delay) throws IOException{ 
 
        double guessturn = initguess; 
        double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear 
 
            agedist = new double[lifespan+1][3]; 
            for (int j=0;j<=lifespan;j++){ 
                agedist[j][0]=lifespan-j; //CM Age 
 
                //For Scenario A 
                if (j>0){agedist[j][1]=guessturn*Math.pow((1-guessturn),lifespan-j);} 
                else if (j==0){agedist[j][1]=Math.pow((1-guessturn),lifespan);} 
 
                //For Scenario B 
               // if (j>0){agedist[j][1]=guessturn*Math.pow((1-TurnoverModelApp.deathrate),lifespan-j);} 
               // else if (j==0){agedist[j][1]=Math.pow((1-TurnoverModelApp.deathrate),lifespan);} 
 
                agedist[j][2]=GetC14atyear(birthyear+j-delay); 
            } 
 
             double[] aveC14postploidy=new double[lifespan+1];for (int 
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];} 
            if (subtract==true){ //remove ploidy 
                for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life 
                     double aveC14foragegroup = agedist[p][2];double massadded=1; 
                    for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p 
                           double percadded = computepersonalizedpolyploidyc14rate(patientid, q,ploidyscale); 
                           aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded); 
                    } 
                    aveC14postploidy[p]=aveC14foragegroup; 
                } 
            } 
            double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 = 
newaveC14+agedist[k][1]*aveC14postploidy[k];} 
 
 
             
            double modeldeltaC14 = newaveC14-GetC14atyear(birthyear); 
 
        return modeldeltaC14; 
    } 
 
 
 
    public static void PrintBombFunction(boolean smoothed) throws IOException{ 
        if (smoothed==false){ 
            TurnoverModelApp.fileWriter(TurnoverModelApp.C14points,TurnoverModelApp.numC14points,2,"/Bomb"); 
        } 
        else if(smoothed == true) 
186 
 
        { 
        int range = 2006-1930; 
        double[][] bomb = new double[range][2]; 
        for (int i=0;i<range;i++){ 
            bomb[i][0]=1930+i; 
            bomb[i][1]=GetC14atyear(1930+i); 
        } 
        TurnoverModelApp.fileWriter(bomb,range,2,"/Bomb"); 
        } 
    } 
 
    public static void VarydC14forBergmannTurnoverAnalysis() throws IOException{ 
        //data is column for each (0.8, 1.0, 1.2); row for each patient 
        double[][] data = new double[TurnoverModelApp.numBergmann][3]; 
 
        double initguess=TurnoverModelApp.initguess; 
 
        for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
            data[i][0]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2], 
(int)TurnoverModelApp.Bergmann[i][3],0.8*TurnoverModelApp.Bergmann[i][4],initguess,true,1,0); 
            data[i][1]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2], 
(int)TurnoverModelApp.Bergmann[i][3],1.0*TurnoverModelApp.Bergmann[i][4],initguess,true,1,0); 
            data[i][2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2], 
(int)TurnoverModelApp.Bergmann[i][3],1.2*TurnoverModelApp.Bergmann[i][4],initguess,true,1,0); 
        } 
        TurnoverModelApp.fileWriter(data,TurnoverModelApp.numBergmann,3,"VaryBergmanndC14"); 
    } 
 
    public void VaryExpansionExponentforTurnover() throws IOException{ 
        double[][] data = new double[TurnoverModelApp.Agerepetitions-1][7]; //Patient Age, M-Exponent = 80%, F-
Exponent = 100%, F-Exponent = 120%, F-Exponent = 80%, F-Exponent = 100%, F-Exponent = 120% 
 
        HierarchicalModel10g("Male",false,true,false,0.8,1,1); 
        for (int i=0;i<TurnoverModelApp.Agerepetitions-
1;i++){data[i][0]=TurnoverModelApp.holddata[i+1][0];data[i][1]=TurnoverModelApp.holddata[i+1][6];} 
        HierarchicalModel10g("Male",false,true,false,1.0,1,1); 
        for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][2]=TurnoverModelApp.holddata[i+1][6];} 
        HierarchicalModel10g("Male",false,true,false,1.2,1,1); 
        for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][3]=TurnoverModelApp.holddata[i+1][6];} 
 
        HierarchicalModel10g("Female",false,true,false,0.8,1,1); 
        for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][4]=TurnoverModelApp.holddata[i+1][6];} 
        HierarchicalModel10g("Female",false,true,false,1.0,1,1); 
        for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][5]=TurnoverModelApp.holddata[i+1][6];} 
        HierarchicalModel10g("Female",false,true,false,1.2,1,1); 
        for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][6]=TurnoverModelApp.holddata[i+1][6];} 
        TurnoverModelApp.fileWriter(data,TurnoverModelApp.Agerepetitions-1,7,"VaryExponentforTurnover"); 
    } 
 
 
 
 
   public void BergmannSensitivityToTrueTurnover() throws IOException{ 
        //patients:  0=patient, 
1=BergOutputifTrueTurn=0.1%,2=BergOutputifTrueTurn=1.0%,3=BergOutputifTrueTurn=10% 
        //True Turn = Constant Through Life but Includes Cell Inter-Life CM Death 
 
        double[] truepercs = 
{0.1,0.2,0.4,0.75,1.0,1.5,1.75,2.0,2.5,3.0,4.0,5.0,6.0,7.0,8.0,9.0,10,12.5,15,17.5,20,25,30,35,40}; 
        //double[] truepercs = {0.1,0.2,0.75,1.0,2.0,4.0,7.0,10,15,20,30,40}; 
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        //double[] truepercs = {22}; 
 
        double[][] patients = new double[truepercs.length][TurnoverModelApp.numBergmann+2]; 
 
       for (int k=0;k<truepercs.length;k++){patients[k][0]=truepercs[k];patients[k][1]=truepercs[k];} 
 
       // int i=0; 
        for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
            System.out.println("1 "+i); 
            for (int k=0;k<truepercs.length;k++){ 
                TurnoverModelApp.counter=i; 
                
patients[k][i+2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverM
odelApp.Bergmann[i][3], 
ComputeDeltaC14forConstantTurnover(i,truepercs[k]/100,true),TurnoverModelApp.initguess,true,1,0); 
            } 
        } 
 
        TurnoverModelApp.fileWriter(patients,truepercs.length,TurnoverModelApp.numBergmann+2,"BergSensitivity"); 
    } 
 
   public void IdentifyBifurcation() throws IOException{ 
       for (int i=0;i<TurnoverModelApp.numBergmann;i++){ 
          double C14 = ComputeDeltaC14forConstantTurnover(i,0.2,true); //must send a DECIMAL (sending 10/100 for 
10% will not work!) 
          System.out.println(C14); 
       } 
   } 
 
   public static void PrintC14forYearRange(int yearstart,int yearend){ 
      // for (int i=0;i<yearend-yearstart;i++){ System.out.println(GetC14atyear(yearstart+i));} 
       for (int 
i=0;i<TurnoverModelApp.numBergmann;i++){System.out.println(GetC14atyear(TurnoverModelApp.Bergmann[i][2])
);} 
   } 
    
 
 
    @SuppressWarnings("unchecked") 
    // <editor-fold defaultstate="collapsed" desc="Generated Code">                           
    private void initComponents() { 
 
        mainPanel = new javax.swing.JPanel(); 
        menuBar = new javax.swing.JMenuBar(); 
        javax.swing.JMenu fileMenu = new javax.swing.JMenu(); 
        javax.swing.JMenuItem exitMenuItem = new javax.swing.JMenuItem(); 
        javax.swing.JMenu helpMenu = new javax.swing.JMenu(); 
        javax.swing.JMenuItem aboutMenuItem = new javax.swing.JMenuItem(); 
        statusPanel = new javax.swing.JPanel(); 
        javax.swing.JSeparator statusPanelSeparator = new javax.swing.JSeparator(); 
        statusMessageLabel = new javax.swing.JLabel(); 
        statusAnimationLabel = new javax.swing.JLabel(); 
        progressBar = new javax.swing.JProgressBar(); 
 
        mainPanel.setName("mainPanel"); // NOI18N 
 
        javax.swing.GroupLayout mainPanelLayout = new javax.swing.GroupLayout(mainPanel); 
        mainPanel.setLayout(mainPanelLayout); 
        mainPanelLayout.setHorizontalGroup( 
            mainPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING) 
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            .addGap(0, 400, Short.MAX_VALUE) 
        ); 
        mainPanelLayout.setVerticalGroup( 
            mainPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING) 
            .addGap(0, 252, Short.MAX_VALUE) 
        ); 
 
        menuBar.setName("menuBar"); // NOI18N 
 
        org.jdesktop.application.ResourceMap resourceMap = 
org.jdesktop.application.Application.getInstance(turnovermodel.TurnoverModelApp.class).getContext().getResourceM
ap(TurnoverModelView.class); 
        fileMenu.setText(resourceMap.getString("fileMenu.text")); // NOI18N 
        fileMenu.setName("fileMenu"); // NOI18N 
 
        javax.swing.ActionMap actionMap = 
org.jdesktop.application.Application.getInstance(turnovermodel.TurnoverModelApp.class).getContext().getActionMap
(TurnoverModelView.class, this); 
        exitMenuItem.setAction(actionMap.get("quit")); // NOI18N 
        exitMenuItem.setName("exitMenuItem"); // NOI18N 
        fileMenu.add(exitMenuItem); 
 
        menuBar.add(fileMenu); 
 
        helpMenu.setText(resourceMap.getString("helpMenu.text")); // NOI18N 
        helpMenu.setName("helpMenu"); // NOI18N 
 
        aboutMenuItem.setAction(actionMap.get("showAboutBox")); // NOI18N 
        aboutMenuItem.setName("aboutMenuItem"); // NOI18N 
        helpMenu.add(aboutMenuItem); 
 
        menuBar.add(helpMenu); 
 
        statusPanel.setName("statusPanel"); // NOI18N 
 
        statusPanelSeparator.setName("statusPanelSeparator"); // NOI18N 
 
        statusMessageLabel.setName("statusMessageLabel"); // NOI18N 
 
        statusAnimationLabel.setHorizontalAlignment(javax.swing.SwingConstants.LEFT); 
        statusAnimationLabel.setName("statusAnimationLabel"); // NOI18N 
 
        progressBar.setName("progressBar"); // NOI18N 
 
        javax.swing.GroupLayout statusPanelLayout = new javax.swing.GroupLayout(statusPanel); 
        statusPanel.setLayout(statusPanelLayout); 
        statusPanelLayout.setHorizontalGroup( 
            statusPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING) 
            .addComponent(statusPanelSeparator, javax.swing.GroupLayout.DEFAULT_SIZE, 400, Short.MAX_VALUE) 
            .addGroup(statusPanelLayout.createSequentialGroup() 
                .addContainerGap() 
                .addComponent(statusMessageLabel) 
                .addPreferredGap(javax.swing.LayoutStyle.ComponentPlacement.RELATED, 226, Short.MAX_VALUE) 
                .addComponent(progressBar, javax.swing.GroupLayout.PREFERRED_SIZE, 
javax.swing.GroupLayout.DEFAULT_SIZE, javax.swing.GroupLayout.PREFERRED_SIZE) 
                .addPreferredGap(javax.swing.LayoutStyle.ComponentPlacement.RELATED) 
                .addComponent(statusAnimationLabel) 
                .addContainerGap()) 
        ); 
        statusPanelLayout.setVerticalGroup( 
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            statusPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING) 
            .addGroup(statusPanelLayout.createSequentialGroup() 
                .addComponent(statusPanelSeparator, javax.swing.GroupLayout.PREFERRED_SIZE, 2, 
javax.swing.GroupLayout.PREFERRED_SIZE) 
                .addPreferredGap(javax.swing.LayoutStyle.ComponentPlacement.RELATED, 
javax.swing.GroupLayout.DEFAULT_SIZE, Short.MAX_VALUE) 
                .addGroup(statusPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.BASELINE) 
                    .addComponent(statusMessageLabel) 
                    .addComponent(statusAnimationLabel) 
                    .addComponent(progressBar, javax.swing.GroupLayout.PREFERRED_SIZE, 
javax.swing.GroupLayout.DEFAULT_SIZE, javax.swing.GroupLayout.PREFERRED_SIZE)) 
                .addGap(3, 3, 3)) 
        ); 
 
        setComponent(mainPanel); 
        setMenuBar(menuBar); 
        setStatusBar(statusPanel); 
    }// </editor-fold>                         
 
    // Variables declaration - do not modify                      
    private javax.swing.JPanel mainPanel; 
    private javax.swing.JMenuBar menuBar; 
    private javax.swing.JProgressBar progressBar; 
    private javax.swing.JLabel statusAnimationLabel; 
    private javax.swing.JLabel statusMessageLabel; 
    private javax.swing.JPanel statusPanel; 
    // End of variables declaration                    
 
    private final Timer messageTimer; 
    private final Timer busyIconTimer; 
    private final Icon idleIcon; 
    private final Icon[] busyIcons = new Icon[15]; 
    private int busyIconIndex = 0; 
 
    private JDialog aboutBox; 
 
 
} 
 
